Emmaus Life Sciences (EMMA) 10-Q 25 Aug 21 2020 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2020	Jul. 31, 2021
Cover [Abstract]
Entity Registrant Name	Emmaus Life Sciences, Inc.
Entity Central Index Key	0000822370
Document Type	10-Q
Document Period End Date	Jun. 30, 2020
Amendment Flag	false
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2020
Current Fiscal Year End Date	--12-31
Entity File Number	001-35527
Entity Tax Identification Number	87-0419387
Entity Incorporation State Country Code	DE
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Address, Address Line One	21250 Hawthorne Boulevard
Entity Address, Address Line Two	Suite 800
Entity Address, City or Town	Torrance
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	90503
City Area Code	310
Local Phone Number	214-0065
Document Quarterly Report	true
Document Transition Report	false
Entity Common Stock, Shares Outstanding		49,311,864

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
CURRENT ASSETS
Cash and cash equivalents	$ 1,032	$ 1,769
Restricted cash	7
Accounts receivable, net	1,457	2,150
Inventories, net	7,863	7,971
Investment in marketable securities	27,007	27,929
Prepaid expenses and other current assets	1,170	1,402
Total current assets	38,536	41,221
Property and equipment, net	141	151
Equity method investment	13,005	13,325
Right of use assets	4,283	4,474
Deposits and other assets	285	285
Total assets	56,250	59,456
CURRENT LIABILITIES
Accounts payable and accrued expenses	10,377	11,498
Operating lease liabilities	1,103	991
Other current liabilities	957	5,748
Revolving line of credit to related parties, net	600	600
Warrant derivative liabilities	1,539	38
Notes payable, current portion	4,271	3,749
Notes payable to related parties	34	193
Convertible debentures, net of discount	7,594	7,015
Convertible note payable, net of discount		2,995
Total current liabilities	26,475	32,827
Operating lease liabilities, less current portion	3,722	3,932
Other long-term liabilities	36,434	33,750
Notes payable, less current portion	488
Convertible note payable	3,150
Total liabilities	70,269	70,509
STOCKHOLDERS’ DEFICIT
Preferred stock — par value $0.001 per share, 15,000,000 shares authorized, none issued or outstanding
Common stock — par value $0.001 per share, 250,000,000 shares authorized, 48,987,189 shares and 48,471,446 shares issued and outstanding at June 30, 2020 and December 31, 2019, respectively	49	48
Additional paid-in capital	216,376	215,207
Accumulated other comprehensive loss	(51)	(79)
Accumulated deficit	(230,393)	(226,229)
Total stockholders’ deficit	(14,019)	(11,053)
Total liabilities & stockholders’ deficit	$ 56,250	$ 59,456

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Jun. 30, 2020	Dec. 31, 2019
Statement Of Financial Position [Abstract]
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, authorized	15,000,000	15,000,000
Preferred stock, issued	0	0
Preferred stock, outstanding	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, authorized	250,000,000	250,000,000
Common stock, issued	48,987,189	48,471,446
Common stock, outstanding	48,987,189	48,471,446

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (Unaudited) - USD ($)	3 Months Ended				6 Months Ended
	Jun. 30, 2020	Mar. 31, 2020	Jun. 30, 2019	Mar. 31, 2019	Jun. 30, 2020	Jun. 30, 2019
Income Statement [Abstract]
REVENUES, NET	$ 4,360,000		$ 5,493,000		$ 11,314,000	$ 10,200,000
COST OF GOODS SOLD	446,000		264,000		924,000	523,000
GROSS PROFIT	3,914,000		5,229,000		10,390,000	9,677,000
OPERATING EXPENSES
Research and development	589,000		540,000		1,206,000	1,053,000
Selling	1,135,000		1,891,000		2,203,000	3,370,000
General and administrative	3,725,000		2,682,000		7,382,000	6,419,000
Total operating expenses	5,449,000		5,113,000		10,791,000	10,842,000
INCOME (LOSS) FROM OPERATIONS	(1,535,000)		116,000		(401,000)	(1,165,000)
OTHER INCOME (EXPENSE)
Loss on debt extinguishment	(1,425,000)				(1,425,000)
Change in fair value of warrant derivative liabilities	(101,000)		854,000		(76,000)	(84,000)
Change in fair value of embedded conversion option	35,000				6,000
Net gains (losses) on investment in marketable securities and long-term investment	(5,631,000)		(10,537,000)		1,208,000	(16,994,000)
Loss on equity method investment	(573,000)		(458,000)		(980,000)	(449,000)
Interest and other income	567,000		307,000		600,000	230,000
Interest expense	(1,309,000)		(7,827,000)		(3,109,000)	(16,439,000)
Total other expenses	(8,437,000)		(17,661,000)		(3,776,000)	(33,736,000)
LOSS BEFORE INCOME TAXES	(9,972,000)		(17,545,000)		(4,177,000)	(34,901,000)
INCOME TAXES (BENEFIT)	(499,000)		51,000		(213,000)	103,000
NET LOSS	(9,473,000)	$ 5,509,000	(17,596,000)	$ (17,408,000)	(3,964,000)	(35,004,000)
COMPONENTS OF OTHER COMPREHENSIVE INCOME (LOSS)
Foreign currency translation adjustments	(33,000)	$ 61,000	6,000	$ 7,000	28,000	13,000
Other comprehensive income (loss)	(33,000)		6,000		28,000	13,000
COMPREHENSIVE LOSS	$ (9,506,000)		$ (17,590,000)		$ (3,936,000)	$ (34,991,000)
NET LOSS PER COMMON SHARE - BASIC AND DILUTED	$ (0.19)		$ (0.47)		$ (0.08)	$ (0.93)
WEIGHTED-AVERAGE COMMON SHARES OUTSTANDING	48,987,189		37,836,678		48,805,829	37,656,058

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' DEFICIT (Unaudited) - USD ($) $ in Thousands	Total	Cumulative Effect, Period of Adoption, Adjustment [Member]	Common Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Accumulated Deficit [Member]	Accumulated Deficit [Member]Cumulative Effect, Period of Adoption, Adjustment [Member]
Balance, beginning at Dec. 31, 2018	$ (21,708)		$ 37	$ 149,682	$ (69)	$ (171,358)
Balance, beginning (ASU 2016-02 [Member]) at Dec. 31, 2018		$ (29)					$ (29)
Balance, beginning (in shares) at Dec. 31, 2018			37,341,393
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beneficial conversion feature relating to convertible notes	3,374			3,374
Exercise of warrants	5			5
Exercise of warrants (in shares)			525
Common stock issued for cash (net of issuance cost)	2,530		$ 1	2,529
Common stock issued for cash (net of issuance cost) (in shares)			322,920
Conversion of notes payable to common stock	329			329
Conversion of notes payable to common stock (in shares)			85,411
Share-based compensation	588			588
Exercise of common stock options	1			1
Exercise of common stock options (in shares)			175
Foreign currency translation effect	7				7
Net income (loss)	(17,408)					(17,408)
Balance, ending at Mar. 31, 2019	(32,311)		$ 38	156,508	(62)	(188,795)
Balance, ending (in shares) at Mar. 31, 2019			37,750,424
Balance, beginning at Dec. 31, 2018	(21,708)		$ 37	149,682	(69)	(171,358)
Balance, beginning (ASU 2016-02 [Member]) at Dec. 31, 2018		(29)					(29)
Balance, beginning (in shares) at Dec. 31, 2018			37,341,393
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Foreign currency translation effect	13
Net income (loss)	(35,004)
Balance, ending at Jun. 30, 2019	(43,161)		$ 38	163,248	(56)	(206,391)
Balance, ending (in shares) at Jun. 30, 2019			37,880,211
Balance, beginning at Dec. 31, 2018	(21,708)		$ 37	149,682	(69)	(171,358)
Balance, beginning (ASU 2016-02 [Member]) at Dec. 31, 2018		$ (29)					$ (29)
Balance, beginning (in shares) at Dec. 31, 2018			37,341,393
Balance, ending at Dec. 31, 2019	(11,053)		$ 48	215,207	(79)	(226,229)
Balance, ending (in shares) at Dec. 31, 2019			48,471,446
Balance, beginning at Mar. 31, 2019	(32,311)		$ 38	156,508	(62)	(188,795)
Balance, beginning (in shares) at Mar. 31, 2019			37,750,424
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beneficial conversion feature relating to convertible notes	5,390			5,390
Exercise of warrants	181			181
Exercise of warrants (in shares)			53,032
Common stock issued for cash (net of issuance cost)	731			731
Common stock issued for cash (net of issuance cost) (in shares)			76,755
Share-based compensation	438			438
Foreign currency translation effect	6				6
Net income (loss)	(17,596)					(17,596)
Balance, ending at Jun. 30, 2019	(43,161)		$ 38	163,248	(56)	(206,391)
Balance, ending (in shares) at Jun. 30, 2019			37,880,211
Balance, beginning at Dec. 31, 2019	(11,053)		$ 48	215,207	(79)	(226,229)
Balance, beginning (in shares) at Dec. 31, 2019			48,471,446
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Common stock issued for cash (net of issuance cost)	142		$ 1	141
Common stock issued for cash (net of issuance cost) (in shares)			515,743
Fair value of warrants including down-round protection adjustments	400			600		(200)
Share-based compensation	209			209
Foreign currency translation effect	61				61
Net income (loss)	5,509					5,509
Balance, ending at Mar. 31, 2020	(4,732)		$ 49	216,157	(18)	(220,920)
Balance, ending (in shares) at Mar. 31, 2020			48,987,189
Balance, beginning at Dec. 31, 2019	(11,053)		$ 48	215,207	(79)	(226,229)
Balance, beginning (in shares) at Dec. 31, 2019			48,471,446
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Foreign currency translation effect	28
Net income (loss)	(3,964)
Balance, ending at Jun. 30, 2020	(14,019)		$ 49	216,376	(51)	(230,393)
Balance, ending (in shares) at Jun. 30, 2020			48,987,189
Balance, beginning at Mar. 31, 2020	(4,732)		$ 49	216,157	(18)	(220,920)
Balance, beginning (in shares) at Mar. 31, 2020			48,987,189
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Share-based compensation	219			219
Foreign currency translation effect	(33)				(33)
Net income (loss)	(9,473)					(9,473)
Balance, ending at Jun. 30, 2020	$ (14,019)		$ 49	$ 216,376	$ (51)	$ (230,393)
Balance, ending (in shares) at Jun. 30, 2020			48,987,189

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (3,964)	$ (35,004)
Adjustments to reconcile net loss to net cash flows used in operating activities
Depreciation and amortization	30	35
Impairment loss on long-term investment		524
Inventory reserve	375
Amortization of discount of notes payable and convertible notes payable	2,102	13,771
Foreign exchange adjustments on convertible notes and notes payable	(70)	(208)
Net losses (gains) on equity investment in marketable securities	(1,208)	16,470
Loss on equity method investee	980	449
Loss on debt settlement	1,425
Share-based compensation	428	1,026
Change in fair value of warrant derivative liabilities	76	84
Change in fair value of embedded conversion option	(6)
Net changes in operating assets and liabilities
Accounts receivable	693	(364)
Inventories	(267)	(1,202)
Prepaid expenses and other current assets	528	149
Other non-current assets	183	(4,298)
Income tax receivable and payable	(295)	(113)
Accounts payable and accrued expenses	(412)	4,054
Deferred revenue		500
Deferred rent		(287)
Other current liabilities	(4,903)	(63)
Other long-term liabilities	2,586	3,217
Net cash flows used in operating activities	(1,719)	(1,260)
CASH FLOWS FROM INVESTING ACTIVITIES
Sale of marketable securities	2,130	221
Purchases of property and equipment	(13)	(21)
Loans to equity method investee	(561)
Net cash flows provided by investing activities	1,556	200
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from notes payable issued, net of issuance cost and discount	998
Payments of notes payable	(200)
Payments of convertible notes	(1,500)	(3,368)
Proceeds from exercise of warrants	142	186
Proceeds from issuance of common stock		3,261
Proceeds from conversion of notes payable to common stock		21
Net cash flows provided by (used in) financing activities	(560)	100
Effect of exchange rate changes on cash	(7)	2
Net decrease in cash, cash equivalents and restricted cash	(730)	(958)
Cash, cash equivalents and restricted cash, beginning of period	1,769	3,905
Cash, cash equivalents and restricted cash, end of period	1,039	2,947
SUPPLEMENTAL DISCLOSURES OF CASH FLOW ACTIVITIES
Interest paid	802	549
Income taxes paid	82	216
NON-CASH INVESTING AND FINANCING ACTIVITIES
Warrants issued	$ 1,825
Beneficial conversion feature relating to convertible notes		8,764
Common stocks issued on exercise of warrants		186
Conversion of notes payable and accrued interest to common stock		$ 329

BASIS OF PRESENTATION

BASIS OF PRESENTATION	6 Months Ended
	Jun. 30, 2020
Organization Consolidation And Presentation Of Financial Statements [Abstract]
BASIS OF PRESENTATION	NOTE 1 — BASIS OF PRESENTATION The accompanying unaudited condensed consolidated interim financial statements of Emmaus Life Sciences, Inc. (formerly, “MYnd Analytics, Inc.”) and its direct and indirect consolidated subsidiaries (collectively, “we,” “our,” “us,” the “Company” or “Emmaus”) have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) on the basis that the Company will continue as a going concern. All significant intercompany transactions have been eliminated. The Company’s unaudited condensed consolidated interim financial statements contain adjustments, including normal recurring accruals necessary to fairly state the Company’s consolidated financial position, results of operations and cash flows. The consolidated interim financial statements should be read in conjunction with the Annual Report on Form 10-K/A for the year ended December 31, 2020 (the “Annual Report”) filed with the Securities and Exchange Commission (“SEC”) on August 10, 2021. The accompanying condensed consolidated balance sheet at December 31, 2019 has been derived from the audited consolidated balance sheet at December 31, 2019 contained in the Form 10-K/A. The results of operations for the three and six months ended June 30, 2020, are not necessarily indicative of the results to be expected for the full year or any future interim period. Organization and Nature of Operations The Company is a commercial-stage biopharmaceutical company engaged in the discovery, development, marketing and sales of innovative treatments and therapies primarily for rare and orphan diseases. On July 17, 2019, we completed a merger transaction with EMI Holding, Inc., formerly known as Emmaus Life Sciences, Inc. (“EMI”), into a subsidiary of the Company (the “Merger”), with EMI surviving the Merger as a wholly owned subsidiary. Immediately after completion of the Merger, we changed our name to “Emmaus Life Sciences, Inc.” The Merger was treated as a reverse recapitalization under the acquisition method of accounting in accordance with accounting principles generally accepted in the U.S. For accounting purposed, EMI was considered to have acquired us. The Merger is intended to qualify as a tax-free reorganization for U.S. federal income tax purposes. In connection with and prior to the Merger, we contributed and transferred to Telemynd, Inc. (“Telemynd”), a newly formed, wholly owned subsidiary of the Company, all or substantially all our historical business, assets and liabilities and our board of directors declared a stock dividend of one share of the Telemynd common stock held by the Company for each outstanding share of our common stock after giving effect to a 1-for-6 reverse stock split of our outstanding shares of common stock. As a result of the spin-off and the Merger, our ongoing business became EMI’s business, which is that of a commercial-stage biopharmaceutical company focused on the development, marketing and sale of innovative treatments and therapies, including those in the rare and orphan disease categories. Principles of consolidation —The consolidated financial statements include the accounts of the Company, EMI and EMI’s wholly‑owned subsidiary, Emmaus Medical, Inc., and Emmaus Medical, Inc.’s wholly‑owned subsidiaries. All significant intercompany transactions have been eliminated. The preparation of the consolidated financial statements requires the use of management estimates that affect the reported amounts of assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses for the reported period. Actual results could differ materially from those estimates. Restatement of Prior Period Amounts — In connection with the preparation of our December 31, 2019 consolidated financial statements, we identified the following material errors in our condensed consolidated financial statements as of and for the three months and six months ended June 30, 2019. 1. The misclassification as equity of warrants issued by EMI in October of 2018, which warrants should have been accounted for as liabilities based upon fair value; and 2. The erroneous consolidation as a variable interest entity, or VIE, of EMI’s interest in EJ Holdings, Inc., which should have been accounted for based upon the equity method. 3. The misstatement of the fair value of cashless exercise warrants originally recorded in the Consolidated Statements of Operations and Comprehensive Loss, which fair value should have been recorded in additional paid-in capital in the Consolidated Balance Sheets. 4. In addition to the errors described above, the restated financial statements also include adjustments to correct certain immaterial errors identified during the audit of the Company’s financial statements for the year ended December 31, 2019. EMMAUS LIFE SCIENCES, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands, except share and per share amounts) (Unaudited) As of June 30, 2019 Previously Reported Adjustment Restated ASSETS CURRENT ASSETS Cash and cash equivalents $ 15,169 $ (12,222 ) (a) $ 2,947 Accounts receivable, net 1,981 301 (c) 2,282 Inventories, net 5,906 — 5,906 Investment in marketable securities 32,890 — 32,890 Prepaid expenses and other current assets 703 (107 ) (a), (c) 596 Total current assets 56,649 (12,028 ) 44,621 Property and equipment, net 145 — 145 Equity method investment — 13,366 (a) 13,366 Right of use assets 4,285 — 4,285 Deposits and other assets 412 — 412 Total other assets 4,697 13,366 18,063 Total assets $ 61,491 $ 1,338 $ 62,829 LIABILITIES AND STOCKHOLDERS’ DEFICIT CURRENT LIABILITIES Accounts payable and accrued expenses $ 11,455 $ 62 (a), (c) $ 11,517 Operating lease liabilities, current portion 857 — 857 Other current liabilities 5,259 2 (c) 5,261 Warrant derivative liabilities — 9,023 (b), (c) 9,023 Notes payable, net of discount 11,163 91 (b) 11,254 Notes payable to related parties 470 — 470 Convertible notes payable, net of discount 13,867 — 13,867 Convertible notes payable to related parties, net of discount 14,180 — 14,180 Total current liabilities 57,251 9,178 66,429 Operating lease liabilities, less current portion 3,781 — 3,781 Other long-term liabilities 35,330 — 35,330 Warrant derivative liabilities 1,200 (1,200 ) (c) — Notes payable, net of discount, less current portion 703 (703 ) (b) — Convertible notes payable, net of discount, less current portion 450 — 450 Total liabilities 98,715 7,275 105,990 STOCKHOLDERS’ DEFICIT Preferred stock — par value $0.001 per share, 20,000,000 shares authorized, none issued or outstanding — — — Common stock — par value $0.001 per share, 250,000,000 shares authorized, 37,880,211 shares outstanding at June 30, 2019 36 2 (d) 38 Additional paid-in capital 153,084 10,164 (b), (e) 163,248 Accumulated other comprehensive income (loss) (56 ) — (56 ) Accumulated deficit (189,503 ) (16,888 ) (e) (206,391 ) Total stockholders’ deficit (36,439 ) (6,722 ) (43,161 ) Noncontrolling interest (785 ) 785 (a) — Total liabilities & stockholders’ deficit $ 61,491 $ 1,338 $ 62,829 (a) EJ Holdings adjustments: the correction of this misstatement resulted in increases of $13.4 million in equity method investment, $172,000 in accounts payable and accrued expenses, and $785,000 in non-controlling interest and decreases of $12.2 million in cash and cash equivalent and $187,000 in prepaid expenses and other current assets. (b) Warrant adjustments: the correction of this misstatement resulted in increases of $7.8 million in warrant derivative current liabilities, and $90,000 in short-term note payable and decreases of $703,000 in long-term notes payable and $9.7 million in additional paid-in capital. (c) Corrections of other misstatement: period adjustment and reclassification of variable consideration resulted in an increase of $301,000 in accounts receivable and a decrease of $110,000 in accounts payable and accrued expenses, a decrease of $10,000 in income tax receivable and an increase of $24,000 in income tax payable; a reclassification of GPB warrants resulted an increase of short-term warrant liability and a decrease of long-term warrant liability of $1.2 million; and correction of tax provision resulted an increase of $90,000 in income tax receivable and a decrease of $24,000 in income tax payable. (d) Retrospective adjustments made to common stock resulted from recapitalization transaction in July 2019. (e) Carryforward impact on 2018 restatement adjustments, including cashless warrant adjustments which resulted in an increase in additional paid-in capital and a decrease in retained earnings of $18.3 million. EMMAUS LIFE SCIENCES, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (In thousands, except share and per share amount) (Unaudited) Three months ended June 30, 2019 Six months ended June 30,2019 Previously Reported Adjustment Restated Previously Reported Adjustment Restated REVENUES, NET $ 5,869 $ (376 ) (c) $ 5,493 $ 11,176 $ (976 ) (c) $ 10,200 COST OF GOODS SOLD 195 69 (c) 264 395 128 (c) 523 GROSS PROFIT 5,674 (445 ) 5,229 10,781 (1,104 ) 9,677 OPERATING EXPENSES Research and development 540 — 540 1,053 — 1,053 Selling 1,903 (12 ) (c) 1,891 3,388 (18 ) (c) 3,370 General and administrative 3,851 (1,169 ) (a), (c) 2,682 7,532 (1,113 ) (a), (c) 6,419 Total operating expenses 6,294 (1,181 ) 5,113 11,973 (1,131 ) 10,842 INCOME (LOSS) FROM OPERATIONS (620 ) 736 116 (1,192 ) 27 (1,165 ) OTHER INCOME (EXPENSE) Change in fair value of warrant derivative liabilities 247 607 (b) 854 199 (283 ) (b) (84 ) Net losses on investment in marketable securities and long-term investment (10,537 ) — (10,537 ) (16,994 ) — (16,994 ) Losses on equity method investment — (458 ) (a) (458 ) — (449 ) (a) (449 ) Interest and other income (loss) 274 33 (a), (c) 307 163 67 (a), (c) 230 Interest expense (8,474 ) 647 (b), (c) (7,827 ) (15,439 ) (1,000 ) (b), (c) (16,439 ) Total other income (expenses) (18,490 ) 829 (17,661 ) (32,071 ) (1,665 ) (33,736 ) LOSS BEFORE INCOME TAXES (19,110 ) 1,565 (17,545 ) (33,263 ) (1,638 ) (34,901 ) INCOME TAXES (BENEFIT) 217 (166 ) (c) 51 217 (114 ) (c) 103 NET LOSS INCLUDING NONCONTROLLING INTERESTS (19,327 ) 1,731 (17,596 ) (33,480 ) (1,524 ) (35,004 ) Net (income) loss attributable to noncontrolling interests 688 (688 ) (a) — 674 (674 ) (a) — NET LOSS ATTRIBUTABLE TO THE COMPANY (18,639 ) 1,043 (17,596 ) (32,806 ) (2,198 ) (35,004 ) COMPONENTS OF OTHER COMPREHENSIVE INCOME (LOSS) Foreign currency translation adjustments (9 ) 15 (a) 6 (2 ) 15 (a) 13 Other comprehensive income (loss) (9 ) 15 6 (2 ) 15 13 COMPREHENSIVE INCOME (LOSS) (19,336 ) 1,746 (17,590 ) (33,482 ) (1,509 ) (34,991 ) Amounts attributable to noncontrolling interest: Net (income) loss attributable to noncontrolling interest 688 (688 ) (a) — 674 (674 ) (a) — Foreign currency translation adjustments 15 (15 ) (a) — 14 (14 ) (a) — Comprehensive (income) loss attributable to noncontrolling interest 703 (703 ) — 688 (688 ) — COMPREHENSIVE INCOME (LOSS) ATTRIBUTABLE TO THE COMPANY $ (18,633 ) $ 1,043 $ (17,590 ) $ (32,794 ) $ (2,197 ) $ (34,991 ) NET LOSS PER COMMON SHARE - BASIC AND DILUTED $ (0.52 ) $ 0.05 $ (0.47 ) $ (0.91 ) $ (0.01 ) $ (0.93 ) WEIGHTED-AVERAGE COMMON SHARES OUTSTANDING 35,857,944 37,836,678 37,836,678 35,857,944 37,656,058 37,656,058 (a) EJ Holdings adjustments: the correction of this misstatement resulted in increases of $33,000 in interest income and $15,000 in foreign currency translation adjustments and decreases of $1.1million in general and administrative expenses, $458,000 in loss on equity method investment, and $688,000 in net loss attributable to noncontrolling interest for three months ended June 30, 2019. The correction of this misstatement resulted in increases of $67,000 in interest income and $14,000 in foreign currency translation adjustments and decreases of $1.1million in general and administrative expense, $449,000 in loss on equity method investment, and $674,000 in net loss attributable to noncontrolling interest for six months ended June 30, 2019. (b) Warrant adjustments: the correction of this misstatement resulted in increases of $647,000 in interest expense and $607,000 in change in fair value of warrant derivative liabilities for the three months ended June 2019. The correction of this misstatement resulted in an increase of $335,000 in interest expense and a decrease of $283,000 in change in fair value of warrant derivative liabilities for six months ended June 30, 2019. ( c ) Corrections of other misstatement: period adjustment of variable consideration resulted in a decrease of $ in revenue s , net; and reclassification of shipping cost and royalty expense to cost of sales resulted in an increase of $ in cost of sales and decreases of $ and $ in selling expense and general and administrative expense, respectively . Corrections of other misstatement for the six months ended June 30, 2019 : period adjustment of variable consideration resulted in a decrease of $ in revenues, net ; reclassification of shipping cost and royalty expense to cost of sales resulted in an increase of $ in cost of sales and decreases of $ and $ in selling expense and general and administrative expense, respectively; correction of stock modification accounting resulted in a decrease of $ 52,000 in general and administrative expense; correction of accounting treatment for convertible notes resulted in an increase of $ 1.3 million in interest expense ; and correction of income tax provision resulted in an decrease of $ 113,000 in income tax provision . EMMAUS LIFE SCIENCES, INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (In thousands) (Unaudited) Six Months Ended June 30, 2019 Previously Reported Adjustment Restated CASH FLOWS FROM OPERATING ACTIVITIES Net loss $ (33,480 ) $ (1,524 ) $ (35,004 ) Adjustments to reconcile net loss to net cash flows from operating activities Depreciation and amortization 35 — 35 Impairment loss on long-term investment 524 — 524 Amortization of discount of convertible notes and notes payable 12,770 1,001 13,771 Foreign exchange adjustments on convertible notes and notes payable 49 (257 ) (208 ) Net losses (gains) on equity investment in marketable securities 16,470 — 16,470 Loss on equity method investments 449 449 Share-based compensation 974 52 1,026 Change in fair value of warrant derivative liabilities (199 ) 283 84 Net changes in operating assets and liabilities Accounts receivable (630 ) 266 (364 ) Inventories (1,202 ) — (1,202 ) Prepaid expenses and other current assets 69 80 149 Other non-current assets (4,298 ) — (4,298 ) Accounts payable and accrued expenses 3,226 828 4,054 Income tax receivable and payable — (113 ) (113 ) Deferred revenue 500 — 500 Deferred rent (287 ) — (287 ) Other current liabilities 79 (142 ) (63 ) Other long-term liabilities 3,217 — 3,217 Net cash flows provided by (used in) operating activities (2,183 ) 923 (1,260 ) CASH FLOWS FROM INVESTING ACTIVITIES Purchases of property and equipment (21 ) — (21 ) Sales of marketable securities 221 — 221 Purchase of marketable securities and investment at cost — — — Net cash flows provided by (used in) investing activities 200 — 200 CASH FLOWS FROM FINANCING ACTIVITIES Payments of convertible notes (3,368 ) — (3,368 ) Proceeds from exercise of warrants 186 — 186 Proceeds from issuance of common stock 3,261 — 3,261 Proceeds from conversion of notes payable to common stock 21 — 21 Net cash flows provided by (used in) financing activities 100 — 100 Effect of exchange rate changes on cash (28 ) 30 2 Net increase (decrease) in cash, cash equivalents and restricted cash (1,911 ) 953 (958 ) Cash and cash equivalents, beginning of period 17,080 (13,175 ) 3,905 Cash and cash equivalents, end of period $ 15,169 $ (12,222 ) $ 2,947 SUPPLEMENTAL DISCLOSURES OF CASH FLOW ACTIVITIES Interest paid $ 934 $ (385 ) $ 549 Income taxes paid $ 217 $ (1 ) $ 216 NON-CASH INVESTING AND FINANCING ACTIVITIES Beneficial conversion feature relating to convertible notes $ 8,764 $ — $ 8,764 Common stocks issued on exercise of warrants $ 186 $ — $ 186 Conversion of notes payable and acrued interest to common stock $ 308 $ — $ 329 Initial recognition of right-of-use lease asset $ 2,922 $ — $ 2,922 Refer to the descriptions of the adjustments in the Condensed Consolidated Balance Sheets and Statements of Comprehensive Loss as of and for the three months ended June 30, 2019 and their impact on net loss above. In addition, a cash flow classification adjustment related to EJ Holdings resulted in a net decrease to cash flows used by operating activities of $953,000 for the six months ended June 30, 2019.

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	6 Months Ended
	Jun. 30, 2020
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 2 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES The Company’s significant accounting policies are described in Note 2, “Summary of Significant Accounting Policies,” in the Company’s Annual Report on Form 10K/A for the year ended December 31, 2020. There have been no material changes in these policies or their application. Management has considered all recent accounting pronouncements issued since the last audit of the Company’s consolidated financial statements and believes that these recent pronouncements will not have a material effect on the Company’s condensed consolidated financial statements. Restricted cash — Restricted cash includes proceeds received from the sales of shares of Telcon RF Pharmaceutical, Inc., a Korean corporation (formerly, Telcon Inc. and herein “Telcon”) earmarked for the purchase of Telcon convertible bond per the December 23, 2019 agreement with Telcon. See Note 5 for the additional details. Reconciliation of cash, cash equivalent and restricted cash are as follows: Six Month Ended June 30 2020 2019 Cash and cash equivalents $ 1,032 $ 2,947 Restricted cash 7 — Total cash, cash equivalents and restricted cash shown in the consolidated statements of cash flows $ 1,039 $ 2,947 Net loss per share — In accordance with ASC 260, “Earnings per Share, ” the basic loss per common share is computed by dividing net loss available to common stockholders by the weighted-average number of common shares outstanding. Dilutive loss per share is computed in a manner similar to basic loss per common share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. As of June 30, 2020 and June 30, 2019, the Company had outstanding potentially dilutive securities exercisable for or convertible into 17,288,829 shares and 17,996,931 shares, respectively, of the Company’s common stock. No potentially dilutive securities were included in the calculation of diluted net loss per share since their effect would be anti-dilutive for all period presented.

REVENUES

REVENUES	6 Months Ended
	Jun. 30, 2020
Revenue From Contract With Customer [Abstract]
REVENUES	NOTE 3 — REVENUES Revenues disaggregated by category were as follows (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2020 2019 Restated 2020 2019 Restated Endari® $ 4,349 $ 5,390 $ 11,063 $ 9,992 Other 11 103 251 208 Revenues, net $ 4,360 $ 5,493 $ 11,314 $ 10,200 The following table summarizes the revenue allowance and accrual activities for the six months ended June 30, 2020 and 2019 (in thousands): Trade Discounts, Allowances and Chargebacks Government Rebates and Other Incentives Returns Total Balance as of December 31, 2019 $ 228 $ 1,354 $ 315 $ 1,897 Provision related to sales in the current year 1,438 1,955 118 3,511 Adjustments related prior period sales 16 (43 ) (43 ) (70 ) Credit and payments made (1,208 ) (1,324 ) — (2,532 ) Balance as of June 30, 2020 $ 474 $ 1,942 $ 390 $ 2,806 Balance as of December 31, 2018 $ 84 $ 798 $ 99 $ 981 Provision related to sales in the current year 649 1,625 121 2,395 Credit and payments made (614 ) (1,135 ) — (1,749 ) Balance as of June 30, 2019, restated $ 119 $ 1,288 $ 220 $ 1,627 The following table summarizes revenues attributable to each of our customers that accounted for 10% or more of our total revenues (as a percentage of total revenues): Three Months Ended June 30, Six Months Ended June 30, 2020 2019 Restated 2020 2019 Restated Customer A 55 % 58 % 54 % 61 % Customer B 20 % 25 % 24 % 22 % The Company is party to a distributor agreement with Telcon pursuant to which it granted Telcon exclusive rights to the Company’s prescription grade L-glutamine (“PGLG”) oral powder for the treatment of diverticulosis in South Korea, Japan and China in exchange for Telcon’s payment of a $10 million upfront fee and agreement to purchase from us specified minimum quantities of the finished product. In a related license agreement with Telcon, the Company agreed to use commercially reasonable best efforts to obtain product registration in these territories within three years of obtaining FDA marketing authorization for PGLG in this indication. Telcon has the right to terminate the distributor agreement in certain circumstances for failure to obtain such product registrations, in which event the Company would be obliged to return to Telcon the $10 million upfront fee. The upfront fee of $10 million is included in other long-term liabilities as unearned revenue as of June 30, 2020 and December 31, 2019. Refer Note 11 and Note 13 for additional transaction details. The Company received an upfront payment of $500,000 in connection with entering into a distribution agreement with a strategic partner in 2018 to distribute Endari® in the Middle East and North Africa region. The payment was recorded as unearned revenue and included in other long-term liabilities to be recognized as revenue when the performance obligations are satisfied. The upfront payment of $500,000 is included in other long-term liabilities as unearned revenue as of December 31, 2019. In June 2020, the distribution agreement was terminated and $500,000 up front payment was recognized as other income.

SELECTED FINANCIAL STATEMENT CA

SELECTED FINANCIAL STATEMENT CAPTIONS - ASSETS	6 Months Ended
	Jun. 30, 2020
Balance Sheet Related Disclosures [Abstract]
SELECTED FINANCIAL STATEMENT CAPTIONS - ASSETS	NOTE 4 — SELECTED FINANCIAL STATEMENT CAPTIONS - ASSETS Inventories consisted of the following (in thousands): June 30, 2020 December 31, 2019 Raw materials and components $ 1,500 $ 1,187 Work-in-process 1,836 1,629 Finished goods 4,948 5,204 Inventory reserve (421 ) (49 ) Total $ 7,863 $ 7,971 Prepaid expenses and other current assets consisted of the following (in thousands): June 30, 2020 December 31, 2019 Prepaid insurance $ 271 $ 735 Other prepaid expenses and current assets 899 667 Total $ 1,170 $ 1,402 Property and equipment consisted of the following (in thousands): June 30, 2020 December 31, 2019 Equipment $ 345 $ 335 Leasehold improvements 39 77 Furniture and fixtures 99 95 Total property and equipment $ 483 507 Less: accumulated depreciation (342 ) (356 ) Property and equipment, net $ 141 $ 151 During the three months ended June 30, 2020 and 2019 , depreciation expense s w ere approximately $ 11,000 and $ 14,000 , respectively. During the six months ended June 30, 2020 and 2019 , depreciation expenses w ere approximately $ 23,000 and $ 28,000 , respectively.

INVESTMENTS

INVESTMENTS	6 Months Ended
	Jun. 30, 2020
Investments [Abstract]
INVESTMENTS	NOTE 5 — INVESTMENTS Equity securities— As of June 30, 2020 and December 31, 2019, the Company held 6,222,837 shares and 6,643,559 shares, respectively, of capital stock of Telcon RF Pharmaceutical, Inc., a Korean corporation (formerly, Telcon Inc. and herein “Telcon”), which were acquired in July 2017 for approximately $31.8 million. As of June 30, 2020, and December 31, 2019, the closing prices per Telecon share on the Korean Securities Dealers Automated Quotations (“KOSDAQ”) were approximately $4.34 and $4.20, respectively. Prior to December 2019, all shares of Telcon common stock were pledged to secure the Company’s obligations under the revised API agreement with Telcon. In December 2019, the API agreement was amended to permit the release of the Telcon shares from the pledge and to permit the Company to sell the shares in exchange for a portion of the net sale proceeds to be used to purchase a 10-year convertible bond of Telcon in the principal amount of approximately $31.8 million to be substituted for the Telcon shares pledged to Telcon to secure the Company’s obligations under the revised API agreement between the Company and Telcon. During the six months ended June 30, 2020, the Company sold 420,772 shares for $2.1 million. Refer to Note 6, 11 and 13 for more information regarding this arrangement. The Company measures all equity investments that do not result in consolidation and are not accounted for under the equity method, at fair value and recognizes any changes in such fair value in earnings. The Company uses quoted market prices to determine the fair value of equity securities with readily determinable fair values. For equity securities without readily determinable fair values, the Company has elected the measurement alternative under which the Company measures these investments at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. Management assesses each of these investments on an individual basis. Additionally, on a quarterly basis, management is required to make a qualitative assessment of whether the investment is impaired; however, the Company is not required to determine the fair value of these investments unless impairment indicators existed. When impairment indicators exist, the Company generally uses discounted cash flow analyses to determine the fair value. For the six months ended June 30, 2019, the Company recognized approximately $524,000 in impairment loss on equity securities without readily determinable fair values attributable to an investment in KPS Co., Ltd. As of June 30, 2020 and December 31, 2019, the carrying values of equity securities were included in the following line items in our consolidated balance sheets (in thousands): June 30, 2020 December 31, 2019 Fair Value with Changes Recognized in Income Fair Value with Changes Recognized in Income Marketable securities $ 27,007 $ 27,929 Total equity securities $ 27,007 $ 27,929 Net unrealized loss on marketable securities available-for-sale at June 30, 2020 and June 30, 2019 was approximately $0.8 million and approximately $16.5 million, respectively. Equity method investment – During 2018, the Company and Japan Industrial Partners, Inc., or JIP, formed EJ Holdings to acquire, own and operate an amino acids manufacturing facility in Ube, Japan. As part of the formation, the Company invested approximately $32,000 in exchange for 40% of EJ Holdings voting shares. JIP owns 60% of EJ Holdings voting shares. In October 2018, the Company entered into a loan agreement with EJ Holdings under which the Company made an unsecured loan to EJ Holdings in the amount of $13.6 million. The loan was valued at $13.9 million and $13.8 million as of June 30, 2020 and December 31, 2019, respectively. The loan proceeds were used by EJ Holdings to purchase the Ube facility in December 2019 and pay related taxes. The loan matures on September 30, 2028 and bears interest at the rate of 1% per annum payable annually. The parties also contemplated that the Ube facility will eventually supply the Company with the facility’s output of amino acids, that the operation of the facility will be principally for our benefit and, as such, that major decisions affecting EJ Holdings and the Ube facility will be made by EJ Holdings’ board of directors, a majority of which are representatives of JIP, in consultation with the Company. During the six months ended June 30, 2020, the Company had made additional EJ Holdings is engaged in phasing in the Ube facility, including obtaining FDA and other regulatory approvals for the manufacture of PGLG in accordance with cGMP. EJ Holdings has had no significant revenues since its inception, has depended on loans from the Company to acquire the Ube facility and fund its operations and will continue to be dependent on loans from us or other financing unless and until the Ube facility is activated and EJ Holdings can secure customers for its products. The Company has determined that EJ Holdings is a variable interest entity, or VIE, based upon the facts that the Company provided the loan financing to acquire the Ube facility and the EJ Holdings activities at the facility are principally for the Company’s benefit . JIP, however, owns 60% of EJ Holdings and is entitled to designate a majority of EJ Holdings’ board of directors and its Chief Executive Officer and outside auditors, and, as such, controls the management, business , and operations of EJ Holdings. Accordingly, the Company accounts for its variable interest in EJ Holdings under the equity method. The Company’s share of the losses reported by EJ Holdings are classified as net losses from equity method investment. The investment is evaluated for impairment annually and if facts and circumstances indicate that the carrying value may not be recoverable, an impairment charge would be recorded. The following table sets forth certain financial information of EJ Holdings for the three months ended and the six months ended June 30, 2020 and 2019 (in thousands). Three Months Ended June 30, Six Months Ended June 30, 2020 2019 2020 2019 (Unaudited) (Unaudited) (Unaudited) (Unaudited) REVENUES, NET $ 61 $ 57 $ 145 $ 114 GROSS PROFIT 61 57 145 114 NET LOSS $ (1,432 ) $ (1,147 ) $ (2,449 ) $ (1,124 )

SELECTED FINANCIAL STATEMENT _2

SELECTED FINANCIAL STATEMENT CAPTIONS - LIABILITIES	6 Months Ended
	Jun. 30, 2020
Payables And Accruals [Abstract]
SELECTED FINANCIAL STATEMENT CAPTIONS - LIABILITIES	NOTE 6 — SELECTED FINANCIAL STATEMENT CAPTIONS - LIABILITIES Accounts payable and accrued expenses consisted of the following at June 30, 2020 and December 31, 2019 (in thousands): June 30, 2020 December 31, 2019 Accounts payable: Clinical and regulatory expenses $ 311 $ 232 Professional fees 960 1,183 Selling expenses 798 1,303 Manufacturing costs 3,824 4,541 Other vendors 128 18 Total accounts payable 6,021 7,277 Accrued interest payable, related parties 246 42 Accrued interest payable 407 991 Accrued expenses: Payroll expenses 998 891 Government rebates and other rebates 1,943 1,355 Due to EJ Holdings 406 238 Other accrued expenses 356 704 Total accrued expenses 3,703 3,188 Total accounts payable and accrued expenses $ 10,377 $ 11,498 Other long-term liabilities consisted of the following at June 30, 2020 and December 31, 2019 (in thousands): June 30, 2020 December 31, 2019 Trade discount $ 26,422 $ 23,242 Unearned revenue 10,000 10,500 Other long-term liabilities 12 8 Total other long-term liabilities $ 36,434 $ 33,750 On June 12, 2017, the Company entered into an API Supply Agreement, as subsequently amended (as so amended, the “API agreement”), with Telcon pursuant to which Telcon advanced to the Company approximately $31.8 million as an advance trade discount in consideration of the Company’s agreement to purchase from Telcon the Company’s requirements for bulk containers of PGLG. The Company purchased $2.0 million and $2.3 million of PGLG from Telcon in the six months ended June 30, 2020 and June 30, 2019, respectively. As of June 30, 2020 and December 31, 2019, accounts payable to Telcon were $3.7 million.

NOTES PAYABLE

NOTES PAYABLE	6 Months Ended
	Jun. 30, 2020
Debt Disclosure [Abstract]
NOTES PAYABLE	NOTE 7 — NOTES PAYABLE Notes payable consisted of the following at June 30, 2020 and December 31, 2019 (in thousands): Year Issued Interest Rate Range Term of Notes Conversion Price Principal Outstanding June 30, 2020 Discount Amount June 30, 2020 Carrying Amount June 30, 2020 Shares Underlying June 30, 2020 Notes payable 2013 10% Due on demand — $ 928 $ — $ 928 — 2019 11% Due on demand - 6 months — 2,839 — 2,839 — 2020 1% - 11% Due on demand - 2 years — 992 — 992 — $ 4,759 $ — $ 4,759 — Current $ 4,271 $ — $ 4,271 — Non-current $ 488 $ — $ 488 — Notes payable - related parties 2016 10% Due on demand — $ 20 $ — $ 20 — 2019 10% Due on demand — 14 — 14 — $ 34 $ — $ 34 — Current $ 34 $ — $ 34 — Convertible debentures 2019 10% 18 months $2.00-$9.52 (a) $ 9,200 $ 1,606 $ 7,594 4,638,333 $ 9,200 $ 1,606 $ 7,594 4,638,333 Current $ 9,200 $ 1,606 $ 7,594 4,638,333 Convertible notes payable 2020 12% 3 years $ 10.00 (b) $ 3,150 $ — $ 3,150 — $ 3,150 $ — $ 3,150 — Non-current $ 3,150 $ — $ 3,150 — Total $ 17,143 $ 1,606 $ 15,537 4,638,333 Year Issued Interest Rate Range Term of Notes Conversion Price Principal Outstanding December 31, 2019 Discount Amount December 31, 2019 Carrying Amount December 31, 2019 Shares Underlying Notes December 31, 2019 Notes payable 2013 10% Due on demand — $ 920 $ — $ 920 — 2019 11% Due on demand - 6 months — 2,829 — 2,829 — $ 3,749 $ — $ 3,749 — Current 3,749 — 3,749 — Notes payable - related parties 2016 10% Due on demand — $ 20 $ — $ 20 — 2018 11% Due on demand — 159 — 159 — 2019 10% Due on demand — 14 — 14 — $ 193 $ — $ 193 — Current $ 193 $ — $ 193 — Convertible debentures 2019 10% 18 months $2.00-$9.52 (a) $ 10,200 $ 3,185 $ 7,015 1,080,415 $ 10,200 $ 3,185 $ 7,015 1,080,415 Current $ 10,200 $ 3,185 $ 7,015 1,080,415 Convertible notes payable 2018 10% 2 years $ 10.00 (b) $ 3,000 $ 5 $ 2,995 363,876 $ 3,000 $ 5 $ 2,995 363,876 Current $ 3,000 $ 5 $ 2,995 363,876 Total $ 17,142 $ 3,190 $ 13,952 1,444,291 (a) The notes are convertible to Emmaus Life Sciences, Inc. shares. (b) The notes are convertible to EMI Holding, Inc. shares. The weighted-average stated interest rate of notes payable was 10% as of June 30, 2020 and December 31, 2019. The weighted-average effective annual interest rate of notes payable as of June 30, 2020 and December 31, 2019 was 34% and 66%, respectively, after giving effect to discounts relating to the conversion feature, warrants and deferred financing cost in connection with these notes. As of June 30, 2020, future contractual principal payments due on notes payable were as follows: Year Ending 2020 (six months) $ 9,040 2021 4,732 2022 221 2023 3,150 Total $ 17,143 Immediately prior to the completion of the Merger, all but one of the convertible notes payable were converted into shares of EMI common stock at their respective conversion prices. Upon completion of the Merger, the conversion shares were exchanged for shares of the Company common stock in the same manner as other outstanding shares of common stock of EMI based on the Merger “exchange ratio.” The unconverted convertible note payable is convertible into shares of common stock of EMI at conversion price of $10.00 per share and included in convertible notes payable The Company estimates the total fair value of any beneficial conversion feature and any accompanying warrants in allocating the proceeds from the sale of convertible notes payable. The proceeds allocated to the beneficial conversion feature were determined by taking the estimated fair value of shares underlying the convertible notes less the fair value of the number of shares that would be issued if the conversion rate equaled the fair value of common stock as of the date of issuance. In situations where the notes included both a beneficial conversion feature and a warrant, the proceeds are allocated to the beneficial conversion feature and the warrants based on their relative fair values. The 10% Senior Secured Debentures of EMI make them convertible into shares of common stock of EMI and to provide for adjustments in the conversion shares issuable upon conversion of the Debentures and the conversion price in the event of a merger, reorganization and similar events. Accordingly, upon completion of the Merger the Amended and Restated 10% Senior Secured Convertible Debentures became convertible into shares of common stock of the Company and included in convertible notes payable. The conversion feature of the Amended and Restated 10% Senior Secured Convertible Debentures was separately accounted for at fair value as derivative liabilities under guidance in ASC 815 that is remeasured at fair value on a recurring basis using Level 3 inputs, with any changes in the fair value of the conversion feature liabilities recorded in earnings. The following table sets forth the fair value of the conversion feature liabilities as of June 30, 2020 and December 31, 2019 (in thousands): Six Months Ended Year ended Conversion feature liabilities - Amended and Restated 10% Senior Convertible Debentures June 30, 2020 December 31, 2019 Balance, beginning of period $ 1 $ — Fair value at issuance date — 132 Fair value at debt modification date 118 — Change in fair value included in the statement of comprehensive income (loss) (6 ) (131 ) Balance, end of period $ 113 $ 1 The value and any change in fair value of conversion feature liabilities are determined using a binomial lattice model. The model produces an estimated fair value based on changes in the price of the underlying common stock over successive periods of time. The fair values as of June 30, 2020, the February 21, 2020 modification date and December 31, 2019 were based upon following assumptions: June 30, 2020 February 21, 2020 (Modification date) December 31, 2019 Stock price $ 1.67 $ 1.89 $ 1.97 Conversion price $ 2.00 $ 3.00 $ 9.52 Selected yield 15.73 % 19.12 % 16.77 % Expected volatility (peer group) 100 % 65 % 50 % Expected life (in years) 0.81 1.16 0.81 Expected dividend yield — — — Risk‑free rate Term structure Term structure Term structure See Note 13 for information regarding the prepayment of the Amended and Restated 10% Senior Secured Convertible Debentures. The Company is party to a revolving line of credit agreement with Dr. Niihara, the Company’s Chairman and Chief Executive Officer. Under the agreement, at the Company’s request from time to time, Dr. Niihara may, but is not obligated to, loan or re-loan to the Company up to $1,000,000. Outstanding amounts under the agreement are due and payable upon demand and bear interest, payable monthly, at a variable annual rate equal to the Prime Rate in effect from time to time plus 3%. In addition to the payment of interest, the Company is obligated to pay Dr. Niihara a “tax gross-up” intended to make him whole for federal and state income taxes payable by him with respect to interest paid to him in the previous year. The outstanding balances under the revolving line of credit agreement of $600,000 as of June 30, 2020 and December 31, 2019 were reflected in revolving line of credit, related party on the Consolidated Balance Sheet. With the tax-gross up, the effective annual interest rate on the outstanding balance as of June 30, 2020 was 10.4%. The revolving line of credit agreement will expire on November 22, 2022. Refer to Note 12 for more information regarding this arrangement. On May 8, 2020, the Company received a loan in the amount of $ 797,840 under the Small Business Administration Paycheck Protection Program (“PPP”). The PPP, established as part of the Coronavirus Aid, Relief and Economic Security Act (“CARES Act”), provides for loans to qualifying businesses for amounts up to 2.5 times of the average monthly payroll expenses of the qualifying business. The loan, which is in the form of a Promissory Note dated April 29, 2020, matures on April 29, 2022 and bears interest at a rate of 1% per annum, payable monthly commencing on December 8, 2020 unless the PPP loan is forgiven prior to the date of the first monthly payment or the loan forgiveness process has commenced. The Note may be prepaid by the Company at any time prior to maturity with no prepayment penalties. The loan and accrued interest are forgivable after a specific period as long as the Company uses the loan proceeds for eligible purposes, including payroll, benefits, rent and utilities, and maintains its payroll levels. The Company has applied for PPP loan forgiveness on October 30, 2020. There is no assurance that the loan will be forgiven. The amount of loan forgiveness would be reduced if the Company were to terminate employees or reduce salaries during such period. The PPP loan was included in notes payable on the Condensed Consolidated Balance Sheet.

STOCKHOLDERS' DEFICIT

STOCKHOLDERS' DEFICIT	6 Months Ended
	Jun. 30, 2020
Stockholders Equity Note [Abstract]
STOCKHOLDERS' DEFICIT	NOTE 8 — STOCKHOLDERS’ DEFICIT Purchase Agreement with GPB —On December 29, 2017, the Company entered into the Purchase Agreement with GPB Debt Holdings II, LLC (“GPB”), pursuant to which the Company issued to GPB a $13 million senior secured convertible promissory note (the “GPB Note”) for an aggregate purchase price of $12.5 million, reflecting a 4.0% original issue discount. In connection with the issuance of GPB Note, the Company issued to GPB a warrant (the “GPB Warrant”) to purchase up to 240,764 of common stock at an exercise price of $10.80 per share, with customary adjustments for stock splits, stock dividends and other recapitalization events. The GPB Warrant became exercisable six months after issuance and has a term of five years from the initial exercise date. The Company determined that under ASC 815-40, GPB Warrant should be separately recognized at fair value as a liability. The warrant liability is remeasured at fair value on a recurring basis using Level 3 inputs and any change in the fair value of the liability is recorded in earnings. The following table presents the change in fair value of the GPB Warrant as of June 30, 2020 and December 31, 2019 (in thousands): Six Months Ended Year Ended June 30, 2020 December 31, 2019 Warrant Liability - GPB Warrants Warrants Balance, beginning of period $ 38 $ 1,399 Change in fair value included in the statement of comprehensive income (loss) 88 (1,361 ) Balance, end of period $ 126 $ 38 The fair value of the warrant derivative liability was determined using the Black-Scholes option pricing model. The value as of the dates set forth in the table above was based on upon following assumptions: June 30, 2020 December 31, 2019 Stock price $ 1.67 $ 1.97 Risk‑free interest rate 0.18 % 1.64 % Expected volatility (peer group) 106.00 % 60.00 % Expected life (in years) 3.00 3.50 Expected dividend yield 0.00 % 0.00 % Number outstanding 252,802 252,802 Purchase Agreement with Holders of 10% Senior Secured Debentures —In October 2018, EMI sold and issued $12.2 million principal amount of 10% Senior Secured Debentures and common stock purchase warrants to purchase an aggregate of up to 1,220,000 shares of EMI common stock to a limited number of accredited investors. EMI’s obligations under the Debentures were secured by a security interest in substantially all EMI assets and guaranteed by EMI’s U.S. subsidiaries. The net proceeds of the sale of the debentures and warrants were used to fund EMI’s original $13.2 million loan to EJ Holdings in October 2018 reflected on the Company’s consolidated balance sheets. As described in Note 7 above, the Debentures were amended and restated in their entirety in conjunction with the Merger. The common stock purchase warrants issued in conjunction with the original Debentures also were amended and restated in their entirety in conjunction with the Merger. The Amended and Restated 10% Senior Secured Convertible Debentures issued in conjunction with the Merger were convertible at the option of each holder into shares of EMI common stock immediately prior to the Merger at a conversion price of $10.00 a share, subject to adjustment for stock splits, merger reorganizations and other customary events. The related amended and restated warrants were exercisable immediately prior to the Merger for an aggregate of 1,460,000 shares of EMI common stock at an initial exercise price of $10.00 per share. The exercise price of the warrants was subject to reduction in connection with a “going public event” such as the Merger based upon the “VWAP” (i.e., volume-weighted average trading price) of the Company common stock at the time of the Merger. Upon completion of the Merger, the amended and restated warrants became exercisable for shares of the Company common stock and Pursuant to the terms of a securities amendment agreement entered into on February 21, 2020, the Amended and Restated were once again amended and restated in their entirety to extend their maturity date to April 21, 2021 and reduce the conversion price thereof to $3.00 per share from $9.52 per share. The related amended and restate common stock purchase warrants also were amended and restated again to reduce the exercise price thereof to $3.00 per share from $5.87 per share. The newly Amended and Restated and related newly amended and restated warrants provide for so-called full-ratchet anti-dilution adjustments in the event we sell or issue shares of common stock or common stock equivalents at an effective price per share less than the conversion price of the debentures or the exercise price of the warrants, subject to certain exceptions. The conversion price of the Amended and Restated Debentures and the exercise price of the related amended and restated warrants were reduced to $2.00 a share as a result of the Company’s sale of 100,000 shares of common stock at a price of $2.00 a share under the Purchase Agreement with Lincoln Park Capital LLC described below and were subsequently reduced again as described in Note 13. The Company evaluated the common stock purchase warrants issued in connection with the original issuance of the 10% Senior Secured Debentures in October 2018 under ASC 815-40 and concluded that the warrants should be separately recognized at fair value as a liability. The liability is remeasured at fair value on a recurring basis using Level 3 input and any changes in fair value is recorded in earnings. In 2019, the D ebentures were amended and restated to be convertible into common stock of EMI immediately prior to completion of the Merger, which resulted in the related warrants being reclassified to equity. Purchase agreement with Holder of a Convertible Promissory Notes - On June 15, 2020, the holder of a convertible promissory note in the principal amount of $3,150,000 agreed to an extension of the maturity date to June 15, 2023 in exchange for an increase in the interest rate on the note from 11% to 12% per annum. In conjunction with this amendment, the Company issued to the holder of note five-year contingent common stock purchase warrants to purchase a total of up to 1,250,000 shares of the Company common stock at an exercise price of $2.05 a share, subject to certain conditions. Under ASC 815-40, the Company concluded that the warrants issued to the note holder should be recognized at fair value as a liability. The warrant liability is remeasured at fair value on a recurring basis using Level 3 input and any changes in the fair value of liability is recorded in earnings. The following table presents the change in fair value of the warrants as of June 30, 2020 (in thousands): Six Months Ended Warrants Derivative Liabilities - convertible promissory note June 30, 2020 Balance, beginning of period $ — Fair value at issuance date 1,425 Change in fair value included in the statement of comprehensive loss (12 ) Balance, end of period $ 1,413 The fair value of the warrant derivative liabilities was determined using the Black-Scholes Merton model and was based upon following assumptions: June 30, 2020 June 15, 2020 (modification date) Exercise price $ 2.05 $ 2.05 Stock price $ 1.67 $ 1.68 Risk‑free interest rate 0.29 % 0.33 % Expected volatility (peer group) 94.00 % 94.00 % Expected life (in years) 4.96 5.00 Expected dividend yield 0.00 % 0.00 % Warrant shares 1,250,000 1,250,000 A summary of outstanding warrants as of June 30, 2020 and December 31, 2019 is presented below: June 30, 2020 December 31, 2019 Warrants outstanding, beginning of period 4,931,099 3,436,431 Assumed as part of Merger — 1,044,939 Granted 1,250,000 500,729 Exercised — (51,000 ) Cancelled, forfeited or expired (115,953 ) — Warrants outstanding, end of period 6,065,146 4,931,099 A summary of outstanding warrants by year issued and exercise price as of June 30, 2020 is presented below: Outstanding Exercisable Year issued and Exercise Price Number of Warrants Issued Weighted-Average Remaining Contractual Life (Years) Weighted-Average Exercise Price Total Weighted-Average Exercise Price Prior to January 1, 2019 $2.00-$10.76 3,439,007 2.12 $ 4.38 3,439,007 $ 4.38 Prior to Jan 1, 2019 Total 3,439,007 3,439,007 At December 31, 2019 $ 6.12 32,391 3.91 $ 6.12 32,391 $ 6.12 $ 12.00 76,575 3.23 $ 12.00 76,575 $ 12.00 $ 14.04 174,999 2.75 $ 14.04 174,999 $ 14.04 $ 31.50 737,975 2.07 $ 31.50 737,975 $ 31.50 $ 36.24 22,333 2.07 $ 36.24 22,333 $ 36.24 $ 60.00 666 0.50 $ 60.00 666 $ 60.00 $ 2.00 256,200 3.21 $ 2.00 256,200 $ 2.00 $ 7.68 75,000 4.05 $ 7.68 75,000 $ 7.68 2019 Total 1,376,139 1,376,139 At June 30, 2020 $ 2.05 1,250,000 4.96 $ 2.05 — $ — Total 6,065,146 4,815,146 Summary of Plans – Upon completion of the Merger, the EMI Amended and Restated 2011 Stock Incentive Plan was assumed by the Company. The 2011 Stock Incentive Plan permits grants of incentive stock options to employees, including executive officers, and other share-based awards such as stock appreciation rights, restricted stock, stock units, stock bonus and unrestricted stock awards to employees, directors, and consultants for up to 9,000,000 shares of common stock . Options granted under the 2011 Stock Incentive Plan expire ten years after grant. Options granted to directors vest in equal quarterly installments and all other option grants vest over a minimum period of three years, in each case, subject to continuous service with the Company. Each stock option outstanding under the 2011 Stock Incentive Plan at the effective time of the Merger was automatically converted into a stock option to purchase a number of shares of the Company’s common stock and at an exercise price calculated based on the exchange ratio in the Merger. The Company also has an Amended and Restated 2012 Omnibus Incentive Compensation Plan under which the Company may grant stock options and other stock awards to selected employees including officers, and to non-employee consultants and non-employee directors. All outstanding stock award under the 2012 Omnibus Incentive Compensation Plan were fully vested prior to the Merger and the Company intends not to make any further awards thereunder. Stock options —During the six months ended June 30, 2020, the Company granted options to purchase 90,000 shares of common stock. During the year ended December 31, 2019, the Company granted stock options to purchase 50,000 shares of Company common stock. All the options are exercisable for ten years from the date of grant and will vest and become exercisable with respect to the underlying shares as follows: as to one‑third two‑thirds . Management has valued stock options at their date of grant utilizing the Black‑Scholes‑Merton Option pricing model. The fair value of the underlying shares was determined by the market value of stock of similar companies and recent arm’s length transactions involving the sale of the Company’s common stock. Prior the Merger, the Company lacked company-specific historical and implied volatility information for its common stock. Therefore, the expected volatility was calculated using the historical volatility of a comparative public traded companies. The following table presents the assumptions used on recent dates on which options were granted by the Company. June 29, 2020 June 19, 2019 Stock Price $ 1.67 $ 10.30 Exercise Price $ 2.05 $ 10.30 Term 5.5-6 years 6 years Risk-Free Rate 0.28% - 0.38% 1.83% Dividend Yield — — Volatility 78.91%-80.49% 67.16 % A summary of outstanding stock options as of June 30, 2020 and December 31, 2019 is presented below. June 30, 2020 December 31, 2019 Number of Options Weighted‑ Average Exercise Price Number of Options Weighted‑ Average Exercise Price Options outstanding, beginning of period 7,245,350 $ 4.68 6,642,200 $ 4.40 Granted or deemed granted 90,000 $ 2.05 636,683 (a) $ 10.10 Exercised — $ — (167 ) $ 5.00 Cancelled, forfeited and expired (142,818 ) $ 5.08 (33,366 ) $ 11.29 Options outstanding, end of period 7,192,532 $ 4.63 7,245,350 $ 4.68 Options exercisable, end of period 6,978,869 $ 4.58 7,001,680 $ 4.47 Options available for future grant 2,302,475 2,167,150 (a) Upon the Merger, the exercise prices of outstanding EMI options and number of shares of the Company common stock underlying the options were adjusted based upon the exchange ratio in the Merger. During the three months ended June 30, 2020 and June 30, 2019, the Company recognized $0.2 million and $0.4 million, respectively, of share-based compensation expense. During the six months ended June 30, 2020 and June 30, 2019, the Company recognized approximately $0.4 million and $1.0 million, respectively, of share-based compensation expense. As of June 30, 2020, there was approximately $1.1 million of total unrecognized compensation expense related to unvested share-based compensation which is expected to be recognized over the weighted-average remaining vesting period of 1.4 years. Purchase Agreement with Lincoln Park Capital Fund, LLC — On February 28, 2020, the Company entered into a Purchase Agreement with Lincoln Park Capital Fund, LLC (“LPC”), pursuant to which the Company may elect to sell to LPC up to $25,000,000 in shares of its common stock, subject to certain limitations and conditions set forth in the Purchase Agreement, including 100,000 initial shares that the Company sold to LPC at a price of $2.00 per share. Pursuant to the Purchase Agreement, on any business day over the 36-month term of the Purchase Agreement the Company has the right at its discretion and subject to certain conditions to direct LPC to purchase up to 20,000 shares of common stock, which amount is subject to increase under certain circumstances based upon increases in the market price of its common stock. The purchase price of the common stock will be based upon the prevailing market price of common stock at the time of the purchase without any fixed discount. In addition, the Company may direct LPC to purchase additional amounts as accelerated purchases and additional accelerated purchases under certain circumstances. Apart from the initial sale of shares described above, the Company is not obliged to sell any shares of common stock pursuant to the Purchase Agreement, and the Company will control the timing and amount of any such sales, but in no event will LPC be required to purchase more than $ 1,000,000 of common stock in any single regular purchase (excluding accelerated or additional accelerated purchases). Concurrently with the execution of the Purchase Agreement on February 28, 2020, the Company entered into a Registration Rights Agreement pursuant to which the Company agreed to file a prospectus supplement pursuant to Rule 424(b) relating to the sale shares of common stock to be issued and sold to LPC under the Purchase Agreement under our effective shelf registration statement or a new registration statement and to use our reasonable best efforts to keep such registration statement effective during the term of the Purchase Agreement. The Purchase Agreement contains customary representations, warranties, indemnification rights and other obligations and agreements of the company and LPC. There are no limitations and conditions to completing future transactions other than a prohibition against entering into a “Variable Rate Transaction” as defined in the Purchase Agreement. There is no upper limit on the price per share that LPC could be obligated to pay for common stock, but shares will only be sold to LPC on a day the Company’s closing price is less than the floor price as set forth in the Purchase Agreement and if the sale of the shares would not result in LPC and its affiliates having beneficial ownership of more than 4.99% of the Company’s total outstanding shares of common stock. The Company has the right to terminate the Purchase Agreement at any time, at no cost or penalty. As consideration for LPC’s commitments under the Purchase Agreement, the Company issued to LPC 415,743 shares of common stock, which valued at $750,000, recorded as an addition to equity for common stock and reduction for cost of capital raised. As of the date of filing of this Quarterly Report, the Company was out of compliance with certain terms and conditions of the Purchase Agreement and unable to utilize the Purchase Agreement. The Company may seek to bring itself into compliance or seek an appropriate waiver from LPC to regain the ability to utilize the Purchase Agreement, but there can be no assurance when or whether the Company may be able to do so. If the Company is able to utilize the Purchase Agreement, whether or to what extent the Company sells shares of common stock to LPC under the Purchase Agreement will depend on a variety of factors to be determined by the company from time to time, including, among others, its net revenue and other results of operations, its working capital and other funding needs, the prevailing market prices of the Company’s common stock and the availability of other sources of funding.

INCOME TAX

INCOME TAX	6 Months Ended
	Jun. 30, 2020
Income Tax Disclosure [Abstract]
INCOME TAX	NOTE 9 — INCOME TAX The quarterly provision for or benefit from income taxes is computed at an estimated annual effective tax rate to the year-to-date pre-tax income (loss). For the three months and six months ended June 30, 2020, the Company recorded an income tax benefit of $0.5 million and $0.2 million, respectively. For the three months and six months ended June 30, 2019, the Company

LEASES

LEASES	6 Months Ended
	Jun. 30, 2020
Leases [Abstract]
LEASES	NOTE 10 — LEASES Operating leases — The Company leases its office space under operating leases with unrelated entities. The Company leased 21,293 square feet of office space for our headquarters in Torrance, California, at a base rental of $78,543 per month, which lease will expire on September 30, 2026. The Company also leased an additional 1,850 square feet office space in New York, New York, at a base rent of $8,479, which leases will expire on January 31, 2023. In addition, the Company leased 1,322 square feet of office space in Tokyo, Japan, at a base rent of approximately $3,000, which the lease will expire on September 30, 2020. The rent expense during the three months ended June 30, 2020 and 2019 amounted to approximately $298,000 and $219,000, respectively, and during the six months ended June 30, 2020 and 2019 amounted approximately $609,000 and $419,000, respectively. Future minimum lease payments under the lease agreements were as follows as of June 30, 2020 (in thousands): Amount 2020 (six months) $ 587 2021 1,106 2022 1,138 2023 1,050 2024 and thereafter 2,984 Total lease payments 6,865 Less: Interest 2,040 Present value of lease liabilities $ 4,825 The Company adopted Accounting Standard Update (“ASU”) 2016-02 – Lease (“Topic 842”) on January 1, 2019 using a modified retrospective approach and elected the transition method and the practical expedients permitted under the transition guidance, which allowed to carryforward the historical lease classification and our assessment on whether a contract is or contains a lease. The Company also elected to combine lease and non-lease components, such as common area maintenance charges, as single lease and elected to use the short-term lease exception permitted by the standard As a result of the adoption of Topic 842 on January 1, 2019, the Company recorded a $3.0 million in operating right-of-use asset and $3.3 million in lease liability and derecognized $287,000 of deferred rent as of the adoption date. These were calculated using the present value of the Company’s remaining lease payments using an estimated incremental borrowing rate. The Company also recorded a $29,000 cumulative effect increased on our accumulated deficit as of January 1, 2019. As of June 30, 2020, the Company had an operating lease right-of-use asset of $4.3 million and lease liability of $4.8 million in the balance sheet. The weighted average remaining term of the Company’s leases as of June 30, 2020 was 6.0 years and the weighted-average discount rate was 12.4%.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	6 Months Ended
	Jun. 30, 2020
Commitments And Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 11 — COMMITMENTS AND CONTINGENCIES API Supply Agreement — On June 12, 2017, the Company entered into an API Supply Agreement (the “API agreement”) with Telcon pursuant to which Telcon paid the Company approximately $31.8 million in consideration of the right to supply 25% of the Company’s requirements for bulk containers of PGLG for a fifteen-year (the “revised API agreement”) . The revised API agreement is effective for a term of five years and will renew automatically for 10 successive one-year renewal periods, except as either party may determine. In the revised API agreement, the Company has agreed to purchase a total of 940,000 kilograms of PGLG at $50 per kilogram, or a total of $47.0 million, over the term of the agreement. In September 2018, the Company entered into an agreement with Ajinomoto Health and Nutrition North America, Inc. (“Ajinomoto”), the producer of the PGLG, and Telcon to facilitate Telcon’s purchase of PGLG from Ajinomoto for resale to the Company under the revised API agreement. On June 16, 2019, the Company entered into an agreement with Telcon to adjust the price payable to Telcon under the revised API agreement from $50 per kilogram of PGLG purchased from Telcon is recorded in inventory at net realizable value and the excess purchase price is recorded against deferred trade discount.

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	6 Months Ended
	Jun. 30, 2020
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	NOTE 12 — RELATED PARTY TRANSACTIONS The following table sets forth information relating to our loans from related persons outstanding as of June 30, 2020 and interest paid during the six months ended June 30, 2020 (in thousands): Class Lender Interest Rate Date of Loan Term of Loan Principal Amount Outstanding at June 30, 2020 Amount of Interest Paid Current, Promissory note payable to related parties: Lan T. Tran (2) 10% 4/29/2016 Due on Demand $ 20 $ — Lan T. Tran (2) 11% 2/10/2018 Due on Demand — 35 Lan T. Tran (2) 10% 2/9/2019 Due on Demand 14 — Subtotal 34 35 Revolving line of credit Yutaka Niihara (2) 5.25% 12/27/2019 Due on Demand 600 18 Subtotal 600 18 Total $ 634 $ 53 The following table sets forth information relating to our loans from related persons outstanding at any time during the year ended December 31, 2019: Class Lender Interest Rate Date of Loan Term of Loan Principal Amount Outstanding at December 31, 2019 Highest Principal Outstanding Amount of Principal Repaid or Converted into Stock Amount of Interest Paid Conversion Rate Current, Promissory note payable to related parties: Lan T. Tran (2) 10% 4/29/2016 Due on Demand $ 20 $ 20 $ — $ — — Hope International Hospice, Inc. (1) 10% 6/3/2016 Due on Demand — 250 250 78 — Lan T. Tran (2) 10% 2/9/2017 Due on Demand — 12 — 2 — Yutaka Niihara (2)(3) 10% 9/14/2017 Due on Demand — 904 27 2 — Lan T. Tran (2) 11% 2/10/2018 Due on Demand 159 159 — — — Lan T. Tran (2) 10% 2/9/2019 Due on Demand 14 14 — — — Subtotal 193 1,359 277 82 Current, Convertible notes payable to related parties: Yasushi Nagasaki (2) 10% 6/29/2012 Due on Demand — 200 200 56 $ 3.30 Yutaka & Soomi Niihara (2)(3) 10% 11/16/2015 2 years — 200 200 73 $ 4.50 Wei Peu Zen (3) 10% 11/6/2017 2 years — 5,000 5,000 597 $ 10.00 Profit Preview International Group, Ltd. (4) 10% 2/1/2018 2 years — 4,037 4,037 385 $ 10.00 Profit Preview International Group, Ltd. (4) 10% 3/21/2018 2 years — 5,363 5,363 442 $ 10.00 Subtotal — 14,800 14,800 1,553 Revolving line of credit Yutaka Niihara (2) 5% 12/27/2019 Due on Demand 600 600 — — Subtotal 600 600 — — Total $ 793 $ 16,759 $ 15,077 $ 1,635 ( 1) Dr. Niihara, a Director and the Chairman, and Chief Executive Officer of the Company, is also a director and the Chief Executive Officer of Hope International Hospice, Inc. (2) Officer. (3) Director. (4) Mr. Zen, a Director of the Company, is the sole owner of Profit Preview International Group, Ltd. See Note 7 for a discussion of the Company’s revolving line of credit agreement with Dr. Niihara. See Notes 6 and 11 for a discussion of the Company’s distribution and supply agreements with Telcon, which holds 4,147,491 shares of the Company common stock, or approximately 8.6% of the common stock outstanding as of June 30, 2020. As of June 30, 2020, the Company held

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	6 Months Ended
	Jun. 30, 2020
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 13 — SUBSEQUENT EVENTS On September 22, 2020, the Company and EMI entered into a securities amendment agreement (the “September 2020 Amendment”) with the holders of our outstanding 10% Senior Secured Convertible Debentures described above. The September 2020 Amendment amended in certain respects the securities purchase agreement among EMI and the Debenture holders originally entered into on September 8, 2018, as amended by the February 2020 Amendment, and provides that the Debentures are to be amended in certain respects as set forth in the form of Allonge Amendment No. 1 to the debentures included in the September 2020 Agreement (the “Allonge”). Pursuant to the Allonge, the aggregate monthly redemption payments under the Debentures were reduced to $500,000 from $1,000,000 in principal amount and the maturity date of the Debentures was extended from April 21, 2021 to August 31, 2021. The monthly redemption payments resumed in September 2020 and will continue on the first day of each month thereafter commencing October 1, 2020. The remaining principal balance of the Debentures will be due and payable upon maturity, subject to mandatory prepayment in connection with certain “Capital Events” as defined. In consideration of the Debenture holder’s financial accommodations to the Company, the Company issued to the holders, pro rata based upon the relative principal amounts of their Debentures, five-year In October 2018, the Company granted to T.R. Winston and its affiliates for services relating to the September 2020 Amendment common stock purchase warrants to purchase up to 75,000 shares of the Company common stock at an exercise price of $2.10 a share and otherwise on terms identical to the warrants issued to the debenture holders described above. In March 2021, the conversion price of the Debentures, and the exercise price of the these and the other warrants related to the Debentures was reduced to $1.54 in connection with our issuance of shares of common stock to Kainos Medicine, Inc. referred to below in this Note 13. On September 28, 2020, the Company entered into a convertible bond purchase agreement with Telcon pursuant to which it purchased The Telcon convertible bond matures on October 16, 2030 and bears interest at the rate of 2.1% a year, payable quarterly. Beginning on October 16, 2021, the holder of the convertible bond will be entitled on a quarterly basis to call for early redemption of all or any portion of the principal amount of the convertible bond. To the extent not previously redeemed, the principal amount of the bond will be due upon maturity. The convertible bond is convertible at the holder’s option at any time and from time to time into common shares of Telcon at an initial conversion price of approximately $8.00 per share. The conversion price is subject to antidilution adjustments in the event of the issuance of Telcon shares or share equivalents at a price below the market price of Telcon shares, a merger or similar reorganization of Telcon or a stock split, reverse stock split, stock dividend or similar event. In connection with the purchase of the convertible bond, the Company entered into a call option agreement dated September 28, 2020 with Telcon pursuant to which Telcon or its designee is entitled to repurchase, at par, up to 50% in principal amount of the convertible bond commencing October 16, 2021 and prior to maturity. If the Company transfers the convertible bond, it will be obliged under the call option agreement to see to it that the transferee is bound by such call option. On October 28, 2020, the Company entered into a loan agreement with EJ Holdings pursuant to which it agreed to loan to EJ Holdings a total of approximately $6.5 million, in monthly installments through March 2021, including approximately $4.0 million, loaned through December 31, 2020. The loans will be unsecured general obligations of EJ Holdings, will bear interest at a nominal annual rate payable on September 30 of each year beginning in 2021 and will be due and payable in a lump sum at maturity on September 30, 2028. The proceeds of the loans will be used by EJ Holdings to fund its activities and operations at its Ube facility as described under “Equity method investment” in Note 5 above. On February 9, 2021, the Company entered into a securities purchase agreement with an effective date of February 8, 2021 pursuant to which the Company agreed to sell and issue to the purchasers thereunder in a private placement pursuant to Rule 4(a)(2) of the Securities Act of 1933, as amended, and Regulation D thereunder a total of up to $17 million in principal amount of convertible promissory notes of the Company for a purchase price equal to the principal amount thereof. As of April 5, 2021, the Company had sold approximately $14.5 million of the convertible promissory notes. Of the net proceeds from the sale of the convertible promissory notes, $6.2 million was used to prepay the outstanding Amended and Restated 10% Senior Secured Convertible Debentures as described above. Commencing one year from the original issue date, the convertible promissory notes will be convertible at the option of the holder into shares of the Company common stock at an initial conversion price of $1.48 per share, which equaled the “Average VWAP” (as defined) of our common stock on the effective date. The initial conversion price will be adjusted as of the end of each three-month period following the original issue date, commencing May 31, 2021, to equal the Average VWAP as of the end of such three-month period if such Average VWAP is less than the then-conversion price. The conversion price will be subject to further adjustment in the event of a stock split, reverse stock split or certain other events specified in the convertible promissory notes. The convertible promissory notes bear interest at the rate of 2% per annum payable semi-annually on the last business day of August and January of each year and will mature on the 3rd anniversary of the original issue date. The convertible promissory notes will become prepayable in whole or in part at the election of the holders on or after February 28, 2022 if our common shall not have been approved for listing on the NYSE American, the Nasdaq Capital Market or other “Trading Market” (as defined). The Company will be entitled to prepay up to 50% of the principal amount of the convertible promissory notes at any time after the first anniversary and on or before the second anniversary of the original issue date for a prepayment amount equal to the principal amount being prepaid, accrued and unpaid interest thereon and a prepayment premium equal to 50% of such principal amount. The convertible promissory notes are general, unsecured obligations of the Company. Effective February 22, 2021, the Company’s subsidiary, Emmaus Medical, Inc., or Emmaus Medical, entered into a purchase and sale agreement with Prestige Capital Finance, LLC, or Prestige Capital, pursuant to which Emmaus Medical may offer and sell to Prestige Capital from time to time eligible accounts receivable in exchange for Prestige Capital’s down payment, or advance, to Emmaus Medical of 70% (subject to increase to 75%) of the face amount of the accounts receivable, subject to a $7,500,000 cap on advances at any time. The balance of the face amount of the accounts receivable will be reserved by Prestige Capital and paid to Emmaus Medical, less discount fees of Prestige Capital ranging from 2.25% to 7.25% of the face amount, as and when Prestige Capital collects the entire face amount of the accounts receivable. Emmaus Medical’s obligations to Prestige Capital under the purchase and sale agreement are secured by a security interest in the accounts receivable and all or substantially all other assets of Emmaus Medical. In connection with the purchase and sale agreement, the Company agreed to guarantee Emmaus Medical’s obligations under the purchase and sale agreement. The Company’s obligations under the guarantee are unsecured.

SUMMARY OF SIGNIFICANT ACCOUN_2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	6 Months Ended
	Jun. 30, 2020
Accounting Policies [Abstract]
Organization and Nature of Operations	Organization and Nature of Operations The Company is a commercial-stage biopharmaceutical company engaged in the discovery, development, marketing and sales of innovative treatments and therapies primarily for rare and orphan diseases. On July 17, 2019, we completed a merger transaction with EMI Holding, Inc., formerly known as Emmaus Life Sciences, Inc. (“EMI”), into a subsidiary of the Company (the “Merger”), with EMI surviving the Merger as a wholly owned subsidiary. Immediately after completion of the Merger, we changed our name to “Emmaus Life Sciences, Inc.” The Merger was treated as a reverse recapitalization under the acquisition method of accounting in accordance with accounting principles generally accepted in the U.S. For accounting purposed, EMI was considered to have acquired us. The Merger is intended to qualify as a tax-free reorganization for U.S. federal income tax purposes. In connection with and prior to the Merger, we contributed and transferred to Telemynd, Inc. (“Telemynd”), a newly formed, wholly owned subsidiary of the Company, all or substantially all our historical business, assets and liabilities and our board of directors declared a stock dividend of one share of the Telemynd common stock held by the Company for each outstanding share of our common stock after giving effect to a 1-for-6 reverse stock split of our outstanding shares of common stock. As a result of the spin-off and the Merger, our ongoing business became EMI’s business, which is that of a commercial-stage biopharmaceutical company focused on the development, marketing and sale of innovative treatments and therapies, including those in the rare and orphan disease categories.
Principles of consolidation	Principles of consolidation —The consolidated financial statements include the accounts of the Company, EMI and EMI’s wholly‑owned subsidiary, Emmaus Medical, Inc., and Emmaus Medical, Inc.’s wholly‑owned subsidiaries. All significant intercompany transactions have been eliminated. The preparation of the consolidated financial statements requires the use of management estimates that affect the reported amounts of assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses for the reported period. Actual results could differ materially from those estimates.
Restatement of Prior Period Amounts	Restatement of Prior Period Amounts — In connection with the preparation of our December 31, 2019 consolidated financial statements, we identified the following material errors in our condensed consolidated financial statements as of and for the three months and six months ended June 30, 2019. 1. The misclassification as equity of warrants issued by EMI in October of 2018, which warrants should have been accounted for as liabilities based upon fair value; and 2. The erroneous consolidation as a variable interest entity, or VIE, of EMI’s interest in EJ Holdings, Inc., which should have been accounted for based upon the equity method. 3. The misstatement of the fair value of cashless exercise warrants originally recorded in the Consolidated Statements of Operations and Comprehensive Loss, which fair value should have been recorded in additional paid-in capital in the Consolidated Balance Sheets. 4. In addition to the errors described above, the restated financial statements also include adjustments to correct certain immaterial errors identified during the audit of the Company’s financial statements for the year ended December 31, 2019. EMMAUS LIFE SCIENCES, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands, except share and per share amounts) (Unaudited) As of June 30, 2019 Previously Reported Adjustment Restated ASSETS CURRENT ASSETS Cash and cash equivalents $ 15,169 $ (12,222 ) (a) $ 2,947 Accounts receivable, net 1,981 301 (c) 2,282 Inventories, net 5,906 — 5,906 Investment in marketable securities 32,890 — 32,890 Prepaid expenses and other current assets 703 (107 ) (a), (c) 596 Total current assets 56,649 (12,028 ) 44,621 Property and equipment, net 145 — 145 Equity method investment — 13,366 (a) 13,366 Right of use assets 4,285 — 4,285 Deposits and other assets 412 — 412 Total other assets 4,697 13,366 18,063 Total assets $ 61,491 $ 1,338 $ 62,829 LIABILITIES AND STOCKHOLDERS’ DEFICIT CURRENT LIABILITIES Accounts payable and accrued expenses $ 11,455 $ 62 (a), (c) $ 11,517 Operating lease liabilities, current portion 857 — 857 Other current liabilities 5,259 2 (c) 5,261 Warrant derivative liabilities — 9,023 (b), (c) 9,023 Notes payable, net of discount 11,163 91 (b) 11,254 Notes payable to related parties 470 — 470 Convertible notes payable, net of discount 13,867 — 13,867 Convertible notes payable to related parties, net of discount 14,180 — 14,180 Total current liabilities 57,251 9,178 66,429 Operating lease liabilities, less current portion 3,781 — 3,781 Other long-term liabilities 35,330 — 35,330 Warrant derivative liabilities 1,200 (1,200 ) (c) — Notes payable, net of discount, less current portion 703 (703 ) (b) — Convertible notes payable, net of discount, less current portion 450 — 450 Total liabilities 98,715 7,275 105,990 STOCKHOLDERS’ DEFICIT Preferred stock — par value $0.001 per share, 20,000,000 shares authorized, none issued or outstanding — — — Common stock — par value $0.001 per share, 250,000,000 shares authorized, 37,880,211 shares outstanding at June 30, 2019 36 2 (d) 38 Additional paid-in capital 153,084 10,164 (b), (e) 163,248 Accumulated other comprehensive income (loss) (56 ) — (56 ) Accumulated deficit (189,503 ) (16,888 ) (e) (206,391 ) Total stockholders’ deficit (36,439 ) (6,722 ) (43,161 ) Noncontrolling interest (785 ) 785 (a) — Total liabilities & stockholders’ deficit $ 61,491 $ 1,338 $ 62,829 (a) EJ Holdings adjustments: the correction of this misstatement resulted in increases of $13.4 million in equity method investment, $172,000 in accounts payable and accrued expenses, and $785,000 in non-controlling interest and decreases of $12.2 million in cash and cash equivalent and $187,000 in prepaid expenses and other current assets. (b) Warrant adjustments: the correction of this misstatement resulted in increases of $7.8 million in warrant derivative current liabilities, and $90,000 in short-term note payable and decreases of $703,000 in long-term notes payable and $9.7 million in additional paid-in capital. (c) Corrections of other misstatement: period adjustment and reclassification of variable consideration resulted in an increase of $301,000 in accounts receivable and a decrease of $110,000 in accounts payable and accrued expenses, a decrease of $10,000 in income tax receivable and an increase of $24,000 in income tax payable; a reclassification of GPB warrants resulted an increase of short-term warrant liability and a decrease of long-term warrant liability of $1.2 million; and correction of tax provision resulted an increase of $90,000 in income tax receivable and a decrease of $24,000 in income tax payable. (d) Retrospective adjustments made to common stock resulted from recapitalization transaction in July 2019. (e) Carryforward impact on 2018 restatement adjustments, including cashless warrant adjustments which resulted in an increase in additional paid-in capital and a decrease in retained earnings of $18.3 million. EMMAUS LIFE SCIENCES, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (In thousands, except share and per share amount) (Unaudited) Three months ended June 30, 2019 Six months ended June 30,2019 Previously Reported Adjustment Restated Previously Reported Adjustment Restated REVENUES, NET $ 5,869 $ (376 ) (c) $ 5,493 $ 11,176 $ (976 ) (c) $ 10,200 COST OF GOODS SOLD 195 69 (c) 264 395 128 (c) 523 GROSS PROFIT 5,674 (445 ) 5,229 10,781 (1,104 ) 9,677 OPERATING EXPENSES Research and development 540 — 540 1,053 — 1,053 Selling 1,903 (12 ) (c) 1,891 3,388 (18 ) (c) 3,370 General and administrative 3,851 (1,169 ) (a), (c) 2,682 7,532 (1,113 ) (a), (c) 6,419 Total operating expenses 6,294 (1,181 ) 5,113 11,973 (1,131 ) 10,842 INCOME (LOSS) FROM OPERATIONS (620 ) 736 116 (1,192 ) 27 (1,165 ) OTHER INCOME (EXPENSE) Change in fair value of warrant derivative liabilities 247 607 (b) 854 199 (283 ) (b) (84 ) Net losses on investment in marketable securities and long-term investment (10,537 ) — (10,537 ) (16,994 ) — (16,994 ) Losses on equity method investment — (458 ) (a) (458 ) — (449 ) (a) (449 ) Interest and other income (loss) 274 33 (a), (c) 307 163 67 (a), (c) 230 Interest expense (8,474 ) 647 (b), (c) (7,827 ) (15,439 ) (1,000 ) (b), (c) (16,439 ) Total other income (expenses) (18,490 ) 829 (17,661 ) (32,071 ) (1,665 ) (33,736 ) LOSS BEFORE INCOME TAXES (19,110 ) 1,565 (17,545 ) (33,263 ) (1,638 ) (34,901 ) INCOME TAXES (BENEFIT) 217 (166 ) (c) 51 217 (114 ) (c) 103 NET LOSS INCLUDING NONCONTROLLING INTERESTS (19,327 ) 1,731 (17,596 ) (33,480 ) (1,524 ) (35,004 ) Net (income) loss attributable to noncontrolling interests 688 (688 ) (a) — 674 (674 ) (a) — NET LOSS ATTRIBUTABLE TO THE COMPANY (18,639 ) 1,043 (17,596 ) (32,806 ) (2,198 ) (35,004 ) COMPONENTS OF OTHER COMPREHENSIVE INCOME (LOSS) Foreign currency translation adjustments (9 ) 15 (a) 6 (2 ) 15 (a) 13 Other comprehensive income (loss) (9 ) 15 6 (2 ) 15 13 COMPREHENSIVE INCOME (LOSS) (19,336 ) 1,746 (17,590 ) (33,482 ) (1,509 ) (34,991 ) Amounts attributable to noncontrolling interest: Net (income) loss attributable to noncontrolling interest 688 (688 ) (a) — 674 (674 ) (a) — Foreign currency translation adjustments 15 (15 ) (a) — 14 (14 ) (a) — Comprehensive (income) loss attributable to noncontrolling interest 703 (703 ) — 688 (688 ) — COMPREHENSIVE INCOME (LOSS) ATTRIBUTABLE TO THE COMPANY $ (18,633 ) $ 1,043 $ (17,590 ) $ (32,794 ) $ (2,197 ) $ (34,991 ) NET LOSS PER COMMON SHARE - BASIC AND DILUTED $ (0.52 ) $ 0.05 $ (0.47 ) $ (0.91 ) $ (0.01 ) $ (0.93 ) WEIGHTED-AVERAGE COMMON SHARES OUTSTANDING 35,857,944 37,836,678 37,836,678 35,857,944 37,656,058 37,656,058 (a) EJ Holdings adjustments: the correction of this misstatement resulted in increases of $33,000 in interest income and $15,000 in foreign currency translation adjustments and decreases of $1.1million in general and administrative expenses, $458,000 in loss on equity method investment, and $688,000 in net loss attributable to noncontrolling interest for three months ended June 30, 2019. The correction of this misstatement resulted in increases of $67,000 in interest income and $14,000 in foreign currency translation adjustments and decreases of $1.1million in general and administrative expense, $449,000 in loss on equity method investment, and $674,000 in net loss attributable to noncontrolling interest for six months ended June 30, 2019. (b) Warrant adjustments: the correction of this misstatement resulted in increases of $647,000 in interest expense and $607,000 in change in fair value of warrant derivative liabilities for the three months ended June 2019. The correction of this misstatement resulted in an increase of $335,000 in interest expense and a decrease of $283,000 in change in fair value of warrant derivative liabilities for six months ended June 30, 2019. ( c ) Corrections of other misstatement: period adjustment of variable consideration resulted in a decrease of $ in revenue s , net; and reclassification of shipping cost and royalty expense to cost of sales resulted in an increase of $ in cost of sales and decreases of $ and $ in selling expense and general and administrative expense, respectively . Corrections of other misstatement for the six months ended June 30, 2019 : period adjustment of variable consideration resulted in a decrease of $ in revenues, net ; reclassification of shipping cost and royalty expense to cost of sales resulted in an increase of $ in cost of sales and decreases of $ and $ in selling expense and general and administrative expense, respectively; correction of stock modification accounting resulted in a decrease of $ 52,000 in general and administrative expense; correction of accounting treatment for convertible notes resulted in an increase of $ 1.3 million in interest expense ; and correction of income tax provision resulted in an decrease of $ 113,000 in income tax provision . EMMAUS LIFE SCIENCES, INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (In thousands) (Unaudited) Six Months Ended June 30, 2019 Previously Reported Adjustment Restated CASH FLOWS FROM OPERATING ACTIVITIES Net loss $ (33,480 ) $ (1,524 ) $ (35,004 ) Adjustments to reconcile net loss to net cash flows from operating activities Depreciation and amortization 35 — 35 Impairment loss on long-term investment 524 — 524 Amortization of discount of convertible notes and notes payable 12,770 1,001 13,771 Foreign exchange adjustments on convertible notes and notes payable 49 (257 ) (208 ) Net losses (gains) on equity investment in marketable securities 16,470 — 16,470 Loss on equity method investments 449 449 Share-based compensation 974 52 1,026 Change in fair value of warrant derivative liabilities (199 ) 283 84 Net changes in operating assets and liabilities Accounts receivable (630 ) 266 (364 ) Inventories (1,202 ) — (1,202 ) Prepaid expenses and other current assets 69 80 149 Other non-current assets (4,298 ) — (4,298 ) Accounts payable and accrued expenses 3,226 828 4,054 Income tax receivable and payable — (113 ) (113 ) Deferred revenue 500 — 500 Deferred rent (287 ) — (287 ) Other current liabilities 79 (142 ) (63 ) Other long-term liabilities 3,217 — 3,217 Net cash flows provided by (used in) operating activities (2,183 ) 923 (1,260 ) CASH FLOWS FROM INVESTING ACTIVITIES Purchases of property and equipment (21 ) — (21 ) Sales of marketable securities 221 — 221 Purchase of marketable securities and investment at cost — — — Net cash flows provided by (used in) investing activities 200 — 200 CASH FLOWS FROM FINANCING ACTIVITIES Payments of convertible notes (3,368 ) — (3,368 ) Proceeds from exercise of warrants 186 — 186 Proceeds from issuance of common stock 3,261 — 3,261 Proceeds from conversion of notes payable to common stock 21 — 21 Net cash flows provided by (used in) financing activities 100 — 100 Effect of exchange rate changes on cash (28 ) 30 2 Net increase (decrease) in cash, cash equivalents and restricted cash (1,911 ) 953 (958 ) Cash and cash equivalents, beginning of period 17,080 (13,175 ) 3,905 Cash and cash equivalents, end of period $ 15,169 $ (12,222 ) $ 2,947 SUPPLEMENTAL DISCLOSURES OF CASH FLOW ACTIVITIES Interest paid $ 934 $ (385 ) $ 549 Income taxes paid $ 217 $ (1 ) $ 216 NON-CASH INVESTING AND FINANCING ACTIVITIES Beneficial conversion feature relating to convertible notes $ 8,764 $ — $ 8,764 Common stocks issued on exercise of warrants $ 186 $ — $ 186 Conversion of notes payable and acrued interest to common stock $ 308 $ — $ 329 Initial recognition of right-of-use lease asset $ 2,922 $ — $ 2,922 Refer to the descriptions of the adjustments in the Condensed Consolidated Balance Sheets and Statements of Comprehensive Loss as of and for the three months ended June 30, 2019 and their impact on net loss above. In addition, a cash flow classification adjustment related to EJ Holdings resulted in a net decrease to cash flows used by operating activities of $953,000 for the six months ended June 30, 2019.
Restricted Cash	Restricted cash — Restricted cash includes proceeds received from the sales of shares of Telcon RF Pharmaceutical, Inc., a Korean corporation (formerly, Telcon Inc. and herein “Telcon”) earmarked for the purchase of Telcon convertible bond per the December 23, 2019 agreement with Telcon. See Note 5 for the additional details. Reconciliation of cash, cash equivalent and restricted cash are as follows: Six Month Ended June 30 2020 2019 Cash and cash equivalents $ 1,032 $ 2,947 Restricted cash 7 — Total cash, cash equivalents and restricted cash shown in the consolidated statements of cash flows $ 1,039 $ 2,947
Net loss per share	Net loss per share — In accordance with ASC 260, “Earnings per Share, ” the basic loss per common share is computed by dividing net loss available to common stockholders by the weighted-average number of common shares outstanding. Dilutive loss per share is computed in a manner similar to basic loss per common share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. As of June 30, 2020 and June 30, 2019, the Company had outstanding potentially dilutive securities exercisable for or convertible into 17,288,829 shares and 17,996,931 shares, respectively, of the Company’s common stock. No potentially dilutive securities were included in the calculation of diluted net loss per share since their effect would be anti-dilutive for all period presented.

BASIS OF PRESENTATION (Tables)

BASIS OF PRESENTATION (Tables)	6 Months Ended
	Jun. 30, 2020
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Schedule of Error Corrections and Prior Period Adjustments	EMMAUS LIFE SCIENCES, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands, except share and per share amounts) (Unaudited) As of June 30, 2019 Previously Reported Adjustment Restated ASSETS CURRENT ASSETS Cash and cash equivalents $ 15,169 $ (12,222 ) (a) $ 2,947 Accounts receivable, net 1,981 301 (c) 2,282 Inventories, net 5,906 — 5,906 Investment in marketable securities 32,890 — 32,890 Prepaid expenses and other current assets 703 (107 ) (a), (c) 596 Total current assets 56,649 (12,028 ) 44,621 Property and equipment, net 145 — 145 Equity method investment — 13,366 (a) 13,366 Right of use assets 4,285 — 4,285 Deposits and other assets 412 — 412 Total other assets 4,697 13,366 18,063 Total assets $ 61,491 $ 1,338 $ 62,829 LIABILITIES AND STOCKHOLDERS’ DEFICIT CURRENT LIABILITIES Accounts payable and accrued expenses $ 11,455 $ 62 (a), (c) $ 11,517 Operating lease liabilities, current portion 857 — 857 Other current liabilities 5,259 2 (c) 5,261 Warrant derivative liabilities — 9,023 (b), (c) 9,023 Notes payable, net of discount 11,163 91 (b) 11,254 Notes payable to related parties 470 — 470 Convertible notes payable, net of discount 13,867 — 13,867 Convertible notes payable to related parties, net of discount 14,180 — 14,180 Total current liabilities 57,251 9,178 66,429 Operating lease liabilities, less current portion 3,781 — 3,781 Other long-term liabilities 35,330 — 35,330 Warrant derivative liabilities 1,200 (1,200 ) (c) — Notes payable, net of discount, less current portion 703 (703 ) (b) — Convertible notes payable, net of discount, less current portion 450 — 450 Total liabilities 98,715 7,275 105,990 STOCKHOLDERS’ DEFICIT Preferred stock — par value $0.001 per share, 20,000,000 shares authorized, none issued or outstanding — — — Common stock — par value $0.001 per share, 250,000,000 shares authorized, 37,880,211 shares outstanding at June 30, 2019 36 2 (d) 38 Additional paid-in capital 153,084 10,164 (b), (e) 163,248 Accumulated other comprehensive income (loss) (56 ) — (56 ) Accumulated deficit (189,503 ) (16,888 ) (e) (206,391 ) Total stockholders’ deficit (36,439 ) (6,722 ) (43,161 ) Noncontrolling interest (785 ) 785 (a) — Total liabilities & stockholders’ deficit $ 61,491 $ 1,338 $ 62,829 (a) EJ Holdings adjustments: the correction of this misstatement resulted in increases of $13.4 million in equity method investment, $172,000 in accounts payable and accrued expenses, and $785,000 in non-controlling interest and decreases of $12.2 million in cash and cash equivalent and $187,000 in prepaid expenses and other current assets. (b) Warrant adjustments: the correction of this misstatement resulted in increases of $7.8 million in warrant derivative current liabilities, and $90,000 in short-term note payable and decreases of $703,000 in long-term notes payable and $9.7 million in additional paid-in capital. (c) Corrections of other misstatement: period adjustment and reclassification of variable consideration resulted in an increase of $301,000 in accounts receivable and a decrease of $110,000 in accounts payable and accrued expenses, a decrease of $10,000 in income tax receivable and an increase of $24,000 in income tax payable; a reclassification of GPB warrants resulted an increase of short-term warrant liability and a decrease of long-term warrant liability of $1.2 million; and correction of tax provision resulted an increase of $90,000 in income tax receivable and a decrease of $24,000 in income tax payable. (d) Retrospective adjustments made to common stock resulted from recapitalization transaction in July 2019. (e) Carryforward impact on 2018 restatement adjustments, including cashless warrant adjustments which resulted in an increase in additional paid-in capital and a decrease in retained earnings of $18.3 million. EMMAUS LIFE SCIENCES, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (In thousands, except share and per share amount) (Unaudited) Three months ended June 30, 2019 Six months ended June 30,2019 Previously Reported Adjustment Restated Previously Reported Adjustment Restated REVENUES, NET $ 5,869 $ (376 ) (c) $ 5,493 $ 11,176 $ (976 ) (c) $ 10,200 COST OF GOODS SOLD 195 69 (c) 264 395 128 (c) 523 GROSS PROFIT 5,674 (445 ) 5,229 10,781 (1,104 ) 9,677 OPERATING EXPENSES Research and development 540 — 540 1,053 — 1,053 Selling 1,903 (12 ) (c) 1,891 3,388 (18 ) (c) 3,370 General and administrative 3,851 (1,169 ) (a), (c) 2,682 7,532 (1,113 ) (a), (c) 6,419 Total operating expenses 6,294 (1,181 ) 5,113 11,973 (1,131 ) 10,842 INCOME (LOSS) FROM OPERATIONS (620 ) 736 116 (1,192 ) 27 (1,165 ) OTHER INCOME (EXPENSE) Change in fair value of warrant derivative liabilities 247 607 (b) 854 199 (283 ) (b) (84 ) Net losses on investment in marketable securities and long-term investment (10,537 ) — (10,537 ) (16,994 ) — (16,994 ) Losses on equity method investment — (458 ) (a) (458 ) — (449 ) (a) (449 ) Interest and other income (loss) 274 33 (a), (c) 307 163 67 (a), (c) 230 Interest expense (8,474 ) 647 (b), (c) (7,827 ) (15,439 ) (1,000 ) (b), (c) (16,439 ) Total other income (expenses) (18,490 ) 829 (17,661 ) (32,071 ) (1,665 ) (33,736 ) LOSS BEFORE INCOME TAXES (19,110 ) 1,565 (17,545 ) (33,263 ) (1,638 ) (34,901 ) INCOME TAXES (BENEFIT) 217 (166 ) (c) 51 217 (114 ) (c) 103 NET LOSS INCLUDING NONCONTROLLING INTERESTS (19,327 ) 1,731 (17,596 ) (33,480 ) (1,524 ) (35,004 ) Net (income) loss attributable to noncontrolling interests 688 (688 ) (a) — 674 (674 ) (a) — NET LOSS ATTRIBUTABLE TO THE COMPANY (18,639 ) 1,043 (17,596 ) (32,806 ) (2,198 ) (35,004 ) COMPONENTS OF OTHER COMPREHENSIVE INCOME (LOSS) Foreign currency translation adjustments (9 ) 15 (a) 6 (2 ) 15 (a) 13 Other comprehensive income (loss) (9 ) 15 6 (2 ) 15 13 COMPREHENSIVE INCOME (LOSS) (19,336 ) 1,746 (17,590 ) (33,482 ) (1,509 ) (34,991 ) Amounts attributable to noncontrolling interest: Net (income) loss attributable to noncontrolling interest 688 (688 ) (a) — 674 (674 ) (a) — Foreign currency translation adjustments 15 (15 ) (a) — 14 (14 ) (a) — Comprehensive (income) loss attributable to noncontrolling interest 703 (703 ) — 688 (688 ) — COMPREHENSIVE INCOME (LOSS) ATTRIBUTABLE TO THE COMPANY $ (18,633 ) $ 1,043 $ (17,590 ) $ (32,794 ) $ (2,197 ) $ (34,991 ) NET LOSS PER COMMON SHARE - BASIC AND DILUTED $ (0.52 ) $ 0.05 $ (0.47 ) $ (0.91 ) $ (0.01 ) $ (0.93 ) WEIGHTED-AVERAGE COMMON SHARES OUTSTANDING 35,857,944 37,836,678 37,836,678 35,857,944 37,656,058 37,656,058 (a) EJ Holdings adjustments: the correction of this misstatement resulted in increases of $33,000 in interest income and $15,000 in foreign currency translation adjustments and decreases of $1.1million in general and administrative expenses, $458,000 in loss on equity method investment, and $688,000 in net loss attributable to noncontrolling interest for three months ended June 30, 2019. The correction of this misstatement resulted in increases of $67,000 in interest income and $14,000 in foreign currency translation adjustments and decreases of $1.1million in general and administrative expense, $449,000 in loss on equity method investment, and $674,000 in net loss attributable to noncontrolling interest for six months ended June 30, 2019. (b) Warrant adjustments: the correction of this misstatement resulted in increases of $647,000 in interest expense and $607,000 in change in fair value of warrant derivative liabilities for the three months ended June 2019. The correction of this misstatement resulted in an increase of $335,000 in interest expense and a decrease of $283,000 in change in fair value of warrant derivative liabilities for six months ended June 30, 2019. ( c ) Corrections of other misstatement: period adjustment of variable consideration resulted in a decrease of $ in revenue s , net; and reclassification of shipping cost and royalty expense to cost of sales resulted in an increase of $ in cost of sales and decreases of $ and $ in selling expense and general and administrative expense, respectively . Corrections of other misstatement for the six months ended June 30, 2019 : period adjustment of variable consideration resulted in a decrease of $ in revenues, net ; reclassification of shipping cost and royalty expense to cost of sales resulted in an increase of $ in cost of sales and decreases of $ and $ in selling expense and general and administrative expense, respectively; correction of stock modification accounting resulted in a decrease of $ 52,000 in general and administrative expense; correction of accounting treatment for convertible notes resulted in an increase of $ 1.3 million in interest expense ; and correction of income tax provision resulted in an decrease of $ 113,000 in income tax provision . EMMAUS LIFE SCIENCES, INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (In thousands) (Unaudited) Six Months Ended June 30, 2019 Previously Reported Adjustment Restated CASH FLOWS FROM OPERATING ACTIVITIES Net loss $ (33,480 ) $ (1,524 ) $ (35,004 ) Adjustments to reconcile net loss to net cash flows from operating activities Depreciation and amortization 35 — 35 Impairment loss on long-term investment 524 — 524 Amortization of discount of convertible notes and notes payable 12,770 1,001 13,771 Foreign exchange adjustments on convertible notes and notes payable 49 (257 ) (208 ) Net losses (gains) on equity investment in marketable securities 16,470 — 16,470 Loss on equity method investments 449 449 Share-based compensation 974 52 1,026 Change in fair value of warrant derivative liabilities (199 ) 283 84 Net changes in operating assets and liabilities Accounts receivable (630 ) 266 (364 ) Inventories (1,202 ) — (1,202 ) Prepaid expenses and other current assets 69 80 149 Other non-current assets (4,298 ) — (4,298 ) Accounts payable and accrued expenses 3,226 828 4,054 Income tax receivable and payable — (113 ) (113 ) Deferred revenue 500 — 500 Deferred rent (287 ) — (287 ) Other current liabilities 79 (142 ) (63 ) Other long-term liabilities 3,217 — 3,217 Net cash flows provided by (used in) operating activities (2,183 ) 923 (1,260 ) CASH FLOWS FROM INVESTING ACTIVITIES Purchases of property and equipment (21 ) — (21 ) Sales of marketable securities 221 — 221 Purchase of marketable securities and investment at cost — — — Net cash flows provided by (used in) investing activities 200 — 200 CASH FLOWS FROM FINANCING ACTIVITIES Payments of convertible notes (3,368 ) — (3,368 ) Proceeds from exercise of warrants 186 — 186 Proceeds from issuance of common stock 3,261 — 3,261 Proceeds from conversion of notes payable to common stock 21 — 21 Net cash flows provided by (used in) financing activities 100 — 100 Effect of exchange rate changes on cash (28 ) 30 2 Net increase (decrease) in cash, cash equivalents and restricted cash (1,911 ) 953 (958 ) Cash and cash equivalents, beginning of period 17,080 (13,175 ) 3,905 Cash and cash equivalents, end of period $ 15,169 $ (12,222 ) $ 2,947 SUPPLEMENTAL DISCLOSURES OF CASH FLOW ACTIVITIES Interest paid $ 934 $ (385 ) $ 549 Income taxes paid $ 217 $ (1 ) $ 216 NON-CASH INVESTING AND FINANCING ACTIVITIES Beneficial conversion feature relating to convertible notes $ 8,764 $ — $ 8,764 Common stocks issued on exercise of warrants $ 186 $ — $ 186 Conversion of notes payable and acrued interest to common stock $ 308 $ — $ 329 Initial recognition of right-of-use lease asset $ 2,922 $ — $ 2,922 Refer to the descriptions of the adjustments in the Condensed Consolidated Balance Sheets and Statements of Comprehensive Loss as of and for the three months ended June 30, 2019 and their impact on net loss above. In addition, a cash flow classification adjustment related to EJ Holdings resulted in a net decrease to cash flows used by operating activities of $953,000 for the six months ended June 30, 2019.

SUMMARY OF SIGNIFICANT ACCOUN_3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	6 Months Ended
	Jun. 30, 2020
Accounting Policies [Abstract]
Reconciliation of Cash, Cash Equivalent and Restricted Cash	Reconciliation of cash, cash equivalent and restricted cash are as follows: Six Month Ended June 30 2020 2019 Cash and cash equivalents $ 1,032 $ 2,947 Restricted cash 7 — Total cash, cash equivalents and restricted cash shown in the consolidated statements of cash flows $ 1,039 $ 2,947

REVENUES (Tables)

REVENUES (Tables)	6 Months Ended
	Jun. 30, 2020
Revenue From Contract With Customer [Abstract]
Summary of revenues disaggregated by category	Revenues disaggregated by category were as follows (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2020 2019 Restated 2020 2019 Restated Endari® $ 4,349 $ 5,390 $ 11,063 $ 9,992 Other 11 103 251 208 Revenues, net $ 4,360 $ 5,493 $ 11,314 $ 10,200
Revenue Allowance and Accrual Activities	The following table summarizes the revenue allowance and accrual activities for the six months ended June 30, 2020 and 2019 (in thousands): Trade Discounts, Allowances and Chargebacks Government Rebates and Other Incentives Returns Total Balance as of December 31, 2019 $ 228 $ 1,354 $ 315 $ 1,897 Provision related to sales in the current year 1,438 1,955 118 3,511 Adjustments related prior period sales 16 (43 ) (43 ) (70 ) Credit and payments made (1,208 ) (1,324 ) — (2,532 ) Balance as of June 30, 2020 $ 474 $ 1,942 $ 390 $ 2,806 Balance as of December 31, 2018 $ 84 $ 798 $ 99 $ 981 Provision related to sales in the current year 649 1,625 121 2,395 Credit and payments made (614 ) (1,135 ) — (1,749 ) Balance as of June 30, 2019, restated $ 119 $ 1,288 $ 220 $ 1,627
Summarizes revenues from each of our customers accounted for 10% or more of total revenues	The following table summarizes revenues attributable to each of our customers that accounted for 10% or more of our total revenues (as a percentage of total revenues): Three Months Ended June 30, Six Months Ended June 30, 2020 2019 Restated 2020 2019 Restated Customer A 55 % 58 % 54 % 61 % Customer B 20 % 25 % 24 % 22 %

SELECTED FINANCIAL STATEMENT _3

SELECTED FINANCIAL STATEMENT CAPTIONS - ASSETS (Tables)	6 Months Ended
	Jun. 30, 2020
Balance Sheet Related Disclosures [Abstract]
Schedule of inventory	Inventories consisted of the following (in thousands): June 30, 2020 December 31, 2019 Raw materials and components $ 1,500 $ 1,187 Work-in-process 1,836 1,629 Finished goods 4,948 5,204 Inventory reserve (421 ) (49 ) Total $ 7,863 $ 7,971
Schedule of prepaid expenses and other current assets	Prepaid expenses and other current assets consisted of the following (in thousands): June 30, 2020 December 31, 2019 Prepaid insurance $ 271 $ 735 Other prepaid expenses and current assets 899 667 Total $ 1,170 $ 1,402
Schedule of property and equipment	Property and equipment consisted of the following (in thousands): June 30, 2020 December 31, 2019 Equipment $ 345 $ 335 Leasehold improvements 39 77 Furniture and fixtures 99 95 Total property and equipment $ 483 507 Less: accumulated depreciation (342 ) (356 ) Property and equipment, net $ 141 $ 151

INVESTMENTS (Tables)

INVESTMENTS (Tables)	6 Months Ended
	Jun. 30, 2020
Investments [Abstract]
Schedule of carrying values of equity securities	As of June 30, 2020 and December 31, 2019, the carrying values of equity securities were included in the following line items in our consolidated balance sheets (in thousands): June 30, 2020 December 31, 2019 Fair Value with Changes Recognized in Income Fair Value with Changes Recognized in Income Marketable securities $ 27,007 $ 27,929 Total equity securities $ 27,007 $ 27,929
Schedule of Certain Financial Information of EJ Holdings	The following table sets forth certain financial information of EJ Holdings for the three months ended and the six months ended June 30, 2020 and 2019 (in thousands). Three Months Ended June 30, Six Months Ended June 30, 2020 2019 2020 2019 (Unaudited) (Unaudited) (Unaudited) (Unaudited) REVENUES, NET $ 61 $ 57 $ 145 $ 114 GROSS PROFIT 61 57 145 114 NET LOSS $ (1,432 ) $ (1,147 ) $ (2,449 ) $ (1,124 )

SELECTED FINANCIAL STATEMENT _4

SELECTED FINANCIAL STATEMENT CAPTIONS - LIABILITIES (Tables)	6 Months Ended
	Jun. 30, 2020
Payables And Accruals [Abstract]
Schedule of accounts payable and accrued expenses	Accounts payable and accrued expenses consisted of the following at June 30, 2020 and December 31, 2019 (in thousands): June 30, 2020 December 31, 2019 Accounts payable: Clinical and regulatory expenses $ 311 $ 232 Professional fees 960 1,183 Selling expenses 798 1,303 Manufacturing costs 3,824 4,541 Other vendors 128 18 Total accounts payable 6,021 7,277 Accrued interest payable, related parties 246 42 Accrued interest payable 407 991 Accrued expenses: Payroll expenses 998 891 Government rebates and other rebates 1,943 1,355 Due to EJ Holdings 406 238 Other accrued expenses 356 704 Total accrued expenses 3,703 3,188 Total accounts payable and accrued expenses $ 10,377 $ 11,498
Schedule of other long-term liabilities	Other long-term liabilities consisted of the following at June 30, 2020 and December 31, 2019 (in thousands): June 30, 2020 December 31, 2019 Trade discount $ 26,422 $ 23,242 Unearned revenue 10,000 10,500 Other long-term liabilities 12 8 Total other long-term liabilities $ 36,434 $ 33,750

NOTES PAYABLE (Tables)

NOTES PAYABLE (Tables)	6 Months Ended
	Jun. 30, 2020
Schedule of notes payable	Notes payable consisted of the following at June 30, 2020 and December 31, 2019 (in thousands): Year Issued Interest Rate Range Term of Notes Conversion Price Principal Outstanding June 30, 2020 Discount Amount June 30, 2020 Carrying Amount June 30, 2020 Shares Underlying June 30, 2020 Notes payable 2013 10% Due on demand — $ 928 $ — $ 928 — 2019 11% Due on demand - 6 months — 2,839 — 2,839 — 2020 1% - 11% Due on demand - 2 years — 992 — 992 — $ 4,759 $ — $ 4,759 — Current $ 4,271 $ — $ 4,271 — Non-current $ 488 $ — $ 488 — Notes payable - related parties 2016 10% Due on demand — $ 20 $ — $ 20 — 2019 10% Due on demand — 14 — 14 — $ 34 $ — $ 34 — Current $ 34 $ — $ 34 — Convertible debentures 2019 10% 18 months $2.00-$9.52 (a) $ 9,200 $ 1,606 $ 7,594 4,638,333 $ 9,200 $ 1,606 $ 7,594 4,638,333 Current $ 9,200 $ 1,606 $ 7,594 4,638,333 Convertible notes payable 2020 12% 3 years $ 10.00 (b) $ 3,150 $ — $ 3,150 — $ 3,150 $ — $ 3,150 — Non-current $ 3,150 $ — $ 3,150 — Total $ 17,143 $ 1,606 $ 15,537 4,638,333 Year Issued Interest Rate Range Term of Notes Conversion Price Principal Outstanding December 31, 2019 Discount Amount December 31, 2019 Carrying Amount December 31, 2019 Shares Underlying Notes December 31, 2019 Notes payable 2013 10% Due on demand — $ 920 $ — $ 920 — 2019 11% Due on demand - 6 months — 2,829 — 2,829 — $ 3,749 $ — $ 3,749 — Current 3,749 — 3,749 — Notes payable - related parties 2016 10% Due on demand — $ 20 $ — $ 20 — 2018 11% Due on demand — 159 — 159 — 2019 10% Due on demand — 14 — 14 — $ 193 $ — $ 193 — Current $ 193 $ — $ 193 — Convertible debentures 2019 10% 18 months $2.00-$9.52 (a) $ 10,200 $ 3,185 $ 7,015 1,080,415 $ 10,200 $ 3,185 $ 7,015 1,080,415 Current $ 10,200 $ 3,185 $ 7,015 1,080,415 Convertible notes payable 2018 10% 2 years $ 10.00 (b) $ 3,000 $ 5 $ 2,995 363,876 $ 3,000 $ 5 $ 2,995 363,876 Current $ 3,000 $ 5 $ 2,995 363,876 Total $ 17,142 $ 3,190 $ 13,952 1,444,291 (a) The notes are convertible to Emmaus Life Sciences, Inc. shares. (b) The notes are convertible to EMI Holding, Inc. shares.
Schedule of future contractual principal payments of notes payable	As of June 30, 2020, future contractual principal payments due on notes payable were as follows: Year Ending 2020 (six months) $ 9,040 2021 4,732 2022 221 2023 3,150 Total $ 17,143
Conversion Feature Liabilities [Member] | Senior Secured Convertible Debentures [Member]
Schedule of fair value of conversion feature liabilities	The following table sets forth the fair value of the conversion feature liabilities as of June 30, 2020 and December 31, 2019 (in thousands): Six Months Ended Year ended Conversion feature liabilities - Amended and Restated 10% Senior Convertible Debentures June 30, 2020 December 31, 2019 Balance, beginning of period $ 1 $ — Fair value at issuance date — 132 Fair value at debt modification date 118 — Change in fair value included in the statement of comprehensive income (loss) (6 ) (131 ) Balance, end of period $ 113 $ 1
Schedule of fair value based upon assumptions	The fair values as of June 30, 2020, the February 21, 2020 modification date and December 31, 2019 were based upon following assumptions: June 30, 2020 February 21, 2020 (Modification date) December 31, 2019 Stock price $ 1.67 $ 1.89 $ 1.97 Conversion price $ 2.00 $ 3.00 $ 9.52 Selected yield 15.73 % 19.12 % 16.77 % Expected volatility (peer group) 100 % 65 % 50 % Expected life (in years) 0.81 1.16 0.81 Expected dividend yield — — — Risk‑free rate Term structure Term structure Term structure

STOCKHOLDERS' DEFICIT (Tables)

STOCKHOLDERS' DEFICIT (Tables)	6 Months Ended
	Jun. 30, 2020
Summary of outstanding warrants	A summary of outstanding warrants as of June 30, 2020 and December 31, 2019 is presented below: June 30, 2020 December 31, 2019 Warrants outstanding, beginning of period 4,931,099 3,436,431 Assumed as part of Merger — 1,044,939 Granted 1,250,000 500,729 Exercised — (51,000 ) Cancelled, forfeited or expired (115,953 ) — Warrants outstanding, end of period 6,065,146 4,931,099 A summary of outstanding warrants by year issued and exercise price as of June 30, 2020 is presented below: Outstanding Exercisable Year issued and Exercise Price Number of Warrants Issued Weighted-Average Remaining Contractual Life (Years) Weighted-Average Exercise Price Total Weighted-Average Exercise Price Prior to January 1, 2019 $2.00-$10.76 3,439,007 2.12 $ 4.38 3,439,007 $ 4.38 Prior to Jan 1, 2019 Total 3,439,007 3,439,007 At December 31, 2019 $ 6.12 32,391 3.91 $ 6.12 32,391 $ 6.12 $ 12.00 76,575 3.23 $ 12.00 76,575 $ 12.00 $ 14.04 174,999 2.75 $ 14.04 174,999 $ 14.04 $ 31.50 737,975 2.07 $ 31.50 737,975 $ 31.50 $ 36.24 22,333 2.07 $ 36.24 22,333 $ 36.24 $ 60.00 666 0.50 $ 60.00 666 $ 60.00 $ 2.00 256,200 3.21 $ 2.00 256,200 $ 2.00 $ 7.68 75,000 4.05 $ 7.68 75,000 $ 7.68 2019 Total 1,376,139 1,376,139 At June 30, 2020 $ 2.05 1,250,000 4.96 $ 2.05 — $ — Total 6,065,146 4,815,146
Schedule of valuation assumptions	Management has valued stock options at their date of grant utilizing the Black‑Scholes‑Merton Option pricing model. The fair value of the underlying shares was determined by the market value of stock of similar companies and recent arm’s length transactions involving the sale of the Company’s common stock. Prior the Merger, the Company lacked company-specific historical and implied volatility information for its common stock. Therefore, the expected volatility was calculated using the historical volatility of a comparative public traded companies. The following table presents the assumptions used on recent dates on which options were granted by the Company. June 29, 2020 June 19, 2019 Stock Price $ 1.67 $ 10.30 Exercise Price $ 2.05 $ 10.30 Term 5.5-6 years 6 years Risk-Free Rate 0.28% - 0.38% 1.83% Dividend Yield — — Volatility 78.91%-80.49% 67.16 %
Summary of stock option activity	A summary of outstanding stock options as of June 30, 2020 and December 31, 2019 is presented below. June 30, 2020 December 31, 2019 Number of Options Weighted‑ Average Exercise Price Number of Options Weighted‑ Average Exercise Price Options outstanding, beginning of period 7,245,350 $ 4.68 6,642,200 $ 4.40 Granted or deemed granted 90,000 $ 2.05 636,683 (a) $ 10.10 Exercised — $ — (167 ) $ 5.00 Cancelled, forfeited and expired (142,818 ) $ 5.08 (33,366 ) $ 11.29 Options outstanding, end of period 7,192,532 $ 4.63 7,245,350 $ 4.68 Options exercisable, end of period 6,978,869 $ 4.58 7,001,680 $ 4.47 Options available for future grant 2,302,475 2,167,150 (a) Upon the Merger, the exercise prices of outstanding EMI options and number of shares of the Company common stock underlying the options were adjusted based upon the exchange ratio in the Merger.
Convertible Promissory Note [Member]
Schedule of change in fair value of warrants	The following table presents the change in fair value of the warrants as of June 30, 2020 (in thousands): Six Months Ended Warrants Derivative Liabilities - convertible promissory note June 30, 2020 Balance, beginning of period $ — Fair value at issuance date 1,425 Change in fair value included in the statement of comprehensive loss (12 ) Balance, end of period $ 1,413
Schedule of fair value based upon assumptions	The fair value of the warrant derivative liabilities was determined using the Black-Scholes Merton model and was based upon following assumptions: June 30, 2020 June 15, 2020 (modification date) Exercise price $ 2.05 $ 2.05 Stock price $ 1.67 $ 1.68 Risk‑free interest rate 0.29 % 0.33 % Expected volatility (peer group) 94.00 % 94.00 % Expected life (in years) 4.96 5.00 Expected dividend yield 0.00 % 0.00 % Warrant shares 1,250,000 1,250,000
GPB Debt Holdings II, LLC [Member]
Schedule of change in fair value of warrants	The following table presents the change in fair value of the GPB Warrant as of June 30, 2020 and December 31, 2019 (in thousands): Six Months Ended Year Ended June 30, 2020 December 31, 2019 Warrant Liability - GPB Warrants Warrants Balance, beginning of period $ 38 $ 1,399 Change in fair value included in the statement of comprehensive income (loss) 88 (1,361 ) Balance, end of period $ 126 $ 38
Schedule of fair value based upon assumptions	The value as of the dates set forth in the table above was based on upon following assumptions: June 30, 2020 December 31, 2019 Stock price $ 1.67 $ 1.97 Risk‑free interest rate 0.18 % 1.64 % Expected volatility (peer group) 106.00 % 60.00 % Expected life (in years) 3.00 3.50 Expected dividend yield 0.00 % 0.00 % Number outstanding 252,802 252,802

LEASES (Tables)

LEASES (Tables)	6 Months Ended
	Jun. 30, 2020
Leases [Abstract]
Schedule of future minimum lease payments	Future minimum lease payments under the lease agreements were as follows as of June 30, 2020 (in thousands): Amount 2020 (six months) $ 587 2021 1,106 2022 1,138 2023 1,050 2024 and thereafter 2,984 Total lease payments 6,865 Less: Interest 2,040 Present value of lease liabilities $ 4,825

RELATED PARTY TRANSACTIONS (Tab

RELATED PARTY TRANSACTIONS (Tables)	6 Months Ended
	Jun. 30, 2020
Related Party Transactions [Abstract]
Schedule of outstanding loans from related parties	The following table sets forth information relating to our loans from related persons outstanding as of June 30, 2020 and interest paid during the six months ended June 30, 2020 (in thousands): Class Lender Interest Rate Date of Loan Term of Loan Principal Amount Outstanding at June 30, 2020 Amount of Interest Paid Current, Promissory note payable to related parties: Lan T. Tran (2) 10% 4/29/2016 Due on Demand $ 20 $ — Lan T. Tran (2) 11% 2/10/2018 Due on Demand — 35 Lan T. Tran (2) 10% 2/9/2019 Due on Demand 14 — Subtotal 34 35 Revolving line of credit Yutaka Niihara (2) 5.25% 12/27/2019 Due on Demand 600 18 Subtotal 600 18 Total $ 634 $ 53 The following table sets forth information relating to our loans from related persons outstanding at any time during the year ended December 31, 2019: Class Lender Interest Rate Date of Loan Term of Loan Principal Amount Outstanding at December 31, 2019 Highest Principal Outstanding Amount of Principal Repaid or Converted into Stock Amount of Interest Paid Conversion Rate Current, Promissory note payable to related parties: Lan T. Tran (2) 10% 4/29/2016 Due on Demand $ 20 $ 20 $ — $ — — Hope International Hospice, Inc. (1) 10% 6/3/2016 Due on Demand — 250 250 78 — Lan T. Tran (2) 10% 2/9/2017 Due on Demand — 12 — 2 — Yutaka Niihara (2)(3) 10% 9/14/2017 Due on Demand — 904 27 2 — Lan T. Tran (2) 11% 2/10/2018 Due on Demand 159 159 — — — Lan T. Tran (2) 10% 2/9/2019 Due on Demand 14 14 — — — Subtotal 193 1,359 277 82 Current, Convertible notes payable to related parties: Yasushi Nagasaki (2) 10% 6/29/2012 Due on Demand — 200 200 56 $ 3.30 Yutaka & Soomi Niihara (2)(3) 10% 11/16/2015 2 years — 200 200 73 $ 4.50 Wei Peu Zen (3) 10% 11/6/2017 2 years — 5,000 5,000 597 $ 10.00 Profit Preview International Group, Ltd. (4) 10% 2/1/2018 2 years — 4,037 4,037 385 $ 10.00 Profit Preview International Group, Ltd. (4) 10% 3/21/2018 2 years — 5,363 5,363 442 $ 10.00 Subtotal — 14,800 14,800 1,553 Revolving line of credit Yutaka Niihara (2) 5% 12/27/2019 Due on Demand 600 600 — — Subtotal 600 600 — — Total $ 793 $ 16,759 $ 15,077 $ 1,635 ( 1) Dr. Niihara, a Director and the Chairman, and Chief Executive Officer of the Company, is also a director and the Chief Executive Officer of Hope International Hospice, Inc. (2) Officer. (3) Director. (4) Mr. Zen, a Director of the Company, is the sole owner of Profit Preview International Group, Ltd.

BASIS OF PRESENTATION (Details

BASIS OF PRESENTATION (Details Narrative)	Jul. 17, 2019shares	Jun. 30, 2020USD ($)	Jun. 30, 2019USD ($)
Variable Interest Entity [Line Items]
Net decrease to cash flow used by operating activities		$ (1,719,000)	$ (1,260,000)
Restatement Adjustment [Member]
Variable Interest Entity [Line Items]
Net decrease to cash flow used by operating activities			923,000
Restatement Adjustment [Member] | EJ Holding, Inc. [Member]
Variable Interest Entity [Line Items]
Net decrease to cash flow used by operating activities			$ (953,000)
Emmaus Life Sciences, Inc. [Member]
Variable Interest Entity [Line Items]
Reverse stock split	1-for-6
Reverse stock split, conversion ratio	0.167
Telemynd [Member]
Variable Interest Entity [Line Items]
Common stock shares, Stock split ratio | shares	1

BASIS OF PRESENTATION (Detail_2

BASIS OF PRESENTATION (Details 1) - USD ($) $ in Thousands		Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018
CURRENT ASSETS
Cash and cash equivalents		$ 1,032		$ 1,769	$ 2,947
Accounts receivable, net		1,457		2,150	2,282
Inventories, net		7,863		7,971	5,906
Investment in marketable securities		27,007		27,929	32,890
Prepaid expenses and other current assets		1,170		1,402	596
Total current assets		38,536		41,221	44,621
Property and equipment, net		141		151	145
Equity method investment					13,366
Right of use assets		4,283		4,474	4,285
Deposits and other assets		285		285	412
Total other assets					18,063
Total assets		56,250		59,456	62,829
CURRENT LIABILITIES
Accounts payable and accrued expenses		10,377		11,498	11,517
Operating lease liabilities, current portion		1,103		991	857
Other current liabilities		957		5,748	5,261
Warrant derivative liabilities		1,539		38	9,023
Notes payable, net of discount		4,271		3,749	11,254
Notes payable to related parties		34		193	470
Convertible notes payable, net of discount				2,995	13,867
Convertible notes payable to related parties, net of discount					14,180
Total current liabilities		26,475		32,827	66,429
Operating lease liabilities, less current portion		3,722		3,932	3,781
Other long-term liabilities		36,434		33,750	35,330
Convertible notes payable, net of discount, less current portion		3,150			450
Total liabilities		70,269		70,509	105,990
STOCKHOLDERS’ DEFICIT
Preferred stock — par value $0.001 per share, 15,000,000 shares authorized, none issued or outstanding
Common stock — par value $0.001 per share, 250,000,000 shares authorized, 37,880,211 shares outstanding at June 30, 2019		49		48	38
Additional paid-in capital		216,376		215,207	163,248
Accumulated other comprehensive loss		(51)		(79)	(56)
Accumulated deficit		(230,393)		(226,229)	(206,391)
Total stockholders’ deficit		(14,019)	$ (4,732)	(11,053)	(43,161)	$ (32,311)	$ (21,708)
Total liabilities & stockholders’ deficit		$ 56,250		$ 59,456	62,829
Previously Reported [Member]
CURRENT ASSETS
Cash and cash equivalents					15,169
Accounts receivable, net					1,981
Inventories, net					5,906
Investment in marketable securities					32,890
Prepaid expenses and other current assets					703
Total current assets					56,649
Property and equipment, net					145
Right of use assets					4,285
Deposits and other assets					412
Total other assets					4,697
Total assets					61,491
CURRENT LIABILITIES
Accounts payable and accrued expenses					11,455
Operating lease liabilities, current portion					857
Other current liabilities					5,259
Notes payable, net of discount					11,163
Notes payable to related parties					470
Convertible notes payable, net of discount					13,867
Convertible notes payable to related parties, net of discount					14,180
Total current liabilities					57,251
Operating lease liabilities, less current portion					3,781
Other long-term liabilities					35,330
Warrant derivative liabilities					1,200
Notes payable, net of discount, less current portion					703
Convertible notes payable, net of discount, less current portion					450
Total liabilities					98,715
STOCKHOLDERS’ DEFICIT
Preferred stock — par value $0.001 per share, 15,000,000 shares authorized, none issued or outstanding
Common stock — par value $0.001 per share, 250,000,000 shares authorized, 37,880,211 shares outstanding at June 30, 2019					36
Additional paid-in capital					153,084
Accumulated other comprehensive loss					(56)
Accumulated deficit					(189,503)
Total stockholders’ deficit					(36,439)
Noncontrolling interest					(785)
Total liabilities & stockholders’ deficit					61,491
Adjustments [Member]
CURRENT ASSETS
Cash and cash equivalents	[1]				(12,222)
Accounts receivable, net	[2]				301
Prepaid expenses and other current assets	[2],[3]				(107)
Total current assets					(12,028)
Equity method investment	[1]				13,366
Total other assets					13,366
Total assets					1,338
CURRENT LIABILITIES
Accounts payable and accrued expenses	[2],[3]				62
Other current liabilities	[2]				2
Warrant derivative liabilities	[2],[4]				9,023
Notes payable, net of discount	[4]				91
Total current liabilities					9,178
Warrant derivative liabilities	[2]				(1,200)
Notes payable, net of discount, less current portion	[4]				(703)
Total liabilities					7,275
STOCKHOLDERS’ DEFICIT
Preferred stock — par value $0.001 per share, 15,000,000 shares authorized, none issued or outstanding
Common stock — par value $0.001 per share, 250,000,000 shares authorized, 37,880,211 shares outstanding at June 30, 2019	[5]				2
Additional paid-in capital	[4],[6]				10,164
Accumulated deficit	[6]				(16,888)
Total stockholders’ deficit					(6,722)
Noncontrolling interest	[1]				785
Total liabilities & stockholders’ deficit					$ 1,338
[1]	EJ Holdings adjustments: the correction of this misstatement resulted in increases of $13.4 million in equity method investment, $172,000 in accounts payable and accrued expenses, and $785,000 in non-controlling interest and decreases of $12.2 million in cash and cash equivalent and $187,000 in prepaid expenses and other current assets
[2]	Corrections of other misstatement: period adjustment and reclassification of variable consideration resulted in an increase of $301,000 in accounts receivable and a decrease of $110,000 in accounts payable and accrued expenses, a decrease of $10,000 in income tax receivable and an increase of $24,000 in income tax payable; a reclassification of GPB warrants resulted an increase of short-term warrant liability and a decrease of long-term warrant liability of $1.2 million; and correction of tax provision resulted an increase of $90,000 in income tax receivable and a decrease of $24,000 in income tax payable.
[3]	EJ Holdings adjustments: the correction of this misstatement resulted in increases of $13.4 million in equity method investment, $172,000 in accounts payable and accrued expenses, and $785,000 in non-controlling interest and decreases of $12.2 million in cash and cash equivalent and $187,000 in prepaid expenses and other current assets.
[4]	Warrant adjustments: the correction of this misstatement resulted in increases of $7.8 million in warrant derivative current liabilities, and $90,000 in short-term note payable and decreases of $703,000 in long-term notes payable and $9.7 million in additional paid-in capital.
[5]	Retrospective adjustments made to common stock resulted from recapitalization transaction in July 2019.
[6]	Carryforward impact on 2018 restatement adjustments, including cashless warrant adjustments which resulted in an increase in additional paid-in capital and a decrease in retained earnings of $18.3 million.

BASIS OF PRESENTATION (Parenthe

BASIS OF PRESENTATION (Parenthetical) (Details 1) - USD ($)		6 Months Ended
		Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
Error Corrections And Prior Period Adjustments Restatement [Line Items]
Preferred stock, par value (in dollars per share)		$ 0.001	$ 0.001	$ 0.001
Preferred stock, authorized		15,000,000	20,000,000	15,000,000
Preferred stock, issued		0	0	0
Preferred stock, outstanding		0	0	0
Common stock, par value (in dollars per share)		$ 0.001	$ 0.001	$ 0.001
Common stock, authorized		250,000,000	250,000,000	250,000,000
Common stock, outstanding		48,987,189	37,880,211	48,471,446
Increase in equity method investment			$ 13,366,000
Increase (decrease) in accounts payable and accrued expenses		$ 10,377,000	11,517,000	$ 11,498,000
Increase (decrease) in cash and cash equivalent		(730,000)	(958,000)
Decrease in prepaid expenses and other current assets		1,170,000	596,000	1,402,000
Increase in warrant derivative current liabilities		1,539,000	9,023,000	38,000
Increase in short-term notes payable		4,271,000	11,254,000	3,749,000
Increase (decrease) in additional paid-in capital		216,376,000	163,248,000	215,207,000
Increase in accounts receivable		1,457,000	2,282,000	2,150,000
Decrease in retained earnings		$ (230,393,000)	(206,391,000)	$ (226,229,000)
Adjustments [Member]
Error Corrections And Prior Period Adjustments Restatement [Line Items]
Increase in equity method investment	[1]		13,366,000
Increase (decrease) in accounts payable and accrued expenses	[2],[3]		62,000
Increase in noncontrolling interest	[1]		785,000
Increase (decrease) in cash and cash equivalent			953,000
Decrease in prepaid expenses and other current assets	[2],[3]		(107,000)
Increase in warrant derivative current liabilities	[2],[4]		9,023,000
Increase in short-term notes payable	[4]		91,000
Decrease in long-term notes payable	[4]		(703,000)
Increase (decrease) in additional paid-in capital	[4],[5]		10,164,000
Increase in accounts receivable	[2]		301,000
Increase in short-term warrant liability			1,200,000
Decrease in long-term warrant liability	[2]		(1,200,000)
Decrease in retained earnings	[5]		(16,888,000)
Adjustments [Member] | Warrant Adjustments [Member]
Error Corrections And Prior Period Adjustments Restatement [Line Items]
Increase in warrant derivative current liabilities			7,800,000
Increase in short-term notes payable			90,000
Decrease in long-term notes payable			(703,000)
Increase (decrease) in additional paid-in capital			(9,700,000)
Adjustments [Member] | Warrant Adjustments [Member] | 2018 Warrant [Member]
Error Corrections And Prior Period Adjustments Restatement [Line Items]
Increase (decrease) in additional paid-in capital			18,300,000
Decrease in retained earnings			(18,300,000)
Adjustments [Member] | Variable Consideration [Member]
Error Corrections And Prior Period Adjustments Restatement [Line Items]
Increase (decrease) in accounts payable and accrued expenses			(110,000)
Increase in accounts receivable			301,000
Increase (decrease) in income tax receivable			(10,000)
Increase (decrease) in income tax payable			24,000
Adjustments [Member] | Tax Provision [Member]
Error Corrections And Prior Period Adjustments Restatement [Line Items]
Increase (decrease) in income tax receivable			90,000
Increase (decrease) in income tax payable			(24,000)
Adjustments [Member] | EJ Holding, Inc. [Member]
Error Corrections And Prior Period Adjustments Restatement [Line Items]
Increase in equity method investment			13,400,000
Increase (decrease) in accounts payable and accrued expenses			172,000
Increase in noncontrolling interest			785,000
Increase (decrease) in cash and cash equivalent			(12,200,000)
Decrease in prepaid expenses and other current assets			$ (187,000)
[1]	EJ Holdings adjustments: the correction of this misstatement resulted in increases of $13.4 million in equity method investment, $172,000 in accounts payable and accrued expenses, and $785,000 in non-controlling interest and decreases of $12.2 million in cash and cash equivalent and $187,000 in prepaid expenses and other current assets
[2]	Corrections of other misstatement: period adjustment and reclassification of variable consideration resulted in an increase of $301,000 in accounts receivable and a decrease of $110,000 in accounts payable and accrued expenses, a decrease of $10,000 in income tax receivable and an increase of $24,000 in income tax payable; a reclassification of GPB warrants resulted an increase of short-term warrant liability and a decrease of long-term warrant liability of $1.2 million; and correction of tax provision resulted an increase of $90,000 in income tax receivable and a decrease of $24,000 in income tax payable.
[3]	EJ Holdings adjustments: the correction of this misstatement resulted in increases of $13.4 million in equity method investment, $172,000 in accounts payable and accrued expenses, and $785,000 in non-controlling interest and decreases of $12.2 million in cash and cash equivalent and $187,000 in prepaid expenses and other current assets.
[4]	Warrant adjustments: the correction of this misstatement resulted in increases of $7.8 million in warrant derivative current liabilities, and $90,000 in short-term note payable and decreases of $703,000 in long-term notes payable and $9.7 million in additional paid-in capital.
[5]	Carryforward impact on 2018 restatement adjustments, including cashless warrant adjustments which resulted in an increase in additional paid-in capital and a decrease in retained earnings of $18.3 million.

BASIS OF PRESENTATION (Detail_3

BASIS OF PRESENTATION (Details 2) - USD ($)		3 Months Ended				6 Months Ended
		Jun. 30, 2020	Mar. 31, 2020	Jun. 30, 2019	Mar. 31, 2019	Jun. 30, 2020	Jun. 30, 2019
Error Corrections And Prior Period Adjustments Restatement [Line Items]
REVENUES, NET		$ 4,360,000		$ 5,493,000		$ 11,314,000	$ 10,200,000
COST OF GOODS SOLD		446,000		264,000		924,000	523,000
GROSS PROFIT		3,914,000		5,229,000		10,390,000	9,677,000
OPERATING EXPENSES
Research and development		589,000		540,000		1,206,000	1,053,000
Selling		1,135,000		1,891,000		2,203,000	3,370,000
General and administrative		3,725,000		2,682,000		7,382,000	6,419,000
Total operating expenses		5,449,000		5,113,000		10,791,000	10,842,000
INCOME (LOSS) FROM OPERATIONS		(1,535,000)		116,000		(401,000)	(1,165,000)
OTHER INCOME (EXPENSE)
Change in fair value of warrant derivative liabilities		(101,000)		854,000		(76,000)	(84,000)
Net losses on investment in marketable securities and long-term investment		(5,631,000)		(10,537,000)		1,208,000	(16,994,000)
Losses on equity method investment		(573,000)		(458,000)		(980,000)	(449,000)
Interest and other income (loss)		567,000		307,000		600,000	230,000
Interest expense		(1,309,000)		(7,827,000)		(3,109,000)	(16,439,000)
Total other expenses		(8,437,000)		(17,661,000)		(3,776,000)	(33,736,000)
LOSS BEFORE INCOME TAXES		(9,972,000)		(17,545,000)		(4,177,000)	(34,901,000)
INCOME TAXES (BENEFIT)		(499,000)		51,000		(213,000)	103,000
NET LOSS		(9,473,000)	$ 5,509,000	(17,596,000)	$ (17,408,000)	(3,964,000)	(35,004,000)
NET LOSS ATTRIBUTABLE TO THE COMPANY				(17,596,000)			(35,004,000)
COMPONENTS OF OTHER COMPREHENSIVE INCOME (LOSS)
Foreign currency translation adjustments		(33,000)	$ 61,000	6,000	$ 7,000	28,000	13,000
Other comprehensive income (loss)		(33,000)		6,000		28,000	13,000
COMPREHENSIVE INCOME (LOSS)				(17,590,000)			(34,991,000)
Amounts attributable to noncontrolling interest:
COMPREHENSIVE LOSS		$ (9,506,000)		$ (17,590,000)		$ (3,936,000)	$ (34,991,000)
NET LOSS PER COMMON SHARE - BASIC AND DILUTED		$ (0.19)		$ (0.47)		$ (0.08)	$ (0.93)
WEIGHTED-AVERAGE COMMON SHARES OUTSTANDING		48,987,189		37,836,678		48,805,829	37,656,058
Previously Reported [Member]
Error Corrections And Prior Period Adjustments Restatement [Line Items]
REVENUES, NET				$ 5,869,000			$ 11,176,000
COST OF GOODS SOLD				195,000			395,000
GROSS PROFIT				5,674,000			10,781,000
OPERATING EXPENSES
Research and development				540,000			1,053,000
Selling				1,903,000			3,388,000
General and administrative				3,851,000			7,532,000
Total operating expenses				6,294,000			11,973,000
INCOME (LOSS) FROM OPERATIONS				(620,000)			(1,192,000)
OTHER INCOME (EXPENSE)
Change in fair value of warrant derivative liabilities				247,000			199,000
Net losses on investment in marketable securities and long-term investment				(10,537,000)			(16,994,000)
Interest and other income (loss)				274,000			163,000
Interest expense				(8,474,000)			(15,439,000)
Total other expenses				(18,490,000)			(32,071,000)
LOSS BEFORE INCOME TAXES				(19,110,000)			(33,263,000)
INCOME TAXES (BENEFIT)				217,000			217,000
NET LOSS				(19,327,000)			(33,480,000)
Net (income) loss attributable to noncontrolling interests				688,000			674,000
NET LOSS ATTRIBUTABLE TO THE COMPANY				(18,639,000)			(32,806,000)
COMPONENTS OF OTHER COMPREHENSIVE INCOME (LOSS)
Foreign currency translation adjustments				(9,000)			(2,000)
Other comprehensive income (loss)				(9,000)			(2,000)
COMPREHENSIVE INCOME (LOSS)				(19,336,000)			(33,482,000)
Amounts attributable to noncontrolling interest:
Net (income) loss attributable to noncontrolling interests				688,000			674,000
Foreign currency translation adjustments				15,000			14,000
Comprehensive (income) loss attributable to noncontrolling interest				703,000			688,000
COMPREHENSIVE LOSS				$ (18,633,000)			$ (32,794,000)
NET LOSS PER COMMON SHARE - BASIC AND DILUTED				$ (0.52)			$ (0.91)
WEIGHTED-AVERAGE COMMON SHARES OUTSTANDING				35,857,944			35,857,944
Adjustments [Member]
Error Corrections And Prior Period Adjustments Restatement [Line Items]
REVENUES, NET	[1]			$ (376,000)			$ (976,000)
COST OF GOODS SOLD	[1]			69,000			128,000
GROSS PROFIT				(445,000)			(1,104,000)
OPERATING EXPENSES
Selling	[1]			(12,000)			(18,000)
General and administrative	[1],[2]			(1,169,000)			(1,113,000)
Total operating expenses				(1,181,000)			(1,131,000)
INCOME (LOSS) FROM OPERATIONS				736,000			27,000
OTHER INCOME (EXPENSE)
Change in fair value of warrant derivative liabilities	[3]			607,000			(283,000)
Losses on equity method investment	[2]			(458,000)			(449,000)
Interest and other income (loss)	[1],[2]			33,000			67,000
Interest expense	[1],[3]			647,000			(1,000,000)
Total other expenses				829,000			(1,665,000)
LOSS BEFORE INCOME TAXES				1,565,000			(1,638,000)
INCOME TAXES (BENEFIT)	[1]			(166,000)			(114,000)
NET LOSS				1,731,000			(1,524,000)
Net (income) loss attributable to noncontrolling interests	[2]			(688,000)			(674,000)
NET LOSS ATTRIBUTABLE TO THE COMPANY				1,043,000			(2,198,000)
COMPONENTS OF OTHER COMPREHENSIVE INCOME (LOSS)
Foreign currency translation adjustments	[2]			15,000			15,000
Other comprehensive income (loss)				15,000			15,000
COMPREHENSIVE INCOME (LOSS)				1,746,000			(1,509,000)
Amounts attributable to noncontrolling interest:
Net (income) loss attributable to noncontrolling interests	[2]			(688,000)			(674,000)
Foreign currency translation adjustments	[2]			(15,000)			(14,000)
Comprehensive (income) loss attributable to noncontrolling interest				(703,000)			(688,000)
COMPREHENSIVE LOSS				$ 1,043,000			$ (2,197,000)
NET LOSS PER COMMON SHARE - BASIC AND DILUTED				$ 0.05			$ (0.01)
WEIGHTED-AVERAGE COMMON SHARES OUTSTANDING				37,836,678			37,656,058
[1]	Corrections of other misstatement: period adjustment of variable consideration resulted in a decrease of $ in revenue s , net; and reclassification of shipping cost and royalty expense to cost of sales resulted in an increase of $ in cost of sales and decreases of $ and $ in selling expense and general and administrative expense, respectively . Corrections of other misstatement for the six months ended June 30, 2019 : period adjustment of variable consideration resulted in a decrease of $ in revenues, net ; reclassification of shipping cost and royalty expense to cost of sales resulted in an increase of $ in cost of sales and decreases of $ and $ in selling expense and general and administrative expense, respectively; correction of stock modification accounting resulted in a decrease of $ 52,000 in general and administrative expense; correction of accounting treatment for convertible notes resulted in an increase of $ 1.3 million in interest expense ; and correction of income tax provision resulted in an decrease of $ 113,000 in income tax provision .
[2]	EJ Holdings adjustments: the correction of this misstatement resulted in increases of $33,000 in interest income and $15,000 in foreign currency translation adjustments and decreases of $1.1million in general and administrative expenses, $458,000 in loss on equity method investment, and $688,000 in net loss attributable to noncontrolling interest for three months ended June 30, 2019.  The correction of this misstatement resulted in increases of $67,000 in interest income and $14,000 in foreign currency translation adjustments and decreases of $1.1million in general and administrative expense, $449,000 in loss on equity method investment, and $674,000 in net loss attributable to noncontrolling interest for six months ended June 30, 2019.
[3]	Warrant adjustments: the correction of this misstatement resulted in increases of $647,000 in interest expense and $607,000 in change in fair value of warrant derivative liabilities for the three months ended June 2019. The correction of this misstatement resulted in an increase of $335,000 in interest expense and a decrease of $283,000 in change in fair value of warrant derivative liabilities for six months ended June 30, 2019.

BASIS OF PRESENTATION (Parent_2

BASIS OF PRESENTATION (Parenthetical) (Details 2) - USD ($)		3 Months Ended		6 Months Ended
		Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Error Corrections And Prior Period Adjustments Restatement [Line Items]
Increase (decrease) in general and administrative expenses		$ 3,725,000	$ 2,682,000	$ 7,382,000	$ 6,419,000
Losses on equity method investment		(573,000)	(458,000)	(980,000)	(449,000)
Increase (decrease) in interest expense		1,309,000	7,827,000	3,109,000	16,439,000
Increase (decrease) in change in fair value of warrant derivative liabilities		(101,000)	854,000	(76,000)	(84,000)
Increase (decrease) in revenues, net		4,360,000	5,493,000	11,314,000	10,200,000
Decrease in selling expense		$ 1,135,000	1,891,000	$ 2,203,000	3,370,000
Adjustments [Member]
Error Corrections And Prior Period Adjustments Restatement [Line Items]
Increase (decrease) in general and administrative expenses	[1],[2]		(1,169,000)		(1,113,000)
Losses on equity method investment	[2]		(458,000)		(449,000)
Decreases in net income (loss) attributable to noncontrolling interest	[2]		688,000		674,000
Increase in foreign currency translation adjustments	[2]		15,000		14,000
Increase (decrease) in interest expense	[1],[3]		(647,000)		1,000,000
Increase (decrease) in change in fair value of warrant derivative liabilities	[3]		607,000		(283,000)
Increase (decrease) in revenues, net	[1]		(376,000)		(976,000)
Decrease in selling expense	[1]		(12,000)		(18,000)
Increase (decrease) income tax provision					(113,000)
Adjustments [Member] | Warrant Adjustments [Member]
Error Corrections And Prior Period Adjustments Restatement [Line Items]
Increase (decrease) in interest expense			647,000		335,000
Increase (decrease) in change in fair value of warrant derivative liabilities			(607,000)		(283,000)
Adjustments [Member] | Variable Consideration [Member]
Error Corrections And Prior Period Adjustments Restatement [Line Items]
Increase (decrease) in revenues, net			(376,000)		(976,000)
Adjustments [Member] | Reclassification of Shipping Cost and Royalty Expense [Member]
Error Corrections And Prior Period Adjustments Restatement [Line Items]
Increase (decrease) in general and administrative expenses			(58,000)		(110,000)
Increase in cost of sales			69,000		128,000
Decrease in selling expense			(12,000)		(18,000)
Adjustments [Member] | Stock Modification Accounting [Member]
Error Corrections And Prior Period Adjustments Restatement [Line Items]
Increase (decrease) in general and administrative expenses					(52,000)
Adjustments [Member] | Accounting Treatment for Convertible Notes [Member]
Error Corrections And Prior Period Adjustments Restatement [Line Items]
Increase (decrease) in interest expense					1,300,000
Adjustments [Member] | EJ Holding, Inc. [Member]
Error Corrections And Prior Period Adjustments Restatement [Line Items]
Increase (decrease) in general and administrative expenses			(1,100,000)		(1,100,000)
Losses on equity method investment			(458,000)		(449,000)
Increase in interest income			33,000		67,000
Decreases in net income (loss) attributable to noncontrolling interest			(688,000)		(674,000)
Increase in foreign currency translation adjustments			$ 15,000		$ 14,000
[1]	Corrections of other misstatement: period adjustment of variable consideration resulted in a decrease of $ in revenue s , net; and reclassification of shipping cost and royalty expense to cost of sales resulted in an increase of $ in cost of sales and decreases of $ and $ in selling expense and general and administrative expense, respectively . Corrections of other misstatement for the six months ended June 30, 2019 : period adjustment of variable consideration resulted in a decrease of $ in revenues, net ; reclassification of shipping cost and royalty expense to cost of sales resulted in an increase of $ in cost of sales and decreases of $ and $ in selling expense and general and administrative expense, respectively; correction of stock modification accounting resulted in a decrease of $ 52,000 in general and administrative expense; correction of accounting treatment for convertible notes resulted in an increase of $ 1.3 million in interest expense ; and correction of income tax provision resulted in an decrease of $ 113,000 in income tax provision .
[2]	EJ Holdings adjustments: the correction of this misstatement resulted in increases of $33,000 in interest income and $15,000 in foreign currency translation adjustments and decreases of $1.1million in general and administrative expenses, $458,000 in loss on equity method investment, and $688,000 in net loss attributable to noncontrolling interest for three months ended June 30, 2019.  The correction of this misstatement resulted in increases of $67,000 in interest income and $14,000 in foreign currency translation adjustments and decreases of $1.1million in general and administrative expense, $449,000 in loss on equity method investment, and $674,000 in net loss attributable to noncontrolling interest for six months ended June 30, 2019.
[3]	Warrant adjustments: the correction of this misstatement resulted in increases of $647,000 in interest expense and $607,000 in change in fair value of warrant derivative liabilities for the three months ended June 2019. The correction of this misstatement resulted in an increase of $335,000 in interest expense and a decrease of $283,000 in change in fair value of warrant derivative liabilities for six months ended June 30, 2019.

BASIS OF PRESENTATION (Detail_4

BASIS OF PRESENTATION (Details 3) - USD ($) $ in Thousands		3 Months Ended				6 Months Ended
		Jun. 30, 2020	Mar. 31, 2020	Jun. 30, 2019	Mar. 31, 2019	Jun. 30, 2020	Jun. 30, 2019
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss		$ (9,473)	$ 5,509	$ (17,596)	$ (17,408)	$ (3,964)	$ (35,004)
Adjustments to reconcile net loss to net cash flows used in operating activities
Depreciation and amortization						30	35
Impairment loss on long-term investment							524
Amortization of discount of notes payable and convertible notes payable						2,102	13,771
Foreign exchange adjustments on convertible notes and notes payable						(70)	(208)
Net losses (gains) on equity investment in marketable securities						(1,208)	16,470
Loss on equity method investments		573		458		980	449
Share-based compensation						428	1,026
Change in fair value of warrant derivative liabilities		101		(854)		76	84
Net changes in operating assets and liabilities
Accounts receivable						693	(364)
Inventories						(267)	(1,202)
Prepaid expenses and other current assets						528	149
Other non-current assets						183	(4,298)
Accounts payable and accrued expenses						(412)	4,054
Income tax receivable and payable						(295)	(113)
Deferred revenue							500
Deferred rent							(287)
Other current liabilities						(4,903)	(63)
Other long-term liabilities						2,586	3,217
Net cash flows used in operating activities						(1,719)	(1,260)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchases of property and equipment						(13)	(21)
Sale of marketable securities						2,130	221
Net cash flows provided by investing activities						1,556	200
CASH FLOWS FROM FINANCING ACTIVITIES
Payments of convertible notes						(1,500)	(3,368)
Proceeds from exercise of warrants						142	186
Proceeds from issuance of common stock							3,261
Proceeds from conversion of notes payable to common stock							21
Net cash flows provided by (used in) financing activities						(560)	100
Effect of exchange rate changes on cash						(7)	2
Net decrease in cash, cash equivalents and restricted cash						(730)	(958)
Cash, cash equivalents and restricted cash, beginning of period			$ 1,769		3,905	1,769	3,905
Cash, cash equivalents and restricted cash, end of period		$ 1,039		2,947		1,039	2,947
SUPPLEMENTAL DISCLOSURES OF CASH FLOW ACTIVITIES
Interest paid						802	549
Income taxes paid						$ 82	216
NON-CASH INVESTING AND FINANCING ACTIVITIES
Beneficial conversion feature relating to convertible notes							8,764
Common stocks issued on exercise of warrants							186
Conversion of notes payable and acrued interest to common stock							329
Initial recognition of right-of-use lease asset							2,922
Previously Reported [Member]
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss				(19,327)			(33,480)
Adjustments to reconcile net loss to net cash flows used in operating activities
Depreciation and amortization							35
Impairment loss on long-term investment							524
Amortization of discount of notes payable and convertible notes payable							12,770
Foreign exchange adjustments on convertible notes and notes payable							49
Net losses (gains) on equity investment in marketable securities							16,470
Share-based compensation							974
Change in fair value of warrant derivative liabilities				(247)			(199)
Net changes in operating assets and liabilities
Accounts receivable							(630)
Inventories							(1,202)
Prepaid expenses and other current assets							69
Other non-current assets							(4,298)
Accounts payable and accrued expenses							3,226
Deferred revenue							500
Deferred rent							(287)
Other current liabilities							79
Other long-term liabilities							3,217
Net cash flows used in operating activities							(2,183)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchases of property and equipment							(21)
Sale of marketable securities							221
Net cash flows provided by investing activities							200
CASH FLOWS FROM FINANCING ACTIVITIES
Payments of convertible notes							(3,368)
Proceeds from exercise of warrants							186
Proceeds from issuance of common stock							3,261
Proceeds from conversion of notes payable to common stock							21
Net cash flows provided by (used in) financing activities							100
Effect of exchange rate changes on cash							(28)
Net decrease in cash, cash equivalents and restricted cash							(1,911)
Cash, cash equivalents and restricted cash, beginning of period					17,080		17,080
Cash, cash equivalents and restricted cash, end of period				15,169			15,169
SUPPLEMENTAL DISCLOSURES OF CASH FLOW ACTIVITIES
Interest paid							934
Income taxes paid							217
NON-CASH INVESTING AND FINANCING ACTIVITIES
Beneficial conversion feature relating to convertible notes							8,764
Common stocks issued on exercise of warrants							186
Conversion of notes payable and acrued interest to common stock							308
Initial recognition of right-of-use lease asset							2,922
Adjustments [Member]
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss				1,731			(1,524)
Adjustments to reconcile net loss to net cash flows used in operating activities
Amortization of discount of notes payable and convertible notes payable							1,001
Foreign exchange adjustments on convertible notes and notes payable							(257)
Loss on equity method investments	[1]			458			449
Share-based compensation							52
Change in fair value of warrant derivative liabilities	[2]			(607)			283
Net changes in operating assets and liabilities
Accounts receivable							266
Prepaid expenses and other current assets							80
Accounts payable and accrued expenses							828
Income tax receivable and payable							(113)
Other current liabilities							(142)
Net cash flows used in operating activities							923
CASH FLOWS FROM FINANCING ACTIVITIES
Effect of exchange rate changes on cash							30
Net decrease in cash, cash equivalents and restricted cash							953
Cash, cash equivalents and restricted cash, beginning of period					$ (13,175)		(13,175)
Cash, cash equivalents and restricted cash, end of period				$ (12,222)			(12,222)
SUPPLEMENTAL DISCLOSURES OF CASH FLOW ACTIVITIES
Interest paid							(385)
Income taxes paid							$ (1)
[1]	EJ Holdings adjustments: the correction of this misstatement resulted in increases of $33,000 in interest income and $15,000 in foreign currency translation adjustments and decreases of $1.1million in general and administrative expenses, $458,000 in loss on equity method investment, and $688,000 in net loss attributable to noncontrolling interest for three months ended June 30, 2019.  The correction of this misstatement resulted in increases of $67,000 in interest income and $14,000 in foreign currency translation adjustments and decreases of $1.1million in general and administrative expense, $449,000 in loss on equity method investment, and $674,000 in net loss attributable to noncontrolling interest for six months ended June 30, 2019.
[2]	Warrant adjustments: the correction of this misstatement resulted in increases of $647,000 in interest expense and $607,000 in change in fair value of warrant derivative liabilities for the three months ended June 2019. The correction of this misstatement resulted in an increase of $335,000 in interest expense and a decrease of $283,000 in change in fair value of warrant derivative liabilities for six months ended June 30, 2019.

SUMMARY OF SIGNIFICANT ACCOUN_4

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019	Jun. 30, 2019	Dec. 31, 2018
Cash And Cash Equivalents [Abstract]
Cash and cash equivalents	$ 1,032	$ 1,769	$ 2,947
Restricted cash	7
Total cash, cash equivalents and restricted cash shown in the consolidated statements of cash flows	$ 1,039	$ 1,769	$ 2,947	$ 3,905

SUMMARY OF SIGNIFICANT ACCOUN_5

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - shares	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Accounting Policies [Abstract]
Potentially dilutive securities outstanding	17,288,829	17,996,931

REVENUES (Details)

REVENUES (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Disaggregation Of Revenue [Line Items]
Revenues, net	$ 4,360	$ 5,493	$ 11,314	$ 10,200
Endari [Member]
Disaggregation Of Revenue [Line Items]
Revenues, net	4,349	5,390	11,063	9,992
Other [Member]
Disaggregation Of Revenue [Line Items]
Revenues, net	$ 11	$ 103	$ 251	$ 208

REVENUES (Details 1)

REVENUES (Details 1) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Disaggregation Of Revenue [Line Items]
Beginning balance	$ 1,897	$ 981
Provision related to sales in the current year	3,511	2,395
Adjustments related prior period sales	(70)
Credit and payments made	(2,532)	(1,749)
Ending balance	2,806	1,627
Trade Discounts, Allowances and Chargebacks [Member]
Disaggregation Of Revenue [Line Items]
Beginning balance	228	84
Provision related to sales in the current year	1,438	649
Adjustments related prior period sales	16
Credit and payments made	(1,208)	(614)
Ending balance	474	119
Government Rebates and Other Incentives [Member]
Disaggregation Of Revenue [Line Items]
Beginning balance	1,354	798
Provision related to sales in the current year	1,955	1,625
Adjustments related prior period sales	(43)
Credit and payments made	(1,324)	(1,135)
Ending balance	1,942	1,288
Returns [Member]
Disaggregation Of Revenue [Line Items]
Beginning balance	315	99
Provision related to sales in the current year	118	121
Adjustments related prior period sales	(43)
Ending balance	$ 390	$ 220

REVENUES (Details 2)

REVENUES (Details 2) - Revenue Benchmark - Customer Concentration Risk	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Customer A [Member]
Entity Wide Revenue Major Customer [Line Items]
Concentration risk, percentage	55.00%	58.00%	54.00%	61.00%
Customer B [Member]
Entity Wide Revenue Major Customer [Line Items]
Concentration risk, percentage	20.00%	25.00%	24.00%	22.00%

REVENUES (Details Narrative)

REVENUES (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019	Dec. 31, 2018
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]
Revenue from contract	$ 4,360,000	$ 5,493,000	$ 11,314,000	$ 10,200,000
Telcon, Inc. ("Telcon") [Member]
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]
Upfront payment			10,000,000
Telcon, Inc. ("Telcon") [Member] | Distribution Agreement [Member]
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]
Revenue from contract			10,000,000		$ 10,000,000
Taiba Middle East FZ LLC [Member]
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]
Upfront payment			$ 500,000
Taiba Middle East FZ LLC [Member] | Distribution Agreement [Member]
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]
Revenue from contract					$ 500,000	$ 500,000

SELECTED FINANCIAL STATEMENT _5

SELECTED FINANCIAL STATEMENT CAPTIONS - ASSETS (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019	Jun. 30, 2019
Inventory Disclosure [Abstract]
Raw materials and components	$ 1,500	$ 1,187
Work-in-process	1,836	1,629
Finished goods	4,948	5,204
Inventory reserve	(421)	(49)
Total	$ 7,863	$ 7,971	$ 5,906

SELECTED FINANCIAL STATEMENT _6

SELECTED FINANCIAL STATEMENT CAPTIONS - ASSETS (Details 1) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019	Jun. 30, 2019
Prepaid Expense And Other Assets Current [Abstract]
Prepaid insurance	$ 271	$ 735
Other prepaid expenses and current assets	899	667
Total	$ 1,170	$ 1,402	$ 596

SELECTED FINANCIAL STATEMENT _7

SELECTED FINANCIAL STATEMENT CAPTIONS - ASSETS (Details 2) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019	Jun. 30, 2019
Property and equipment
Property and equipment, gross	$ 483	$ 507
Less: accumulated depreciation	(342)	(356)
Property and equipment, net	141	151	$ 145
Equipment [Member]
Property and equipment
Property and equipment, gross	345	335
Leasehold Improvements [Member]
Property and equipment
Property and equipment, gross	39	77
Furniture and Fixtures [Member]
Property and equipment
Property and equipment, gross	$ 99	$ 95

SELECTED FINANCIAL STATEMENT _8

SELECTED FINANCIAL STATEMENT CAPTIONS - ASSETS (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Property Plant And Equipment [Abstract]
Depreciation expense	$ 11,000	$ 14,000	$ 23,000	$ 28,000

INVESTMENTS (Details Narrative)

INVESTMENTS (Details Narrative) - USD ($)	Feb. 21, 2020	Oct. 31, 2018	Jul. 31, 2017	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019	Dec. 31, 2018
Schedule Of Investments [Line Items]
Shares held as marketable securities				6,222,837
Impairment loss on equity securities					$ 524,000
Net unrealized loss on marketable securities available-for-sale				$ 800,000	$ 16,500,000
Debt instrument, maturity date	Apr. 21, 2021
EJ Holding, Inc. [Member]
Schedule Of Investments [Line Items]
Investment amount							$ 32,000
Percentage of voting interest							40.00%
Unsecured debt		$ 13,600,000		13,900,000		$ 13,800,000
Debt instrument, maturity date		Sep. 30, 2028
Debt instrument annual interest		1.00%
Unsecured debt, additional borrowings				561,000
Loans receivable				$ 14,500,000
Telcon, Inc. ("Telcon") [Member]
Schedule Of Investments [Line Items]
Shares held as marketable securities				6,222,837		6,643,559
Investment			$ 31,800,000
Investment, closing price				$ 4.34		$ 4.20
Telcon, Inc. ("Telcon") [Member] | API Supply Agreement [Member] | 10-year Convertible Bond [Member]
Schedule Of Investments [Line Items]
Convertible notes payable, carrying amount						$ 31,800,000
Shares issued				420,772
Proceeds from sale of convertible notes				$ 2,100,000
Japan Industrial Partners [Member] | EJ Holding, Inc. [Member]
Schedule Of Investments [Line Items]
Equity interest							60.00%

INVESTMENTS (Details 1)

INVESTMENTS (Details 1) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Schedule Of Investments [Line Items]
Fair Value with Changes Recognized in Income	$ 27,007	$ 27,929
Marketable Equity Securities [Member]
Schedule Of Investments [Line Items]
Fair Value with Changes Recognized in Income	$ 27,007	$ 27,929

INVESTMENTS (Details 2)

INVESTMENTS (Details 2) - USD ($) $ in Thousands	3 Months Ended				6 Months Ended
	Jun. 30, 2020	Mar. 31, 2020	Jun. 30, 2019	Mar. 31, 2019	Jun. 30, 2020	Jun. 30, 2019
Schedule Of Investments [Line Items]
REVENUES, NET	$ 4,360		$ 5,493		$ 11,314	$ 10,200
GROSS PROFIT	3,914		5,229		10,390	9,677
Net loss	(9,473)	$ 5,509	(17,596)	$ (17,408)	(3,964)	(35,004)
EJ Holding, Inc. [Member]
Schedule Of Investments [Line Items]
REVENUES, NET	61		57		145	114
GROSS PROFIT	61		57		145	114
Net loss	$ (1,432)		$ (1,147)		$ (2,449)	$ (1,124)

SELECTED FINANCIAL STATEMENT _9

SELECTED FINANCIAL STATEMENT CAPTIONS - LIABILITIES (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019	Jun. 30, 2019
Accounts payable:
Clinical and regulatory expenses	$ 311	$ 232
Professional fees	960	1,183
Selling expenses	798	1,303
Manufacturing costs	3,824	4,541
Other vendors	128	18
Total accounts payable	6,021	7,277
Accrued interest payable, related parties	246	42
Accrued interest payable	407	991
Accrued expenses:
Payroll expenses	998	891
Government rebates and other rebates	1,943	1,355
Due to EJ Holdings	406	238
Other accrued expenses	356	704
Total accrued expenses	3,703	3,188
Total accounts payable and accrued expenses	$ 10,377	$ 11,498	$ 11,517

SELECTED FINANCIAL STATEMENT_10

SELECTED FINANCIAL STATEMENT CAPTIONS - LIABILITIES (Details 1) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019	Jun. 30, 2019
Other Long Term Liabilities [Line Items]
Other long-term liabilities	$ 36,434	$ 33,750	$ 35,330
Other Long-Term Liabilities [Member]
Other Long Term Liabilities [Line Items]
Other long-term liabilities	12	8
Unearned Revenue [Member]
Other Long Term Liabilities [Line Items]
Other long-term liabilities	10,000	10,500
Trade Discount [Member]
Other Long Term Liabilities [Line Items]
Other long-term liabilities	$ 26,422	$ 23,242

SELECTED FINANCIAL STATEMENT_11

SELECTED FINANCIAL STATEMENT CAPTIONS - LIABILITIES (Details Narrative) - USD ($) $ in Thousands	Jun. 12, 2017	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
Summary of Significant Accounting Policy [Line Items]
Convertible notes payable to related parties, net of discount			$ 14,180
API Supply Agreement [Member] | Telcon, Inc. ("Telcon") [Member]
Summary of Significant Accounting Policy [Line Items]
Proceeds from supply agreement	$ 31,800
API Supply Agreement [Member] | Telcon, Inc. ("Telcon") [Member] | Pharmaceutical Grade L-glutamine [Member]
Summary of Significant Accounting Policy [Line Items]
PGLG, purchase price		$ 2,000	$ 2,300
Convertible notes payable to related parties, net of discount		$ 3,700		$ 3,700

NOTES PAYABLE (Details)

NOTES PAYABLE (Details) $ / shares in Units, $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2020USD ($)Equity_Instrument$ / shares	Dec. 31, 2019USD ($)Equity_Instrument
Debt Instrument [Line Items]
Conversion Price | $ / shares	$ 10
Principal Outstanding	$ 17,143	$ 17,142
Discount Amount	1,606	3,190
Carrying Amount	$ 15,537	$ 13,952
Shares Underlying Notes | Equity_Instrument	4,638,333	1,444,291
2013 Notes payable [Member]
Debt Instrument [Line Items]
Interest rate	10.00%	10.00%
Term of Notes	Due on demand	Due on demand
Principal Outstanding	$ 928	$ 920
Carrying Amount	$ 928	$ 920
2019 Notes payable [Member]
Debt Instrument [Line Items]
Interest rate	11.00%	11.00%
Principal Outstanding	$ 2,839	$ 2,829
Carrying Amount	$ 2,839	$ 2,829
2019 Notes payable [Member] | Minimum [Member]
Debt Instrument [Line Items]
Term of Notes	Due on demand	Due on demand
2019 Notes payable [Member] | Maximum [Member]
Debt Instrument [Line Items]
Term of Notes	6 months	6 months
2020 Notes payable [Member]
Debt Instrument [Line Items]
Principal Outstanding	$ 992
Carrying Amount	$ 992
2020 Notes payable [Member] | Minimum [Member]
Debt Instrument [Line Items]
Interest rate	1.00%
Term of Notes	Due on demand
2020 Notes payable [Member] | Maximum [Member]
Debt Instrument [Line Items]
Interest rate	11.00%
Term of Notes	2 years
Notes Payable [Member]
Debt Instrument [Line Items]
Principal Outstanding	$ 4,759	$ 3,749
Carrying Amount	4,759	3,749
Principal Outstanding, Current	4,271	3,749
Notes payable, current	4,271	$ 3,749
Principal Outstanding, Non Current	488
Notes payable, non-current	$ 488
2016 Notes payable - related parties [Member]
Debt Instrument [Line Items]
Interest rate	10.00%	10.00%
Term of Notes	Due on demand	Due on demand
Principal Outstanding	$ 20	$ 20
Carrying Amount	$ 20	$ 20
2019 Notes payable - related parties [Member]
Debt Instrument [Line Items]
Interest rate	10.00%	10.00%
Term of Notes	Due on demand	Due on demand
Principal Outstanding	$ 14	$ 14
Carrying Amount	14	14
Notes payable - related parties [Member]
Debt Instrument [Line Items]
Principal Outstanding	34	193
Carrying Amount	34	193
Principal Outstanding, Current	34	193
Notes payable, current	$ 34	$ 193
2018 Notes payable - related parties [Member]
Debt Instrument [Line Items]
Interest rate		11.00%
Term of Notes		Due on demand
Principal Outstanding		$ 159
Carrying Amount		$ 159

NOTES PAYABLE (Details 1)

NOTES PAYABLE (Details 1) $ / shares in Units, $ in Thousands		6 Months Ended	12 Months Ended
		Jun. 30, 2020USD ($)Equity_Instrument$ / shares	Dec. 31, 2019USD ($)Equity_Instrument$ / shares
Debt Instrument [Line Items]
Conversion Price | $ / shares		$ 10
Principal Outstanding		$ 17,143	$ 17,142
Discount Amount		1,606	3,190
Carrying Amount		$ 15,537	$ 13,952
Shares Underlying Notes | Equity_Instrument		4,638,333	1,444,291
2019 Convertible Debentures [Member]
Debt Instrument [Line Items]
Interest rate		10.00%	10.00%
Term of Notes		18 months	18 months
Principal Outstanding		$ 9,200	$ 10,200
Discount Amount		1,606	3,185
Carrying Amount		$ 7,594	$ 7,015
Shares Underlying Notes | Equity_Instrument		4,638,333	1,080,415
2019 Convertible Debentures [Member] | Minimum [Member]
Debt Instrument [Line Items]
Conversion Price | $ / shares	[1]	$ 2	$ 2
2019 Convertible Debentures [Member] | Maximum [Member]
Debt Instrument [Line Items]
Conversion Price | $ / shares	[1]	$ 9.52	$ 9.52
Convertible Debentures [Member]
Debt Instrument [Line Items]
Principal Outstanding		$ 9,200	$ 10,200
Discount Amount		1,606	3,185
Carrying Amount		$ 7,594	$ 7,015
Shares Underlying Notes | Equity_Instrument		4,638,333	1,080,415
Principal Outstanding, Current		$ 9,200	$ 10,200
Discount Amount, Current		1,606	3,185
Convertible Debentures, Current		$ 7,594	$ 7,015
Shares Underlying Notes, Current | Equity_Instrument		4,638,333	1,080,415
[1]	The notes are convertible to Emmaus Life Sciences, Inc. shares.

NOTES PAYABLE (Details 2)

NOTES PAYABLE (Details 2) $ / shares in Units, $ in Thousands		6 Months Ended	12 Months Ended
		Jun. 30, 2020USD ($)Equity_Instrument$ / shares	Dec. 31, 2019USD ($)Equity_Instrument$ / shares	Jun. 30, 2019USD ($)
Debt Instrument [Line Items]
Conversion Price | $ / shares		$ 10
Principal Outstanding		$ 17,143	$ 17,142
Discount Amount		1,606	3,190
Carrying Amount		$ 15,537	$ 13,952
Shares Underlying Notes | Equity_Instrument		4,638,333	1,444,291
Convertible notes payable, Current			$ 2,995	$ 13,867
Convertible notes payable, Non Current		$ 3,150		$ 450
2020 Convertible Notes Payable [Member]
Debt Instrument [Line Items]
Interest rate		12.00%
Term of Notes		3 years
Conversion Price | $ / shares	[1]	$ 10
Principal Outstanding		$ 3,150
Carrying Amount		3,150
Convertible Notes Payable [Member]
Debt Instrument [Line Items]
Principal Outstanding		3,150	3,000
Discount Amount			5
Carrying Amount		3,150	$ 2,995
Shares Underlying Notes | Equity_Instrument			363,876
Principal Outstanding, Current			$ 3,000
Discount Amount, Current			5
Convertible notes payable, Current			$ 2,995
Shares Underlying Notes, Current | Equity_Instrument			363,876
Principal Outstanding, Non Current		3,150
Convertible notes payable, Non Current		$ 3,150
2018 Convertible Notes Payable [Member]
Debt Instrument [Line Items]
Interest rate			10.00%
Term of Notes			2 years
Conversion Price | $ / shares	[1]		$ 10
Principal Outstanding			$ 3,000
Discount Amount			5
Carrying Amount			$ 2,995
Shares Underlying Notes | Equity_Instrument			363,876
[1]	The notes are convertible to EMI Holding, Inc. shares.

NOTES PAYABLE (Details Narrativ

NOTES PAYABLE (Details Narrative) - USD ($)	May 08, 2020	Feb. 21, 2020	Jun. 30, 2020	Dec. 31, 2019
Debt Instrument [Line Items]
Weighted-average stated interest rate			10.00%	10.00%
Weighted average effective annual interest rate			34.00%	66.00%
Conversion Price			$ 10
Debt instrument, maturity date		Apr. 21, 2021
Paycheck Protection Program [Member]
Debt Instrument [Line Items]
Interest rate	1.00%
Principal amount	$ 797,840
Debt instrument, maturity date	Apr. 29, 2022
Date of Loan	Apr. 29, 2020
Debt prepayment description			The Note may be prepaid by the Company at any time prior to maturity with no prepayment penalties.
Debt instrument, forgiveness description			The amount of loan forgiveness would be reduced if the Company were to terminate employees or reduce salaries during such period.
Revolving Line of Credit Facility [Member] | Prime Rate [Member]
Debt Instrument [Line Items]
Debt instrument variable annual rate				3.00%
Revolving Line of Credit Facility [Member] | Dr. Yutaka Niihara [Member]
Debt Instrument [Line Items]
Line of credit maximum borrowing capacity				$ 1,000,000
Line of credit outstanding balances			$ 600,000	$ 600,000
Line of credit effective annual interest rate			10.40%
Line of credit expiration date			Nov. 22, 2022
10% of Senior Secured Debentures [Member]
Debt Instrument [Line Items]
Interest rate			10.00%

NOTES PAYABLE (Details 3)

NOTES PAYABLE (Details 3) $ in Thousands	Jun. 30, 2020USD ($)
Long Term Debt By Maturity [Abstract]
2020 (six months)	$ 9,040
2021	4,732
2022	221
2023	3,150
Total	$ 17,143

NOTES PAYABLE (Details 4)

NOTES PAYABLE (Details 4) - Amended and Restated 10% Senior Secured Convertible Debentures [Member] - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2020	Dec. 31, 2019
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation Calculation Roll Forward
Balance, beginning of period	$ 1
Fair value at issuance date		$ 132
Fair value at debt modification date	118
Change in fair value included in the statement of comprehensive income (loss)	(6)	(131)
Balance, end of period	$ 113	$ 1

NOTES PAYABLE (Details 5)

NOTES PAYABLE (Details 5)	Feb. 21, 2020$ / shares	Jun. 30, 2020$ / shares	Dec. 31, 2019$ / shares	Jun. 29, 2020$ / shares	Jun. 19, 2019$ / shares
Debt Instrument [Line Items]
Stock price				$ 1.67	$ 10.30
Conversion Price		$ 10
Binomial Lattice Model [Member]
Debt Instrument [Line Items]
Stock price	$ 1.89	1.67	$ 1.97
Conversion Price	$ 3	$ 2	$ 9.52
Binomial Lattice Model [Member] | Measurement Input, Selected Yield [Member]
Debt Instrument [Line Items]
Embedded derivative liability measurement input	19.12	15.73	16.77
Binomial Lattice Model [Member] | Measurement Input, Expected Volatility (Peer Group) [Member]
Debt Instrument [Line Items]
Embedded derivative liability measurement input	65	100	50
Binomial Lattice Model [Member] | Measurement Input, Expected Life (in Years) [Member]
Debt Instrument [Line Items]
Expected life (in years)	1 year 1 month 28 days	9 months 21 days	9 months 21 days
Binomial Lattice Model [Member] | Measurement Input, Risk Free Rate [Member]
Debt Instrument [Line Items]
Risk‑free rate	Term structure	Term structure	Term structure

STOCKHOLDERS' DEFICIT (Details

STOCKHOLDERS' DEFICIT (Details Narrative) - USD ($)

Jun. 15, 2020

Feb. 28, 2020

Feb. 21, 2020

Dec. 29, 2017

Oct. 31, 2018

Jun. 30, 2020

Mar. 31, 2020

Jun. 30, 2019

Mar. 31, 2019

Jun. 30, 2020

Jun. 30, 2019

Dec. 31, 2019

Jun. 29, 2020

Jan. 31, 2020

Jul. 17, 2019

Jul. 16, 2019

Jun. 19, 2019

Class Of Warrant Or Right [Line Items]

Debt instrument exercise price

$ 3

$ 5.87

Conversion Price

$ 10

$ 10

Maturity date

Apr. 21, 2021

Conversion debentures price

$ 3

$ 9.52

Stock price

$ 1.67

$ 10.30

Convertible notes principal amount

$ 15,537,000

$ 15,537,000

$ 13,952,000

Share-based compensation

$ 428,000

$ 1,026,000

Period remaining for recognition of unrecognized compensation cost

1 year 4 months 24 days

Value of common stock issued

$ 142,000

$ 731,000

$ 2,530,000

Common Stock [Member]

Class Of Warrant Or Right [Line Items]

Common stock issued for cash (net of issuance cost) (in shares)

515,743

76,755

322,920

Value of common stock issued

$ 1,000

$ 1,000

2011 Stock Incentive Option Plan [Member]

Class Of Warrant Or Right [Line Items]

Total unrecognized compensation cost

1,100,000

$ 1,100,000

2011 Stock Incentive Option Plan [Member] | Adjustment of Merger Exchange Ratio [Member]

Class Of Warrant Or Right [Line Items]

Exercisable term

10 years

2011 Stock Incentive Option Plan [Member] | Adjustment of Merger Exchange Ratio [Member] | Common Stock [Member]

Class Of Warrant Or Right [Line Items]

Stock options granted to purchase common stock

90,000

50,000

2011 Stock Incentive Option Plan [Member] | Adjustment of Merger Exchange Ratio [Member] | Share Based Compensation Award, Tranche One [Member]

Class Of Warrant Or Right [Line Items]

Vesting period

1 year

Vesting percentage

33.33%

2011 Stock Incentive Option Plan [Member] | Adjustment of Merger Exchange Ratio [Member] | Share Based Compensation Award, Tranche Two [Member]

Class Of Warrant Or Right [Line Items]

Vesting period

2 years

Vesting percentage

66.67%

2011 Stock Incentive Option Plan [Member] | Stock Options [Member]

Class Of Warrant Or Right [Line Items]

Number of shares authorized under the plan

9,000,000

Expiration period

10 years

Vesting period

3 years

Share-based compensation

$ 200,000

$ 400,000

$ 400,000

$ 1,000,000

Amended and Restated Warrants [Member]

Class Of Warrant Or Right [Line Items]

Debt instrument exercise price

$ 5.87

Amended and Restated Debentures [Member]

Class Of Warrant Or Right [Line Items]

Debt instrument exercise price

2

Conversion debentures price

$ 2

Initial shares under purchase agreement

100,000

Stock price

$ 2

Convertible Promissory Note [Member]

Class Of Warrant Or Right [Line Items]

Stock price

$ 1.68

$ 1.67

$ 1.67

Convertible Debt [Member] | Convertible Promissory Note [Member]

Class Of Warrant Or Right [Line Items]

Debt instrument exercise price

$ 2.05

Number of common stock to be purchased

1,250,000

Maturity date

Jun. 15, 2023

Convertible notes principal amount

$ 3,150,000

Convertible Debt [Member] | Convertible Promissory Note [Member] | Maximum [Member]

Class Of Warrant Or Right [Line Items]

Interest rate

12.00%

Convertible Debt [Member] | Convertible Promissory Note [Member] | Minimum [Member]

Class Of Warrant Or Right [Line Items]

Interest rate

11.00%

Senior Secured Convertible Debentures [Member] | Amended and Restated Debentures [Member]

Class Of Warrant Or Right [Line Items]

Percentage of monthly payments interest rate

10.00%

GPB Debt Holdings II, LLC [Member] | Amended and Restated Warrants [Member]

Class Of Warrant Or Right [Line Items]

Debt instrument exercise price

$ 10

GPB Debt Holdings II, LLC [Member] | Maximum [Member] | Amended and Restated Warrants [Member]

Class Of Warrant Or Right [Line Items]

Debt face amount percentage

1,460,000

GPB Debt Holdings II, LLC [Member] | Senior Secured Convertible Promissory Note [Member]

Class Of Warrant Or Right [Line Items]

Debt face amount percentage

240,764

Debt instrument exercise price

$ 10.80

Initial warrants exercisable period after issuance

5 years

GPB Debt Holdings II, LLC [Member] | Purchase Agreement With 10% Senior Secured Debentures [Member] | Securities Purchase Agreement [Member]

Class Of Warrant Or Right [Line Items]

Percentage of monthly payments interest rate

10.00%

Principal amount of debentures and warrants issued

$ 12,200,000

Debenture and warrants issued to original loan

$ 13,200,000

GPB Debt Holdings II, LLC [Member] | Purchase Agreement With 10% Senior Secured Debentures [Member] | Maximum [Member] | Securities Purchase Agreement [Member]

Class Of Warrant Or Right [Line Items]

Number of common stock to be purchased

1,220,000

GPB Debt Holdings II, LLC [Member] | Amended and Restated Debentures [Member]

Class Of Warrant Or Right [Line Items]

Conversion Price

$ 10

GPB Debt Holdings II, LLC [Member] | Convertible Debt [Member] | Senior Secured Convertible Promissory Note [Member]

Class Of Warrant Or Right [Line Items]

Convertible notes amount

$ 13,000,000

Convertible notes aggregate purchase price

$ 12,500,000

Original issue discount percentage

4.00%

Lincoln Park Capital Fund, LLC [Member]

Class Of Warrant Or Right [Line Items]

Initial shares under purchase agreement

100,000

Stock price

$ 2

Maximum number of common shares elect to sell

25,000,000

Maximum purchase shares of common stock

20,000

Maximum purchase of common stock in single regular purchase

$ 1,000,000

Common stock issued for cash (net of issuance cost) (in shares)

415,743

Value of common stock issued

$ 750,000

Lincoln Park Capital Fund, LLC [Member] | Minimum [Member]

Class Of Warrant Or Right [Line Items]

Affiliates beneficial ownership percentage

4.99%

STOCKHOLDERS' DEFICIT (Details)

STOCKHOLDERS' DEFICIT (Details) - GPB Debt Holdings II, LLC [Member] - Liability Instrument - Warrants [Member] - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2020	Dec. 31, 2019
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation Calculation Roll Forward
Balance, beginning of period	$ 38	$ 1,399
Change in fair value included in the statement of comprehensive income (loss)	88	(1,361)
Balance, end of period	$ 126	$ 38

STOCKHOLDERS' DEFICIT (Detail_2

STOCKHOLDERS' DEFICIT (Details 1)	Jun. 30, 2020$ / sharesshares	Jun. 29, 2020$ / shares	Dec. 31, 2019$ / sharesshares	Jun. 19, 2019$ / shares
Class Of Warrant Or Right [Line Items]
Stock price		$ 1.67		$ 10.30
GPB Debt Holdings II, LLC [Member]
Class Of Warrant Or Right [Line Items]
Stock price	$ 1.67		$ 1.97
Number outstanding | shares	252,802		252,802
GPB Debt Holdings II, LLC [Member] | Measurement Input, Risk Free Interest Rate [Member]
Class Of Warrant Or Right [Line Items]
Warrants and rights outstanding, measurement input	0.18		1.64
GPB Debt Holdings II, LLC [Member] | Measurement Input, Expected Volatility (Peer Group) [Member]
Class Of Warrant Or Right [Line Items]
Warrants and rights outstanding, measurement input	106		60
GPB Debt Holdings II, LLC [Member] | Measurement Input, Expected Life (in Years) [Member]
Class Of Warrant Or Right [Line Items]
Expected life (in years)	3 years		3 years 6 months
GPB Debt Holdings II, LLC [Member] | Measurement Input, Expected Dividend Yield [Member]
Class Of Warrant Or Right [Line Items]
Warrants and rights outstanding, measurement input	0		0

STOCKHOLDERS' DEFICIT (Detail_3

STOCKHOLDERS' DEFICIT (Details 2) - Convertible Promissory Note [Member] - Liability Instrument - Warrants [Member] $ in Thousands	6 Months Ended
	Jun. 30, 2020USD ($)
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation Calculation Roll Forward
Fair value at issuance date	$ 1,425
Change in fair value included in the statement of comprehensive income (loss)	(12)
Balance, end of period	$ 1,413

STOCKHOLDERS' DEFICIT (Detail_4

STOCKHOLDERS' DEFICIT (Details 3)	Jun. 30, 2020$ / sharesshares	Jun. 29, 2020$ / shares	Jun. 15, 2020$ / sharesshares	Jun. 19, 2019$ / shares
Class Of Warrant Or Right [Line Items]
Stock price | $ / shares		$ 1.67		$ 10.30
Warrant shares | shares	6,065,146
Convertible Promissory Note [Member]
Class Of Warrant Or Right [Line Items]
Stock price | $ / shares	$ 1.67		$ 1.68
Warrant shares | shares	1,250,000		1,250,000
Convertible Promissory Note [Member] | Measurement Input, Exercise Price
Class Of Warrant Or Right [Line Items]
Warrants and rights outstanding, measurement input	2.05		2.05
Convertible Promissory Note [Member] | Measurement Input, Risk Free Rate [Member]
Class Of Warrant Or Right [Line Items]
Warrants and rights outstanding, measurement input	0.29		0.33
Convertible Promissory Note [Member] | Measurement Input, Expected Volatility (Peer Group) [Member]
Class Of Warrant Or Right [Line Items]
Warrants and rights outstanding, measurement input	94		94
Convertible Promissory Note [Member] | Measurement Input, Expected Life (in Years) [Member]
Class Of Warrant Or Right [Line Items]
Expected life (in years)	3 years		3 years 6 months
Convertible Promissory Note [Member] | Measurement Input, Expected Dividend Yield [Member]
Class Of Warrant Or Right [Line Items]
Warrants and rights outstanding, measurement input	0		0

STOCKHOLDERS' DEFICIT (Detail_5

STOCKHOLDERS' DEFICIT (Details 4) - shares	6 Months Ended	12 Months Ended
	Jun. 30, 2020	Dec. 31, 2019
Class Of Warrant Or Right [Line Items]
Warrants outstanding, ending	6,065,146
Warrant [Member]
Class Of Warrant Or Right [Line Items]
Warrants outstanding, beginning	4,931,099	3,436,431
Assumed as part of Merger		1,044,939
Granted	1,250,000	500,729
Exercised		(51,000)
Cancelled, forfeited or expired	(115,953)
Warrants outstanding, ending	6,065,146	4,931,099

STOCKHOLDERS' DEFICIT (Detail_6

STOCKHOLDERS' DEFICIT (Details 5)	6 Months Ended
	Jun. 30, 2020$ / sharesshares
Class Of Warrant Or Right [Line Items]
Number of Warrants Issued, Outstanding	6,065,146
Total, Exercisable	4,815,146
Warrants Issued Prior to January 1, 2019 - Exercise Price $2.00-$10.76 [Member]
Class Of Warrant Or Right [Line Items]
Number of Warrants Issued, Outstanding	3,439,007
Weighted Average Remaining Contractual Life (Years), Outstanding	2 years 1 month 13 days
Weighted Average Exercise Price, Outstanding | $ / shares	$ 4.38
Total, Exercisable	3,439,007
Weighted Average Exercise Price, Exercisable | $ / shares	$ 4.38
Warrants Issued Prior to January 1, 2019 [Member]
Class Of Warrant Or Right [Line Items]
Number of Warrants Issued, Outstanding	3,439,007
Total, Exercisable	3,439,007
Warrants Issued in 2019 - Exercise Price $ 6.12 [Member]
Class Of Warrant Or Right [Line Items]
Number of Warrants Issued, Outstanding	32,391
Weighted Average Remaining Contractual Life (Years), Outstanding	3 years 10 months 28 days
Weighted Average Exercise Price, Outstanding | $ / shares	$ 6.12
Total, Exercisable	32,391
Weighted Average Exercise Price, Exercisable | $ / shares	$ 6.12
Warrants Issued in 2019 - Exercise Price $12.00 [Member]
Class Of Warrant Or Right [Line Items]
Number of Warrants Issued, Outstanding	76,575
Weighted Average Remaining Contractual Life (Years), Outstanding	3 years 2 months 23 days
Weighted Average Exercise Price, Outstanding | $ / shares	$ 12
Total, Exercisable	76,575
Weighted Average Exercise Price, Exercisable | $ / shares	$ 12
Warrants Issued in 2019 - Exercise Price $14.04 [Member]
Class Of Warrant Or Right [Line Items]
Number of Warrants Issued, Outstanding	174,999
Weighted Average Remaining Contractual Life (Years), Outstanding	2 years 9 months
Weighted Average Exercise Price, Outstanding | $ / shares	$ 14.04
Total, Exercisable	174,999
Weighted Average Exercise Price, Exercisable | $ / shares	$ 14.04
Warrants Issued in 2019 - Exercise Price $ 31.50 [Member]
Class Of Warrant Or Right [Line Items]
Number of Warrants Issued, Outstanding	737,975
Weighted Average Remaining Contractual Life (Years), Outstanding	2 years 25 days
Weighted Average Exercise Price, Outstanding | $ / shares	$ 31.50
Total, Exercisable	737,975
Weighted Average Exercise Price, Exercisable | $ / shares	$ 31.50
Warrants Issued in 2019 - Exercise Price $ 36.24 [Member]
Class Of Warrant Or Right [Line Items]
Number of Warrants Issued, Outstanding	22,333
Weighted Average Remaining Contractual Life (Years), Outstanding	2 years 25 days
Weighted Average Exercise Price, Outstanding | $ / shares	$ 36.24
Total, Exercisable	22,333
Weighted Average Exercise Price, Exercisable | $ / shares	$ 36.24
Warrants Issued in 2019 - Exercise Price $ 60.00 [Member]
Class Of Warrant Or Right [Line Items]
Number of Warrants Issued, Outstanding	666
Weighted Average Remaining Contractual Life (Years), Outstanding	6 months
Weighted Average Exercise Price, Outstanding | $ / shares	$ 60
Total, Exercisable	666
Weighted Average Exercise Price, Exercisable | $ / shares	$ 60
Warrants Issued in 2019 - Exercise Price $ 2.00 [Member]
Class Of Warrant Or Right [Line Items]
Number of Warrants Issued, Outstanding	256,200
Weighted Average Remaining Contractual Life (Years), Outstanding	3 years 2 months 15 days
Weighted Average Exercise Price, Outstanding | $ / shares	$ 2
Total, Exercisable	256,200
Weighted Average Exercise Price, Exercisable | $ / shares	$ 2
Warrants Issued in 2019 - Exercise Price $ 7.68 [Member]
Class Of Warrant Or Right [Line Items]
Number of Warrants Issued, Outstanding	75,000
Weighted Average Remaining Contractual Life (Years), Outstanding	4 years 18 days
Weighted Average Exercise Price, Outstanding | $ / shares	$ 7.68
Total, Exercisable	75,000
Weighted Average Exercise Price, Exercisable | $ / shares	$ 7.68
Warrants Issued in 2019 [Member]
Class Of Warrant Or Right [Line Items]
Number of Warrants Issued, Outstanding	1,376,139
Total, Exercisable	1,376,139
Warrants Issued in 2020 - Exercise Price $ 2.05 [Member]
Class Of Warrant Or Right [Line Items]
Number of Warrants Issued, Outstanding	1,250,000
Weighted Average Remaining Contractual Life (Years), Outstanding	4 years 11 months 15 days
Weighted Average Exercise Price, Outstanding | $ / shares	$ 2.05

STOCKHOLDERS' DEFICIT (Detail_7

STOCKHOLDERS' DEFICIT (Details 6) - $ / shares	Jun. 29, 2020	Jun. 19, 2019
Class Of Warrant Or Right [Line Items]
Stock price	$ 1.67	$ 10.30
Exercise Price	$ 2.05	$ 10.30
Term		6 years
Risk-Free Rate		1.83%
Risk-Free Rate, Minimum	0.28%
Risk-Free Rate, Maximum	0.38%
Volatility		67.16%
Volatility, Minimum	78.91%
Volatility, Maximum	80.49%
Minimum [Member]
Class Of Warrant Or Right [Line Items]
Term	5 years 6 months
Maximum [Member]
Class Of Warrant Or Right [Line Items]
Term	6 years

STOCKHOLDERS' DEFICIT (Detail_8

STOCKHOLDERS' DEFICIT (Details 7) - 2011 Stock Incentive Option Plan [Member] - $ / shares	6 Months Ended	12 Months Ended
	Jun. 30, 2020	Dec. 31, 2019
Class Of Warrant Or Right [Line Items]
Number of Options outstanding, beginning	7,245,350	6,642,200
Number of Options, Granted or deemed granted	90,000	636,683	[1]
Number of Options, Exercised		(167)
Number of Options, Cancelled, forfeited and expired	(142,818)	(33,366)
Number of Options outstanding, end	7,192,532	7,245,350
Number of Options, Options exercisable	6,978,869	7,001,680
Number of Options, Options available for future grant	2,302,475	2,167,150
Weighted-Average Exercise Price, Options outstanding, beginning	$ 4.68	$ 4.40
Weighted-Average Exercise Price, Granted or deemed granted	2.05	10.10
Weighted-Average Exercise Price, Exercised		5
Weighted-Average Exercise Price, Cancelled, forfeited and expired	5.08	11.29
Weighted-Average Exercise Price, Options outstanding, end	4.63	4.68
Weighted-Average Exercise Price, Options exercisable	$ 4.58	$ 4.47
[1]	Upon the Merger, the exercise prices of outstanding EMI options and number of shares of the Company common stock underlying the options were adjusted based upon the exchange ratio in the Merger.

INCOME TAX (Details Narrative)

INCOME TAX (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Income tax provision (benefit)	$ (499,000)	$ 51,000	$ (213,000)	$ 103,000
Provision for federal income tax			0
Unrecognized tax benefit	$ 0		$ 0		$ 0

LEASES (Details Narrative)

LEASES (Details Narrative)	Jan. 01, 2019USD ($)	Jun. 30, 2020USD ($)ft²	Jun. 30, 2019USD ($)	Jun. 30, 2020USD ($)ft²	Jun. 30, 2019USD ($)	Dec. 31, 2019USD ($)
Leases [Line Items]
Rent expense		$ 298,000	$ 219,000	$ 609,000	$ 419,000
Right of use assets		4,283,000	4,285,000	4,283,000	4,285,000	$ 4,474,000
Operating lease liabilities		4,825,000		4,825,000
Deferred rent					(287,000)
Cumulative-effect increased on our accumulated deficit		$ (230,393,000)	$ (206,391,000)	$ (230,393,000)	$ (206,391,000)	$ (226,229,000)
Weighted average remaining term of leases		6 years		6 years
Weighted average discount rate		12.40%		12.40%
ASC 842 [Member]
Leases [Line Items]
Change in accounting principle, accounting standards update, adoption date		Jan. 1, 2019		Jan. 1, 2019
Change in accounting principle, accounting standards update, adopted [true false]		true		true
Right of use assets	$ 3,000,000
Operating lease liabilities	3,300,000
Deferred rent	(287,000)
ASC 842 [Member] | Cumulative Effect, Period of Adoption, Adjustment [Member]
Leases [Line Items]
Cumulative-effect increased on our accumulated deficit	$ 29,000
Torrance, California [Member]
Leases [Line Items]
Operating lease, leased space | ft²		21,293		21,293
Operating lease, base rental per month				$ 78,543
Operating lease, expiration date				Sep. 30, 2026
New York [Member]
Leases [Line Items]
Operating lease, expiration date				Jan. 31, 2023
Operating lease, additional space for rent | ft²		1,850		1,850
Operating lease, additional base rent per month				$ 8,479
Tokyo, Japan [Member]
Leases [Line Items]
Operating lease, leased space | ft²		1,322		1,322
Operating lease, expiration date				Sep. 30, 2020
Operating lease base rent				$ 3,000

LEASES (Details)

LEASES (Details) $ in Thousands	Jun. 30, 2020USD ($)
Leases [Abstract]
2020 (six months)	$ 587
2021	1,106
2022	1,138
2023	1,050
2024 and thereafter	2,984
Total lease payments	6,865
Less: Interest	2,040
Present value of lease liabilities	$ 4,825

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Details Narrative) - Telcon RF Pharmaceuticals, Inc. ("Telcon") [Member] $ in Millions	Jul. 12, 2017USD ($)Numberkg$ / kg	Jun. 12, 2017USD ($)	Jun. 30, 2020$ / kg
API Supply Agreement [Member]
Proceeds from supply agreement		$ 31.8
API Supply Agreement [Member] | Pharmaceutical Grade L-glutamine [Member]
Percentage of right to supply		25.00%
Agreement term		15 years
Revised API Agreement [Member]
Agreement term	5 years
Number of renewals | Number	10
Purchase quantity | kg	940,000
Unit price of grade L-glutamine | $ / kg	50		100
Purchase amount	$ 47

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details) - USD ($) $ / shares in Units, $ in Thousands		6 Months Ended		12 Months Ended
		Jun. 30, 2020		Dec. 31, 2019
Short-term Debt [Line Items]
Principal Amount Outstanding		$ 15,537		$ 13,952
Conversion Rate (in dollars per share)		$ 10
Yutaka Niihara [Member]
Short-term Debt [Line Items]
Interest Rate		5.25%		5.00%
Date of Loan		Dec. 27, 2019		Dec. 27, 2019
Term of Loan		Due on Demand		Due on Demand
Principal Amount Outstanding		$ 600		$ 600
Amount of Interest Paid		18
Highest Principal Outstanding				600
Revolving Line of Credit Facility [Member]
Short-term Debt [Line Items]
Principal Amount Outstanding		600		600
Amount of Interest Paid		$ 18
Highest Principal Outstanding				$ 600
Lan T. Tran [Member]
Short-term Debt [Line Items]
Interest Rate	[1]	10.00%		10.00%
Date of Loan	[1]	Apr. 29, 2016		Apr. 29, 2016
Term of Loan	[1]	Due on Demand		Due on Demand
Principal Amount Outstanding	[1]	$ 20		$ 20
Highest Principal Outstanding	[1]			$ 20
Lan T. Tran [Member]
Short-term Debt [Line Items]
Interest Rate	[1]	11.00%		11.00%
Date of Loan	[1]	Feb. 10, 2018		Feb. 10, 2018
Term of Loan	[1]	Due on Demand		Due on Demand
Principal Amount Outstanding	[1]			$ 159
Amount of Interest Paid	[1]	$ 35
Highest Principal Outstanding	[1]			$ 159
Lan T. Tran [Member]
Short-term Debt [Line Items]
Interest Rate	[1]	10.00%		10.00%
Date of Loan	[1]	Feb. 9, 2019		Feb. 9, 2019
Term of Loan	[1]	Due on Demand		Due on Demand
Principal Amount Outstanding	[1]	$ 14		$ 14
Highest Principal Outstanding	[1]			$ 14
Promissory note payable to related parties [Member]
Short-term Debt [Line Items]
Term of Loan				Subtotal
Principal Amount Outstanding		34	[1]	$ 193
Amount of Interest Paid		35	[1]	82
Highest Principal Outstanding				1,359
Amount of Principal Repaid				$ 277
Promissory note payable and Revolving line of credit [Member]
Short-term Debt [Line Items]
Principal Amount Outstanding		634
Amount of Interest Paid		$ 53
Hope International Hospice, Inc. [Member]
Short-term Debt [Line Items]
Interest Rate	[2]			10.00%
Date of Loan	[2]			Jun. 3, 2016
Term of Loan	[2]			Due on Demand
Amount of Interest Paid	[2]			$ 78
Highest Principal Outstanding	[2]			250
Amount of Principal Repaid	[2]			$ 250
Lan T. Tran [Member]
Short-term Debt [Line Items]
Interest Rate	[1]			10.00%
Date of Loan	[1]			Feb. 9, 2017
Term of Loan	[1]			Due on Demand
Amount of Interest Paid	[1]			$ 2
Highest Principal Outstanding	[1]			$ 12
Yutaka Niihara [Member]
Short-term Debt [Line Items]
Interest Rate	[1],[3]			10.00%
Date of Loan	[1],[3]			Sep. 14, 2017
Term of Loan	[1],[3]			Due on Demand
Amount of Interest Paid	[1],[3]			$ 2
Highest Principal Outstanding	[1],[3]			904
Amount of Principal Repaid	[1],[3]			$ 27
Yasushi Nagasaki [Member]
Short-term Debt [Line Items]
Interest Rate	[1]			10.00%
Date of Loan	[1]			Jun. 29, 2012
Term of Loan	[1]			Due on Demand
Amount of Interest Paid	[1]			$ 56
Highest Principal Outstanding	[1]			200
Amount of Principal Repaid	[1]			$ 200
Conversion Rate (in dollars per share)	[1]			$ 3.30
Yutaka & Soomi Niihara [Member]
Short-term Debt [Line Items]
Interest Rate	[1],[3]			10.00%
Date of Loan	[1],[3]			Nov. 16, 2015
Term of Loan	[1],[3]			2 years
Amount of Interest Paid	[1],[3]			$ 73
Highest Principal Outstanding	[1],[3]			200
Amount of Principal Repaid	[1],[3]			$ 200
Conversion Rate (in dollars per share)	[1],[3]			$ 4.50
Wei Peu Zen [Member]
Short-term Debt [Line Items]
Interest Rate	[3]			10.00%
Date of Loan	[3]			Nov. 6, 2017
Term of Loan	[3]			2 years
Amount of Interest Paid	[3]			$ 597
Highest Principal Outstanding	[3]			5,000
Amount of Principal Repaid	[3]			$ 5,000
Conversion Rate (in dollars per share)	[3]			$ 10
Profit Preview International Group, Ltd. [Member]
Short-term Debt [Line Items]
Interest Rate	[4]			10.00%
Date of Loan	[4]			Feb. 1, 2018
Term of Loan	[4]			2 years
Amount of Interest Paid	[4]			$ 385
Highest Principal Outstanding	[4]			4,037
Amount of Principal Repaid	[4]			$ 4,037
Conversion Rate (in dollars per share)	[4]			$ 10
Profit Preview International Group, Ltd. [Member]
Short-term Debt [Line Items]
Interest Rate	[4]			10.00%
Date of Loan	[4]			Mar. 21, 2018
Term of Loan	[4]			2 years
Amount of Interest Paid	[4]			$ 442
Highest Principal Outstanding	[4]			5,363
Amount of Principal Repaid	[4]			$ 5,363
Conversion Rate (in dollars per share)	[4]			$ 10
Convertible notes payable - related party non-current [Member]
Short-term Debt [Line Items]
Amount of Interest Paid				$ 1,553
Highest Principal Outstanding				14,800
Amount of Principal Repaid				14,800
Promissory note payable and convertible notes payable - related party [Member]
Short-term Debt [Line Items]
Principal Amount Outstanding				793
Amount of Interest Paid				1,635
Highest Principal Outstanding				16,759
Amount of Principal Repaid				$ 15,077
[1]	Officer
[2]	Dr. Niihara, a Director and the Chairman, and Chief Executive Officer of the Company, is also a director and the Chief Executive Officer of Hope International Hospice, Inc.
[3]	Director
[4]	Mr. Zen, a Director of the Company, is the sole owner of Profit Preview International Group, Ltd.

RELATED PARTY TRANSACTIONS (D_2

RELATED PARTY TRANSACTIONS (Details Narrative)	Jun. 30, 2020shares
Related Party Transactions [Abstract]
Marketable securities common stock outstanding	4,147,491
Percentage of marketable securities common stock outstanding	8.60%
Shares held as marketable securities	6,222,837

SUBSEQUENT EVENTS (Details Narr

SUBSEQUENT EVENTS (Details Narrative) - USD ($)

Apr. 05, 2021

Feb. 22, 2021

Feb. 09, 2021

Sep. 28, 2020

Sep. 22, 2020

Feb. 21, 2020

Jul. 31, 2020

Jun. 30, 2020

Jun. 30, 2019

Dec. 31, 2018

Mar. 31, 2021

Oct. 31, 2020

Oct. 28, 2020

Jan. 31, 2020

Subsequent Event [Line Items]

Debt instrument, maturity date

Apr. 21, 2021

Exercise price

$ 3

$ 5.87

Conversion debentures price

$ 3

$ 9.52

Net proceeds from the sale of the convertible promissory notes

$ 21,000

Conversion Price

$ 10

Securities Amendment Agreement [Member]

Subsequent Event [Line Items]

Monthly redemptions description

Pursuant to the Allonge, the aggregate monthly redemption payments under the Debentures were reduced to $500,000 from $1,000,000 in principal amount and the maturity date of the Debentures was extended from April 21, 2021 to August 31, 2021. The monthly redemption payments resumed in September 2020 and will continue on the first day of each month thereafter commencing October 1, 2020. The remaining principal balance of the Debentures will be due and payable upon maturity, subject to mandatory prepayment in connection with certain “Capital Events” as defined.

Convertible Bond Purchase Agreement [Member] | T.R. Winston & Company, LLC [Member]

Subsequent Event [Line Items]

Exercise price

$ 2.10

Convertible Bond Purchase Agreement [Member] | Maximum [Member] | T.R. Winston & Company, LLC [Member]

Subsequent Event [Line Items]

Number of common stock to be purchased

75,000

10% of Senior Secured Debentures [Member]

Subsequent Event [Line Items]

Debt instrument annual interest

10.00%

Subsequent Event [Member]

Subsequent Event [Line Items]

Debt instrument annual interest

2.10%

Common stock purchase period

5 years

Exercise price

$ 2

Convertible bond maturity date

Oct. 16, 2030

Convertible bond initial conversion price

$ 8

Call option agreement date

Sep. 28, 2020

Subsequent Event [Member] | EJ Holding, Inc. [Member]

Subsequent Event [Line Items]

Unsecured long-term debt

$ 4,000,000

$ 6,500,000

Subsequent Event [Member] | Maximum [Member]

Subsequent Event [Line Items]

Number of common stock to be purchased

1,840,000

Percentage of principal amount of convertible bond to be repurchased

50.00%

Subsequent Event [Member] | Securities Amendment Agreement [Member]

Subsequent Event [Line Items]

Monthly redemption payment on principal amount

$ 500,000,000

$ 1,000,000,000

Debt instrument, maturity date

Aug. 31, 2021

Apr. 21, 2021

Subsequent Event [Member] | Convertible Bond Purchase Agreement [Member] | T.R. Winston & Company, LLC [Member]

Subsequent Event [Line Items]

Convertible notes payable, carrying amount

$ 26,100,000

Subsequent Event [Member] | Convertible Bond Purchase Agreement [Member] | Kainos Medicine, Inc [Member]

Subsequent Event [Line Items]

Conversion debentures price

$ 1.54

Subsequent Event [Member] | Securities Purchase Agreement [Member] | Senior Secured Convertible Debentures [Member]

Subsequent Event [Line Items]

Debt instrument annual interest

10.00%

Convertible promissory notes amount used to prepay outstanding

$ 6,200,000

Subsequent Event [Member] | 10% of Senior Secured Debentures [Member] | Securities Amendment Agreement [Member]

Subsequent Event [Line Items]

Debt instrument annual interest

10.00%

Subsequent Event [Member] | Convertible Promissory Note [Member] | Securities Purchase Agreement [Member]

Subsequent Event [Line Items]

Debt instrument annual interest

2.00%

Date of Loan

Feb. 8, 2021

Net proceeds from the sale of the convertible promissory notes

$ 14,500,000

Conversion Price

$ 1.48

Debt instrument, frequency of periodic payment

The convertible promissory notes bear interest at the rate of 2% per annum payable semi-annually on the last business day of August and January of each year and will mature on the 3rd anniversary of the original issue date.

Debt instrument percentage of accrued and unpaid interest on prepayment of principal amount

50.00%

Subsequent Event [Member] | Convertible Promissory Note [Member] | Securities Purchase Agreement [Member] | Maximum [Member]

Subsequent Event [Line Items]

Convertible notes aggregate purchase price

$ 17,000,000

Debt instrument prepayment percentage on principle amount

50.00%

Subsequent Event [Member] | Convertible Promissory Note [Member] | Purchase and Sale Agreement [Member] | Prestige Capital Finance, LLC [Member]

Subsequent Event [Line Items]

Percentage of face amount of applicable at time of sale accounts receivable

70.00%

Percentage of face amount of applicable subject to increase at time of sale accounts receivable

75.00%

Accounts receivable face amount

$ 7,500,000

Face amount of accounts receivable discount rate

2.25%

Subsequent Event [Member] | Convertible Promissory Note [Member] | Purchase and Sale Agreement [Member] | Maximum [Member] | Prestige Capital Finance, LLC [Member]

Subsequent Event [Line Items]

Face amount of accounts receivable discount rate

7.25%